Great Basin Scientific (GBSN) 10-K 1 Mar 16 2015 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2015	Feb. 25, 2016	Jun. 30, 2015
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	FY
Trading Symbol	GBSN
Entity Registrant Name	Great Basin Scientific, Inc.
Entity Central Index Key	1,512,138
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		114,231,984
Entity Public Float			$ 17,800,000

BALANCE SHEETS

BALANCE SHEETS - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Current assets:
Cash	$ 4,787,759	$ 2,017,823
Restricted Cash	13,800,000
Accounts receivable, net	411,390	267,485
Inventory	1,133,142	457,094
Prepaid and other current assets	564,910	376,778
Total current assets	20,697,201	3,119,180
Intangible assets, net	119,171	216,580
Property and equipment, net	7,741,991	4,237,467
Total assets	28,558,363	7,573,227
Current liabilities:
Accounts payable	2,432,459	1,369,169
Accrued expenses	1,313,149	612,359
Current portion of notes payable	5,693	49,994
Current portion of convertible notes payable, net of discount	1,638,717
Notes payable-related party, net of discount	500,000	441,667
Current portion of capital lease obligations	1,305,426	947,422
Total current liabilities	7,195,444	3,420,611
Notes payable, net of current portion		5,693
Convertible notes payable, net of current portion and debt discount	525,000
Capital lease obligations, net of current portion	851,410	2,156,837
Derivative liability	43,181,472	9,998,636
Total liabilities	$ 51,753,326	$ 15,581,777
Commitments and contingencies
Stockholders' deficit:
Preferred stock, $.001 par value, 5,000,000 shares authorized; 88,347 and 0 shares issued and outstanding, respectively	$ 88
Common stock, $.0001 par value: 200,000,000 and 50,000,000 shares authorized, respectively; 10,390,408 and 84,777 shares issued and outstanding, respectively	1,039	$ 8
Additional paid-in capital	98,707,775	55,996,138
Accumulated deficit	(121,903,865)	(64,004,696)
Total stockholders' deficit	(23,194,963)	(8,008,550)
Total liabilities and stockholders' deficit	$ 28,558,363	$ 7,573,227

BALANCE SHEETS (Parenthetical)

BALANCE SHEETS (Parenthetical) - $ / shares	Dec. 31, 2015	Dec. 11, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001		$ 0.001
Preferred stock, shares authorized	5,000,000		5,000,000
Preferred stock, shares issued	88,347		0
Preferred Stock, Shares Outstanding	88,347		0
Common stock, par value	$ 0.0001	$ 0.0001	$ 0.0001
Common stock, shares authorized	200,000,000		50,000,000
Common stock, shares issued	10,390,408		84,777
Common stock, shares outstanding	10,390,408		84,777

STATEMENTS OF OPERATIONS

STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Income Statement [Abstract]
Revenues	$ 2,142,040	$ 1,606,254
Cost of sales	4,813,415	3,968,185
Gross loss	(2,671,375)	(2,361,931)
Operating expenses
Research and development	8,485,668	4,609,913
Selling and marketing	5,007,320	2,301,610
General and administrative	6,241,433	2,928,186
Gain on sale of assets		(8,166)
Total operating expenses	19,734,421	9,831,543
Loss from operations	(22,405,796)	(12,193,474)
Other income (expense):
Interest expense	(11,757,445)	(1,136,054)
Interest income	18,193	3,176
Loss on extinguishment of warrants	(4,038,063)
Change in fair value of derivative liability	(19,714,808)	(8,396,169)
Change in fair value of derivative liability	(19,714,808)	(8,396,169)
Total other income (expense)	(35,492,123)	(9,529,047)
Loss before provision for income taxes	(57,897,919)	(21,722,521)
Provision for income taxes	(1,250)	(5,297)
Net loss	$ (57,899,169)	$ (21,727,818)
Net loss per common share-basic and diluted	$ (51.17)	$ (1,039.41)
Weighted average common shares-basic and diluted	1,131,502	20,904

STATEMENTS OF STOCKHOLDERS' DEF

STATEMENTS OF STOCKHOLDERS' DEFICIT - USD ($)	Total	Series A Warrants	Series C Warrant	Preferred Stock, Shares	Preferred Stock, SharesSeries A Warrants	Preferred Stock, SharesSeries C Warrant	Preferred Stock, SharesClass C Warrant	Common Stock, Shares	Common Stock, SharesSeries A Warrants	Common Stock, SharesSeries C Warrant	Common Stock, SharesSeries A and B Warrants	Common Stock, SharesClass C Warrant	Additional Paid-In Capital	Additional Paid-In CapitalSeries A Warrants	Additional Paid-In CapitalSeries C Warrant	Additional Paid-In CapitalSeries A and B Warrants	Additional Paid-In CapitalClass C Warrant	Accumulated Deficit
Beginning balance, value at Dec. 31, 2013	$ (32,543,420)												$ 9,733,458					$ (42,276,878)
Beginning balance, shares at Dec. 31, 2013								1,926
Issuance of stock and warrants	6,375,837							$ 2					6,375,835
Issuance of stock and warrants (in shares)								19,167
Exercise of common stock warrants	31,600												31,600
Exercise of common stock warrants (in shares)								2,634
Employee stock option expense	297,244												297,244
Conversion of preferred stock into common stock	41,135,411							$ 6					41,135,405
Conversion of preferred stock into common stock, shares								61,050
Derivative liability on warrants issued and exercised	(1,602,467)												(1,602,467)
Modification of warrants	25,063												25,063
Net loss for the year	(21,727,818)																	(21,727,818)
Ending balance, value at Dec. 31, 2014	(8,008,550)							$ 8					55,996,138					(64,004,696)
Ending balance, shares at Dec. 31, 2014								84,777
Issuance of stock and warrants	57,213			$ 2,724									54,489
Issuance of stock and warrants (in shares)				2,724,000				0
Exercise of common stock warrants		$ 2,252,020	$ 979,200						$ 2					$ 2,252,018	$ 979,200
Cash exercise of unit purchase option	162,250			$ 15									162,235
Exercise of common stock warrants (in shares)					0	0			17,917	6,400
Cash exercise of unit purchase option(in shares)				14,750				0
Cashless exercise of warrants											$ 1	$ 1,010				$ (1)	$ (1,010)
Cashless exercise of warrants (in shares)							0				9,220	10,095,399
Employee stock option expense	110,124												110,124
Conversion of preferred stock into common stock				$ (2,651)				$ 18					2,633
Conversion of preferred stock into common stock, shares				(2,650,403)				176,695
Derivative liability on warrants issued and exercised	39,151,949												39,151,949
Net loss for the year	(57,899,169)																	(57,899,169)
Ending balance, value at Dec. 31, 2015	$ (23,194,963)			$ 88				$ 1,039					$ 98,707,775					$ 121,903,865
Ending balance, shares at Dec. 31, 2015				88,347				10,390,408

STATEMENTS OF CASH FLOWS

STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Cash flows from operating activities:
Net loss	$ (57,899,169)	$ (21,727,818)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,612,086	1,157,976
Change in fair value of derivative liability	19,714,808	8,396,169
Interest from issuance of convertible note	10,594,182
Loss on extinguishment of warrants	4,038,063
(Gain) loss on sale of assets		(8,166)
Interest converted to preferred stock		13,129
Employee stock compensation	110,124	297,244
Warrant issuance and modifications	612,006	25,063
Debt discount amortization	122,050	41,667
Asset disposal		11,124
Changes in operating assets and liabilities:
Increase in accounts receivable, net	(143,905)	(83,070)
Increase in inventory	(676,048)	(136,855)
Increase in prepaid and other assets	(56,797)	(217,597)
Increase in accounts payable	602,056	37,171
Increase in accrued liabilities	700,790	(203,455)
Net cash used in operating activities	(20,669,754)	(12,397,418)
Cash flows from investing activities:
Acquisition of property and equipment	(1,566,044)	(248,133)
Construction of equipment	(3,226,943)	(971,122)
Proceeds from sale of assets		35,000
Proceeds from sale leaseback		1,500,000
Net cash used in investing activities	(4,792,987)	315,745
Cash flows from financing activities:
Proceeds from issuance of common stock		6,375,837
Proceeds from exercise of warrants	3,161,220	31,600
Proceeds from issuance of convertible notes payable	4,135,000	100,000
Proceeds from issuance of convertible notes payable - related party		300,000
Proceeds from issuance of preferred stock		6,569,886
Proceeds from follow-on offering	21,933,874
Proceeds from issuance of notes payable - related party	250,000	890,000
Principal payments of capital leases	(947,423)	(944,606)
Principal payments of notes payable	(49,994)	(44,644)
Principal payments of notes payable - related party	(250,000)	(390,000)
Net cash provided by financing activities	28,232,677	12,888,073
Net increase in cash	2,769,936	806,400
Cash, beginning of the period	2,017,823	1,211,423
Cash, end of the period	4,787,759	2,017,823
Supplemental disclosures of cash flow information:
Interest paid	1,055,255	1,121,066
Income taxes paid	1,250	6,447
Supplemental schedule of non-cash investing and financing activities:
Conversion of preferred stock to common stock	2,651	18,846,539
Issuance of preferred stock as debt discount	0	100,000
Restricted Cash from Convertible Debt	13,800,000
Conversion of note payable to preferred stock	0	400,000
Assets acquired through capital leases	0	807,272
Offering costs incurred but unpaid	235,020	64,760
Property and equipment included in accounts payable	226,214	393,119
Cashless exercise of warrants	1,011
Change in derivative liability from convertible debt	15,731,315
Change in derivative liability from exercised and issued warrants	$ 39,151,949	$ 1,586,181

DESCRIPTION OF BUSINESS

DESCRIPTION OF BUSINESS	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
DESCRIPTION OF BUSINESS	NOTE 1 DESCRIPTION OF BUSINESS Great Basin Scientific, Inc. (the “Company”) (d.b.a., Great Basin Corporation) is a Delaware corporation headquartered in Salt Lake City, Utah. The Company was originally incorporated as Diagnostic Micro Arrays, Inc., a Nevada corporation, on June 27, 2003. The Company changed its name to Great Basin Scientific, Inc. on April 19, 2006. On August 12, 2008, the Company took steps to change its corporate domicile from Nevada to Delaware by forming Great Basin Scientific, Inc., a Delaware corporation, and on August 29, 2008, Great Basin Scientific, Inc., a Nevada corporation, was merged with and into Great Basin Scientific, Inc., a Delaware corporation, wherein the Delaware corporation was the sole surviving entity. The Company is a molecular diagnostic testing company focused on the development and commercialization of its patented, molecular diagnostic platform designed to test for infectious disease, especially hospital-acquired infections. The Company believes that small to medium sized hospital laboratories, those under 400 beds, are in need of simpler and more affordable molecular diagnostic testing methods. The Company markets a system that combines both affordability and ease-of-use, when compared to other commercially available molecular testing methods, which it believes will accelerate the adoption of molecular testing in small to medium sized hospitals. The system includes an analyzer, which is provided for our customers’ use without charge in the United States, and a diagnostic cartridge, which is sold to our customers. The testing platform has the capability to identify up to 64 individual targets at one time. If the test identifies one to three targets, they are referred to as low-plex tests, or tests, and if they identify four or more targets they are referred to as multi-plex panels, or panels. The Company currently has two commercially available tests, the first for clostridium difficile, or C. diff

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation These financial statements have been prepared to reflect the financial position, results of operations and cash flows of the Company and have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). Reverse Stock Split On December 11, 2015, the Company effected a reverse stock split of the Company’s common stock whereby each sixty shares of common stock was replaced with one share of common stock (with no fractional shares issued). The par value of the common stock was adjusted from $0.001 per share to $0.0001 per share as a result of the reverse stock split. The authorized shares of the common stock were not adjusted. All common share and per share amounts for all periods presented in these financial statements have been adjusted retroactively to reflect the reverse stock split. The quantity of Series E Preferred Stock, Common Warrants, Class A, Class B, Series A, Series B and Series C Warrants as well as employee and other options were not included in the reverse stock split and their outstanding quantities have not been adjusted. However, the conversion and exchange ratios were adjusted as a result of the reverse stock split such that upon conversion each 60 shares of Series E Preferred Stock will be converted into four shares of common stock and upon exercise each 60 warrants or options will be converted into one share of common stock. Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. Such estimates include the warranty reserve, accounts receivable and inventory reserves, intangible assets and other long lived assets, legal and regulatory contingencies, income taxes, share based arrangements, the derivative liability and others. These estimates and assumptions are based on management’s best estimates and judgments. Actual amounts and results could differ from those estimates. Cash and Cash Equivalents The Company considers highly liquid investments with insignificant interest rate risk and original maturities to the Company of three months or less to be cash equivalents. Cash equivalents consist primarily of interest and non-interest bearing bank accounts held in checking, savings and money market accounts. These assets are generally available on a daily or weekly basis and are highly liquid in nature. If the balances are greater than $250,000, the Company does not have FDIC coverage on the entire amount of bank deposits. Restricted Cash Cash and cash equivalents that are restricted as to withdrawal or use under the terms of certain contractual agreements are recorded as restricted cash on our balance sheet. On December 30, 2015, the Company entered into a Securities Purchase Agreement pursuant to which the Company issued $22.1 million senior secured convertible notes and received $18.4 million in cash proceeds. Under the terms of the notes, at closing an initial tranche of $4.6 million was available for immediate use by the Company for general corporate purposes. The remaining cash proceeds of $13.8 million is available in three additional tranches that are subject to an account control agreement whereby the restrictions on the proceeds are terminated when the Company meets certain equity conditions (see NOTE 8 CONVERTIBLE NOTES PAYABLE). The restricted cash is deposited in an account that is not FDIC insured. Accounts Receivable Accounts receivable are generated from the sale of single use diagnostic test cartridges to end users in the United States and to a network of distributors outside the United States. These accounts receivable are recorded at the invoiced amount, net of allowances for doubtful amounts. The Company routinely reviews outstanding accounts receivable balances for estimated uncollectible accounts and establishes or adjusts the allowances for doubtful accounts receivable using the specific identification method and records a reserve for amounts not expected to be fully recovered. Actual balances are not applied against the reserve until substantially all collection efforts have been exhausted. The Company does not have customer acceptance provisions, but it does provide its customers a limited right of return for defective diagnostic test cartridges. The allowance for doubtful accounts at December 31, 2015 and 2014 was $16,892 and $5,482, respectively. Inventories Inventories are stated at the lower of cost or market with cost determined according to the average cost method. Manufactured inventory consists of raw material, direct labor and manufacturing overhead cost components. The Company reviews the components of its inventory on a regular basis for excess and obsolete inventory and makes appropriate adjustments when necessary. Inventories consisted of the following at December 31, 2015 and 2014: December 31, 2015 2014 Raw materials $ 758,870 $ 360,019 Work-in-process 277,827 91,153 Finished goods 96,445 5,922 Total inventories $ 1,133,142 $ 457,094 Property and Equipment Property and equipment is recorded at cost and depreciated over the estimated useful lives of the assets (which range from three to ten years) using the straight-line method. Amortization of leasehold improvements is computed on the straight-line method over the shorter of the lease term or estimated useful lives of the assets. The analyzers that the Company manufactures and retains title over are placed with customers and are recorded in property and equipment under “Analyzers.” The materials used for the manufacture of the analyzers are recorded in property and equipment under “Construction in progress.” Major renewals and betterments are capitalized and depreciated over their estimated useful lives while minor expenditures for maintenance and minor repairs are charged to operations as incurred. The Company classifies assets to be sold as assets held for sale when (i) Company management has approved and commits to a plan to sell the asset, (ii) the asset is available for immediate sale in its present condition and is ready for sale, (iii) an active program to locate a buyer and other actions required to sell the asset have been initiated, (iv) the sale of the asset is probable, (v) the asset is being actively marketed for sale at a price that is reasonable in relation to its current fair value, and (vi) it is unlikely that significant changes to the plan will be made or that the plan will be withdrawn. Assets classified as held for sale are recorded at the lower of the carrying amount or fair value less the cost to sell and are a component of prepaid and other current assets in the balance sheets. The Company did not have any assets classified as held for sale as of December 31, 2015 and 2014. Intangible Assets The Company records its intangible assets at cost which consist of two licensing and royalty agreements for certain intellectual property rights used in the development and manufacture of our products. These intangible assets are being amortized over an estimated useful life of seven years from the date that the technology licenses became effective. As of December 31, 2015 and 2014, intangible assets totaled $600,000 valued at cost, less accumulated amortization of $480,829 and $383,420, respectively. The Company recorded amortization associated with these agreements of $97,407 and $117,445 for the years ended December 31, 2015 and 2014, respectively. Estimated future intangible asset amortization expense for the next five years are as follows: Years ended December 31, 2016 $ 76,580 2017 42,591 Total estimated amortization expense $ 119,171 Impairment of Long Lived Assets Long-lived tangible assets, including property and equipment, and definite-lived intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying value of the asset may not be recoverable. The Company regularly evaluates whether events or circumstances have occurred that indicate possible impairment and relies on a number of factors, including expected future operating results, business plans, economic projections, and anticipated future cash flows. The Company uses an estimate of the future undiscounted net cash flows and comparisons to like-kind assets, as appropriate, of the related asset over the remaining life in measuring whether the assets are recoverable. Measurement of the amount of impairment, if any, is based upon the difference between the asset’s carrying value and estimated fair value. Fair value is determined through various valuation techniques, including cost-based, market and income approaches as considered necessary. Derivative Instruments The Company accounts for derivative instruments under the provisions of ASC 815 Derivatives and Hedging Fair Value of Financial Instruments The Company measures at fair value certain of its financial and non-financial assets and liabilities by using a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, essentially an exit price, based on the highest and best use of the asset or liability. The levels of the fair value hierarchy are: Level 1—Quoted market prices in active markets for identical assets or liabilities; Level 2—Significant other observable inputs (e.g. quoted prices for similar items in active markets, quoted prices for identical or similar items in markets that are not active, inputs other than quoted prices that are observable, such as interest rate and yield curves, and market-corroborated inputs); and Level 3—Unobservable inputs in which there is little or no market data, which require the reporting unit to develop its own assumptions. The following tables set forth the financial liabilities measured at fair value on a recurring basis by level within the fair value hierarchy at December 31, 2015 and 2014 (see NOTE 12 DERIVATIVE LIABILITIES): Fair Value Measurements at December 31, 2015 Description Level 1 Level 2 Level 3 Total Derivative liability Common stock warrants $ — $ — $ 26,592,532 $ 26,592,532 Convertible notes payable $ — $ — $ 16,588,940 $ 16,588,940 Total derivative liability $ — $ — $ 43,181,472 $ 43,181,472 Fair Value Measurements at December 31, 2014 Description Level 1 Level 2 Level 3 Total Derivative liability Common stock warrants $ — $ — $ 9,998,636 $ 9,998,636 Total derivative liability $ — $ — $ 9,998,636 $ 9,998,636 The internal models used to determine fair value for these Level 3 instruments use certain significant unobservable inputs and their use requires determination of relevant inputs and assumptions. Accordingly, changes in these unobservable inputs may have a significant impact on fair value. Such inputs include risk free interest rate, expected average life, expected dividend yield, and expected volatility. These Level 3 liabilities would decrease (increase) in value based upon an increase (decrease) in risk free interest rate and expected dividend yield. Conversely, the fair value of these Level 3 liabilities would generally increase (decrease) in value if the expected average life or expected volatility were to increase (decrease). Revenue Recognition The Company derives its product revenue from the sale of single use diagnostic test cartridges sold through our dedicated sales force, except in the European Union where the Company sells through a network of distributors. Product revenue is recognized when all four of the following criteria are met: (1) persuasive evidence that an arrangement exists; (2) delivery of the products has occurred; (3) the selling price of the product is fixed or determinable; and (4) collectability of that price is reasonably assured. Change in title to the product and recognition of revenue from sales of diagnostic test cartridges occurs at the time of shipment. Shipping and handling fees and related freight costs and supplies for test kits are billed to customers. Additional costs associated with shipping products to customers are included as a component of cost of sales. Research and Development Costs Research and development costs are charged to operations as incurred. Research and development costs include, among other things, salaries and wages for research scientists and staff (including stock-based compensation), materials and supplies used in the development of new products, developing and validating the manufacturing process, costs for clinical trials, and costs for research and development facilities and equipment. Stock Based Compensation The Company has accounted for stock-based compensation under the provisions of Financial Accounting Standards Board Accounting Standards Codification (“FASB ASC”) 718, “Compensation—Stock Compensation” . Financial Instruments and Concentration of Credit Risk The Company’s financial instruments include cash and cash equivalents, accounts receivable, and accounts payable. The carrying amount of cash and cash equivalents, accounts receivable, and accounts payable approximate fair value because of their immediate or short-term maturities. All of the Company’s accounts receivable result from sales in the normal course of business to its customers primarily throughout the United States. The Company attempts to limit its credit risk by performing credit evaluations of new customers and maintaining adequate allowances for potential credit losses. As of December 31, 2015, 17% of the accounts receivable balance resulted from one customer. As of December 31, 2014, 30% of the accounts receivable balance resulted from one customer. Historically, the Company has not experienced any credit losses on such receivables. Allowances for bad debt in the amount of $16,892 and $5,482 were recorded against accounts receivable for the years ended December 31, 2015 and 2014, respectively. There was no bad debt for the year ended December 31, 2015. The Company cannot ensure that such losses will not be realized in the future. The Company’s customers consist of hospitals, clinics, laboratories and other healthcare providers in the United States, the European Union and New Zealand. For the year ended December 31, 2015, there were no customers that accounted for more than 10% of revenues. For the year ended December 31, 2014, 11% of revenues resulted from one customer who accounted for more than 10% of revenues. Income Taxes The Company accounts for income taxes under FASB ASC 740, “Income Taxes”. Deferred income tax assets and liabilities are determined based upon differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Accounting standards require the consideration of a valuation allowance for deferred tax assets if it is “more likely than not” that some component or all of the benefits of deferred tax assets will not be realized. The tax effects from an uncertain tax position can be recognized in the financial statements only if the position is more likely than not of being sustained if the position were to be challenged by a taxing authority. The Company has examined the tax positions taken in its tax returns and determined that there are no uncertain tax positions. As a result, the Company has recorded no uncertain tax liabilities in its balance sheet. Loss per Common Share Basic loss per share (“EPS”) is computed by dividing net loss, less cumulative preferred stock dividends for the period, including undeclared or unpaid cumulative dividends (the numerator) by the weighted average number of common shares outstanding for the period (the denominator). Diluted EPS is computed by dividing net loss by the weighted average number of common shares and potential common shares outstanding (if dilutive) during each period. Potential common shares include convertible preferred stock, stock options and warrants. The number of potential common shares outstanding is computed using the treasury stock method. As the Company has incurred losses for the years ended December 31, 2015 and 2014, the potentially dilutive shares are anti-dilutive and are thus not added into the loss per share calculations. As of December 31, 2015 and 2014, there were 27,468,018 and 102,516 potentially dilutive shares, respectively. Reclassification During 2015, the Company’s auditors identified a clerical error made by the Company during the preparation of the 2014 cash flow statement, wherein the amount for a certain fixed asset that was included in accounts payable had the sign inadvertently switched. The Company has corrected the presentation of the 2014 cash flows for this clerical item and in doing so, the statement of cash flows for 2014 was adjusted to increase net cash used in operating activities by $786,238, with a corresponding decrease in net cash used from investing activities. Other than the 2014 cash flow statement, no other cash flow statement for any annual or quarterly period, was impacted by this presentation correction. The Company has evaluated the effect of the incorrect presentation, both qualitatively and quantitatively, and concluded that it did not have a material impact on, nor require amendment of, any previously filed annual or quarterly financial statements. New Accounting Pronouncements From time to time, new accounting pronouncements are issued by the FASB that are adopted by the Company as of the specified effective date. If not discussed, management believes that the impact of recently issued standards, which are not yet effective, will not have a material impact on the Company’s financial statements upon adoption. In November 2015, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2015-17, “Balance Sheet Classification of Deferred Taxes,” that requires companies to classify all deferred tax assets and liabilities, along with any valuation allowance, as noncurrent on the balance sheet instead of separating deferred taxes into current and noncurrent amounts. The guidance does not change the existing requirement that only permits offsetting within a jurisdiction. The ASU is effective for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. Early adoption is permitted. During the fourth quarter of 2015, the Company elected early adoption of this standard as it improved the efficiency of the year end financial reporting process for income taxes and applied the changes retrospectively to all prior periods presented in its financial statements. In July 2015, the FASB issued ASU 2015-11, “Simplifying the Measurement of Inventory,” that simplifies the subsequent measurement of inventories by replacing the current lower of cost or market test with a lower of cost or net realizable value test. The ASU is effective for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. Early adoption is permitted. The Company is still evaluating the impact this standard will have on its financial statements and related disclosures. In April 2015, the FASB issued ASU 2015-03, “Simplifying the Presentation of Debt Issuance Costs,” which requires debt issuance costs to be presented in the balance sheet as a direct deduction from the carrying value of the associated debt liability, consistent with the presentation of debt discounts or premiums. The ASU is effective for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. During the year 2015, the Company elected early adoption of this standard and applied the changes in its financial statements and related disclosures. In August 2014, the FASB issued ASU No. 2014-15 Disclosure of Uncertainties About an Entity’s Ability to Continue as a Going Concern In May 2014, the FASB issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”), which supersedes nearly all existing revenue recognition guidance under GAAP. The core principle is that a company should recognize revenue when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, more judgment and estimates may be required within the revenue recognition process than are required under existing GAAP. The standard is effective for annual periods beginning after December 15, 2016, and interim periods therein, and shall be applied either retrospectively to each period presented or as a cumulative-effect adjustment as of the date of adoption. In April 2015, the FASB deferred the effective date of ASU 2014-09 to fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017. The Company is currently in the process of determining the impact of adoption of the provisions of ASU 2014-09 on its financial statements and related disclosures.

GOING CONCERN

GOING CONCERN	12 Months Ended
	Dec. 31, 2015
Text Block [Abstract]
GOING CONCERN	NOTE 3 GOING CONCERN The Company’s financial statements have been prepared on a going concern basis which contemplates the realization of assets and the liquidation of liabilities in the ordinary course of business. The Company has incurred substantial losses from operations causing negative working capital and negative operating cash flows, which raise substantial doubt about the Company’s ability to continue as a going concern. The Company sustained a net loss for the year ended December 31, 2015 of $57,899,169 and a net loss for the year ended December 31, 2014 of $21,727,818, and has an accumulated deficit of $121,903,865 as of December 31, 2015. The Company intends to develop its products and expand its customer base, but does not have sufficient realized revenues or operating cash flows in order to finance these activities internally. As a result, the Company intends to seek financing in order to fund its working capital and development needs. The Company has been able to meet its short-term needs through private placements of convertible preferred securities, an initial public offering (“IPO”), a secondary public offering, convertible debt financing and the sale and leaseback of analyzers used to report test results. The Company will continue to seek funding through the issuance of additional equity securities, debt financing, the sale and leaseback of analyzers, or a combination of these items. Any proceeds received from these items could provide the needed funds for continued operations and development programs. The Company can provide no assurance that it will be able to obtain sufficient additional financing that it needs to alleviate doubt about its ability to continue as a going concern. If the Company is able to obtain sufficient additional financing proceeds, the Company cannot be certain that this additional financing will be available on acceptable terms, if at all. To the extent the Company raises additional funds by issuing equity securities, the Company’s stockholders may experience significant dilution. Any debt financing, if available, may involve restrictive covenants that impact the Company’s ability to conduct business. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. If the Company is unable to obtain additional financings, the impact on the Company’s operations will be material and adverse.

PROPERTY AND EQUIPMENT

PROPERTY AND EQUIPMENT	12 Months Ended
	Dec. 31, 2015
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT	NOTE 4 PROPERTY AND EQUIPMENT Property and equipment consisted of the following at December 31, 2015 and December 31, 2014: December 31, 2015 2014 Construction in progress $ 680,679 $ 1,133,654 Analyzers 5,045,481 1,139,352 Computers and office equipment 462,441 290,754 Machinery and equipment 2,372,558 1,060,993 Leasehold improvements 393,271 366,945 Furniture and fixtures 72,618 16,145 Equipment under capital lease 2,148,476 2,148,476 11,175,522 6,156,319 Less: accumulated depreciation and amortization (3,433,531 ) (1,918,852 ) Total property and equipment, net $ 7,741,991 $ 4,237,467 The total expense for depreciation of fixed assets and amortization of leasehold improvements was $1,514,679 and $1,040,531 for the years ended December 31, 2015 and 2014, respectively. Of this amount $1,199,183 and $601,947 was for depreciation of equipment under capital leases for the year ended December 31, 2015 and 2014, respectively.

ACCRUED EXPENSES

ACCRUED EXPENSES	12 Months Ended
	Dec. 31, 2015
Payables and Accruals [Abstract]
ACCRUED EXPENSES	NOTE 5 ACCRUED EXPENSES Accrued liabilities consisted of the following as of December 31, 2015 and 2014: December 31, 2015 2014 Accrued payroll $ 1,094,666 $ 421,645 Royalties 75,642 166,540 Accrued interest 44,291 — Accrued property and use tax 10,905 10,905 Other 87,645 13,269 Total accrued liabilities $ 1,313,149 $ 612,359

LEASE COMMITMENTS

LEASE COMMITMENTS	12 Months Ended
	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
LEASE COMMITMENTS	NOTE 6 LEASE COMMITMENTS Capital Leases The Company has entered into two lease agreements for the sale-leaseback of molecular diagnostic analyzers. The first agreement was entered into in November 2013 and provided for the sale of 125 molecular diagnostic analyzers for a sales price of $2,500,000, which are being leased back for a base period of thirty-six monthly payments of $74,875. The second agreement was entered into in April 2014 for the sale of 75 molecular diagnostic analyzers for a sales price of $1,500,000, which are being leased back for a base period of twenty-four monthly payments of $64,665. At the end of each lease term, the leases shall automatically renew for twelve additional months at the current monthly rate unless the Company gives written notice 150 days prior to the end of the lease. If timely notice is given the Company shall have the opportunity to: 1) repurchase the analyzers for a negotiated purchase price, not to exceed forty percent of their original cost; or 2) terminate the lease, return the property and enter into a new lease with new property that replaces the property of the old lease. Both the Company and the lessor shall have the right to reject any terms of option 1 or 2 and if rejected, the 12 month extension shall apply. As such, the Company is amortizing the capital lease over a forty-eight month period for the first agreement and a thirty-six month period for the second agreement. The second agreement also has a rewrite clause wherein the leasing company agrees to use its commercially best efforts to rewrite the lease agreement at more favorable terms when the Company raises sufficient capital to cover current and future expenses for a minimum of 12 months. The Company’s obligations under the lease agreements are secured by a $500,000 letter of credit. The Letter of Credit was issued by a bank at the behest of a non-profit foundation and Spring Forth Investments LLC both of which are related parties through Mr. David Spafford, a director of the Company. The Company is obligated to reimburse the non-profit foundation and Spring Forth Investments LLC for any draws made under the Letter of Credit. The lease agreement is also secured by personal guarantees from Mr. Ryan Ashton, the Chief Executive Officer of the Company, and Mr. Spafford (See Note 14 RELATED PARTY TRANSACTIONS). The lease is accounted for as a capital lease sale-leaseback transaction in accordance with ASC 840, “Leases”. Annual future minimum lease payments of capital leases for the next five years are as follows: Years ended December 31, 2016 $ 1,694,006 2017 923,908 Total capital lease payments 2,617,914 Less amount representing interest (461,078 ) Total future minimum lease payments 2,156,836 Less current portion of capital leases (1,305,426 ) Long term portion of capital leases $ 851,410 Operating leases The Company leases approximately 33,000 square feet of building space located in Salt Lake City, Utah pursuant to two lease agreements totaling $21,226 in base rent per month. The leases expire on April 30, 2016 and each have two options, with each option for a three year renewal period. We also lease approximately 13,399 square feet of office space located at another location in Salt Lake City, Utah for use as our executive offices and labs. Base rent payments due under the lease are expected to be approximately $1,231,526 in the aggregate over the term of the lease of 65 months beginning on December 1, 2015. While the tenant improvements are being completed, we are leasing temporary office space in the same building on a monthly basis for base rent of $8,437 per month. The Company also leases certain office equipment such as copiers and printers under operating lease agreements that expire at various dates. Amounts charged to expense under operating leases were $279,296 and $293,773 for the years ended December 31, 2015 and 2014, respectively. Operating lease commitments for the next five years are as follows: Years ended December 31, 2016 $ 355,797 2017 246,255 2018 252,092 2019 259,132 2020 266,455 Total operating lease commitments $ 1,379,731

NOTES PAYABLE

NOTES PAYABLE	12 Months Ended
	Dec. 31, 2015
Debt Disclosure [Abstract]
NOTES PAYABLE	NOTE 7 NOTES PAYABLE The Company purchased certain machinery and equipment under two note payable agreements which consist of the following as of December 31, 2015 and 2014: December 31, 2015 2014 Note payable, 15.2% interest, monthly payments of $1,328, due February 6, 2016, secured by equipment $ 2,607 $ 16,938 Note payable, 10.0% interest, monthly payments of $3,161, due January 1, 2016, secured by equipment 3,086 38,749 Total notes payable 5,693 55,687 Less: current portion of notes payable (5,693 ) (49,994 ) Long term portion of notes payable $ — $ 5,693

CONVERTIBLE NOTES PAYABLE

CONVERTIBLE NOTES PAYABLE	12 Months Ended
	Dec. 31, 2015
Text Block [Abstract]
CONVERTIBLE NOTES PAYABLE	NOTE 8 CONVERTIBLE NOTES PAYABLE On December 30, 2015, the Company entered into a Securities Purchase Agreement (“SPA”) with certain investors pursuant to which it agreed to issue $22.1 million in senior secured convertible notes (“Notes”) and Series D Warrants (further described below). The Notes are convertible into 11,945,946 shares of Common Stock at a price equal to $1.85 per share, subject to adjustment for certain dilutive events and currently subject to a 19.9% cap as described below. $20 million of the notes were issued for cash proceeds totaling $18.4 million with an original issue discount in the amount of $1.6 million which is equal to sixteen (16) months of simple interest at a rate of six percent (6.0%) per annum on the aggregate principal of the Notes (assuming, that the entire aggregate original principal amount remains outstanding through the maturity date). $2.1 million of the Notes were issued to extinguish 1,050,000 outstanding Series C Warrants at an extinguish value of $2.00 per warrant. The Notes are senior secured obligations of the Company and will rank senior to all outstanding and future indebtedness of the Company. They will be secured by a first priority perfected security interest (subject to permitted liens as defined in the Notes) in all of the current and future assets of the Company. The Notes contain standard and customary events of default and the entire principal balance is subject to the default and redemption provisions contained in the Notes, regardless of whether or not any of the proceeds have been released from the Company’s restricted accounts. The Notes also have a provision that the Company is required to reserve at least 120,000,000 shares of authorized and unissued common stock for issuance pursuant to the Notes and associated Series D warrants. In connection with the issuance of the Notes under the SPA, the Company issued Series D Warrants (the “Series D Warrants”), exercisable to acquire 3,503,116 shares of Common Stock, subject to a one time adjustment on December 31, 2016 under the terms of the Series D Warrants (see NOTE 11 WARRANTS). Each Series D Warrant is exercisable by the holder beginning six months after December 30, 2015 and continuing for a period five years thereafter. Each Series D Warrant was exercisable initially at $1.85 per share of common stock, subject to adjustments for certain dilutive events and subject to an exercise price floor equal to $1.16 per share. The Company has agreed to make amortization payments with respect to the Notes in twelve (12) equal installments beginning four (4) months after the original date of issuance of December 30, 2015 (each, an “Installment Date”). On each installment date, assuming certain equity conditions are met, the installment payment shall automatically be converted into shares of Common Stock at (i) at 80% of the five day volume weighted average price of the common stock for the first four payments and (ii) at 85% of the five day volume weighted average price of the common stock for the last 8 payments with both conversion rates being subject to a floor conversion price of $0.20. Under the terms of the Notes, at closing the Company received an initial tranche of $4.6 million for immediate use for general corporate purposes. The remaining cash proceeds of $13.8 million are being held in a restricted account and will be released to the Company from the Company’s restricted accounts in subsequent equal tranches subject to certain equity conditions and the following terms and conditions: (1) 25% will be released 30 trading days following the later of (i) the “Control Account Release Eligibility Date” and (ii) the first installment date under the Note, (2) 25% will be released 90 trading days following the Control Account Release Eligibility Date and (3) 25% will be released 120 trading days following the Control Account Release Eligibility Date. “Control Account Release Eligibility Date” means the later of (x) the date the Company obtains the required stockholder approval of the issuance of the shares of common stock upon conversion of the notes pursuant to the rules of the NASDAQ Stock Market and (y) the earlier of (I) the date a resale registration statement registering all of the shares of Common Stock issuable upon conversion of the Notes and (II) the initial date the shares of Common Stock issuable upon conversion of the Notes may be freely sold by a non-affiliate of the Company pursuant to Rule 144 of the Securities Act of 1933, as amended (the “Securities Act”). If shareholder approval is not obtained the Notes will go into default and restricted cash will not be released. The dilutive events that provide for the adjustment of the conversion price of the Notes and the exercise price of the Series D Warrants relate to any transaction in which the Company issues or is deemed to have issued shares of common stock for consideration per share less than the conversion price then in effect. The issuance of shares of common stock upon conversion of the Notes is subject to the rules of the NASDAQ Capital Market which requires an initial cap of 19.9% of the Company’s issued and outstanding shares of common stock on December 30, 2015 unless and until the Company’s stockholders approve removal of the cap. Further, the current exercise price floor of $1.16 on the exercise price of the Series D Warrants is subject to removal upon approval of the Company’s stockholders at which point the exercise price of the Series D Warrants will automatically reset pursuant to its anti-dilution provisions as if the exercise price floor was not applicable since the issuance of the Series D Warrants. Convertible Notes of $20 Million Issued for Cash $20 million of the Notes were issued for cash proceeds of $18.4 million with an original issue discount in the amount of $1.6 million. In addition the Company incurred debt issuance costs in the amount of $568,685. The conversion feature in the Notes represents an embedded derivative that requires bifurcation due to the ratchet provision described above related to the conversion feature. The provisions in the Series D Warrants also require the Company to account for the warrants as derivative liabilities. The original issue discount, the fair value of the embedded conversion feature, the fair value of the Series D Warrants and the debt issuance costs are all together considered the debt discount. Any excess of the total debt discount and the face value of the convertible notes are recorded to interest expense in the statement of operations. The initial fair value of the embedded conversion feature on the $20 million portion of the note was valued using a binomial model with Monte Carlo simulation, resulting in a fair value of $14,788,365. The initial fair value of the Series D Warrants related to the $20 million note was also valued using a binomial model with Monte Carlo simulation, resulting in a fair value of $13,637,132. The Company recorded a charge to interest expense in the amount of $10,594,182 in the statement of operations for the year ended December 31, 2015, representing the excess of the total debt discount over the face value of the convertible notes. The Company recorded a debt discount in the amount of $20 million which will be amortized over the life of the note using the effective interest method. As of December 31, 2015, $63,717 of the debt discount had been amortized to interest expense. Convertible Notes of $2.1 Million Issued for Series C Warrants $2.1 million of the Notes and related Series D Warrants were issued to extinguish 1,050,000 outstanding Series C Warrants. Since the Series C Warrants were derivative liabilities at the time of the transaction, the Company has accounted for this as an extinguishment of liabilities. Accordingly, all consideration issued to extinguish the liabilities were recorded at their fair value on the date of the extinguishment and the liabilities extinguished were removed at their carrying value. Since the liabilities extinguished were derivative liabilities, their carrying value is continuously adjusted to equal their fair value. The fair value of the Series C Warrants that were extinguished was calculated using the predetermined inputs to Black Scholes formula as defined in the Series C Warrant, resulting in a fair value of $2,340,240 for the extinguished warrants. The initial fair value of the embedded conversion feature on the $2.1 million portion of the Notes was valued using a binomial model with Monte Carlo simulation, resulting in a fair value of $1,865,729. The initial fair value of the Series D Warrants related to the $2.1 million note was also valued using a binomial model with Monte Carlo simulation, resulting in a fair value of $2,412,574. The host debt instrument’s fair value was deemed to be $2.1 million. The Company recorded a loss in the amount of $4,038,063 in its statement of operations for the year ended December 31, 2015, representing the excess of the consideration provided over the liability extinguished. The following table summarizes the convertible notes outstanding at December 31, 2015: Convertible notes payable, principal $ 22,100,000 Debt discounts (19,936,283 ) Net convertible note payable 2,163,717 Less current portion (1,638,717 ) Convertible notes payable, long term $ 525,000

NOTES PAYABLE-RELATED PARTY

NOTES PAYABLE-RELATED PARTY	12 Months Ended
	Dec. 31, 2015
Text Block [Abstract]
NOTES PAYABLE-RELATED PARTY	NOTE 9 NOTES PAYABLE—RELATED PARTY In July 2014, the Company entered into a note agreement for $500,000 with Spring Forth Investments, LLC a company owned by Mr. David Spafford, a director. The original maturity date for the note was July 18, 2015, which was extended by the Company to July 18, 2016 by giving notice and paying an extension fee of $10,000. The note pays interest at an annual rate of 20% and is paid monthly. The Company prepaid the last three months of interest for a total of $25,000 at the time of issuance of the note. As additional consideration for the note, the Company issued 4,000,000 Series D preferred stock units (which were separable into 4,000,000 shares of Series D preferred stock, 20,000 Class A warrants to purchase one share of common stock for every 60 Class A Warrants at an exercise price of $295.20 per share and 20,000 Class B warrants to purchase one share of common stock for every 60 Class B warrants at an exercise price of $12.00 per share) at a value of $100,000 or $0.025 per unit. On the date of the IPO, the 4,000,000 shares of Series D Preferred Stock converted into 334 shares of Common Stock at a conversion ratio of 12,000 to 1. The Series D preferred stock units were accounted as a debt discount to be amortized over the life of the note. As of December 31, 2015 there was no unamortized debt discount. In February 2015, the Company entered into another loan agreement for $250,000 with Spring Forth Investments, LLC. The loan had an interest rate of twelve percent (12%) per year and matured the earlier of (i) 90 days from the date of the loan agreement, or (ii) five days after the closing of a registered public offering of securities of the Company. In April 2015, the Company paid off the note along with the accrued interest in the amount of $4,192 and a termination fee of $12,500.

COMMON AND PREFERRED STOCK

COMMON AND PREFERRED STOCK	12 Months Ended
	Dec. 31, 2015
Equity [Abstract]
COMMON AND PREFERRED STOCK	NOTE 10 COMMON AND PREFERRED STOCK Common Stock The Company had 200,000,000 and 50,000,000 shares of common stock authorized at a par value of $0.0001 per share as of December 31, 2015 and 2014, respectively. As of December 31, 2015 and 2014 there were 10,390,408 and 84,777 shares of common stock issued and outstanding, respectively. The Company has reserved 120,000,000 of authorized but unissued shares of common stock for issuance pursuant to the convertible notes and associated Series D Warrants. During the year ended December 31, 2014, the Company issued 771 shares of common stock to Spring Forth Investments pursuant to the exercise of the conversion option of 9,250,000 shares of Series A preferred stock at a conversion ratio of 12,000 to 1 (SEE NOTE 14 RELATED PARTY TRANSACTIONS). The Company also issued 2,634 shares of common stock to various unaffiliated investors upon the exercise of 158,000 of Class B warrants for cash proceeds of $31,600. In October 2014, the Company completed an IPO, whereby the Company sold 19,167 shares of its common stock and 1,150,000 Series A Warrants, which were sold in units of one share of common stock for every 60 units and one Series A Warrant at a public offering price of $7.00 per unit. Each Series A Warrant is exercisable for one share of common stock for every 60 warrants and one Series B Warrant. In addition, the underwriter was granted 57,500 common warrants and also exercised its option to purchase 172,500 Series A Warrants each of which is exercisable for one share of common stock for every 60 warrants. The shares began trading on the NASDAQ Capital Market on October 9, 2014. The aggregate net proceeds received by the Company from the offering were approximately $6.4 million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company. Upon the closing of the IPO, all outstanding shares of convertible preferred stock converted into 60,279 shares of common stock. During the year ended December 31, 2015, the Company issued 17,917 shares of common stock pursuant to the cash exercise of 1,074,082 Series A Warrants for total net proceeds of $2,252,020. In conjunction with the exercise of the Series A Warrants, 1,074,082 Series B Warrants to purchase shares of common stock were also issued. During the year ended December 31, 2015, the Company issued 176,695 shares of common stock pursuant to the conversion of 2,650,403 shares of Series E Convertible preferred stock at a conversion ratio of 60 preferred shares to 4 common shares. During the year ended December 31, 2015, the Company issued 9,220 shares of common stock pursuant to the cashless exercise of both 508,641 Class A Warrants and 334,889 Class B Warrants. During the year ended December 31, 2015, the Company issued 10,101,480 shares of common stock pursuant to the exercise of 15,630,027 Series C Warrants. Of these, 10,095,080 shares of common stock were issued as a result of the cashless exercise of 15,246,027 Series C Warrants and 6,400 shares of common stock were issued as a result of the cash exercise of 384,000 Series C Warrants for total net proceeds of $979,200. Preferred Stock The Company had 5,000,000 shares of preferred stock authorized at a par value of $0.001 per share as of December 31, 2015 and 2014. As of December 31, 2015 there are 88,347 shares of Series E Preferred Stock issued and outstanding. There were no shares of preferred stock outstanding as of December 31, 2014. The preferred stock may be issued from time to time by the board of directors as shares of one or more classes or series with authority to fix the designation and relative powers including voting powers, preferences, rights, qualifications, limitations, and restrictions relating to the shares of each class or series. During the year ended December 31, 2014 the Company issued 14,888,211 shares of Series C preferred stock for cash in the amount of $366,250 or $0.0246 per share. The Company also sold 285,566,560 shares of Series D preferred stock units for gross proceeds in the amount of $7,139,164 or $0.025 per unit and after deducting offering costs and expenses, the Company received $6,203,636 in net proceeds. The preferred stock units were separated into 285,566,560 shares of Series D preferred stock, 1,427,832 Class A warrants with an exercise price of $4.92 to purchase one share of common stock for every 60 warrants and 1,427,832 Class B warrants with an exercise price of $0.20 to purchase one share of common stock for every 60 warrants. In conjunction with the offering an additional 7,200,000, 466,436 and 251,216 of Series D preferred stock warrants, Class A warrants and Class B warrants, respectively, were granted as part of the offering costs. During the year ended December 31, 2014, the Company converted notes payable in the amount of $400,000 plus $13,129 in accrued interest into 16,525,121 Series D preferred stock units at a conversion price of $0.025 per share. These units consist of 16,525,121 shares of Series D preferred stock, 82,625 Class A warrants with an exercise price of $4.92 to purchase one share of common stock for every 60 warrants and 82,625 Class B warrants with an exercise price of $0.20 to purchase one share of common stock for every 60 warrants. The shares of Series D preferred stock are convertible into shares of common stock at a ratio of 12,000 : 1, at the option of the holder at any time after issuance. The conversion of the notes was pursuant to the terms of the notes that upon a qualified equity financing of at least $5 million the notes would be converted into shares of the equity securities at the price per share at which the equity securities were issued in the qualified equity financing. The sale of the Series D preferred stock units through July 2014 met this threshold and triggered the conversion. During the year ended December 31, 2014, as additional consideration for the issuance of the Spring Forth Note (See NOTE 9 NOTES PAYABLE—RELATED PARTY) the Company issued 4,000,000 Series D preferred stock units (which were separable into 4,000,000 shares of Series D preferred stock, 20,000 Class A warrants with an exercise price of $4.92 to purchase one share of common stock for every 60 warrants and 20,000 Class B warrants with an exercise price of $0.20 to purchase one share of common stock for every 60 warrants) at a value of $100,000 or $0.025 per unit. During the year ended December 31, 2014, Spring Forth Investments exercised its conversion option and converted 9,250,000 shares of Series A preferred stock valued at $1,480,000 into 771 shares of common stock. The Series C and Series D preferred stock had a conversion price adjustment provision that in the event the Company sells shares of any additional stock, subject to certain exceptions, at a price per share less than the original issue price of the respective series preferred stock, the conversion price shall be adjusted to a price equal to the price paid per share for such additional stock. These conversion price adjustment provisions, and other relevant features of the preferred stock, were analyzed in accordance with the provisions of FASB ASC 815, “Derivatives and Hedging”. The Company evaluated the conversion price adjustment provision embedded in the preferred stock and other relevant features and determined, in accordance with the provisions of the referenced accounting guidance, that such conversion option or other relevant features do not meet the criteria requiring bifurcation as a derivative liability of these instruments. The characteristics of the common stock that is issuable upon a holder’s exercise of the conversion option embedded in the convertible preferred stock are deemed to be clearly and closely related to the characteristics of the preferred shares. Further, the Company determined the other relevant features of the preferred stock are clearly and closely related to the equity host and do not qualify for derivative accounting. During the year ended December 31, 2014, the Company filed a seventh amended and restated Certificate of Incorporation authorizing a modification to the number of authorize shares of common stock and preferred stock. The number of common shares authorized was amended to 50,000,000 shares and the number of preferred shares authorized was amended to 5,000,000 shares. In October 2014, upon the closing of the IPO, all outstanding shares of convertible preferred stock converted into 60,279 shares of common stock at a conversion ratio of 12,000 to 1. In February 2015 the Company initiated a Units Offering (the “February 2015 Units Offering”) whereby the Company sold 2,724,000 units at a price of $8.80 per unit for net proceeds of $21.8 million after deducting underwriting commissions and offering costs. Each unit consisted of one share of our Series E Convertible Preferred Stock and eight Series C Warrants (the “Units”). The original terms of the Units provided that shares of Series E Convertible Preferred Stock and the Series C Warrants would automatically separate on August 25, 2015. However, the shares of Series E Convertible Preferred Stock and the Series C Warrants would separate prior to August 25, 2015 if at any time after 30 days from February 25, 2015 the closing price of our common stock was greater than $240.00 per share for 20 consecutive trading days (the “Separation Trigger Date”). The Company refers to this separation herein as Early Separation. In the event of Early Separation, the shares of Series E Convertible Preferred Stock and the Series C Warrants would separate 15 days after the Separation Trigger Date. In June 2015, the above terms of the Series E Convertible Preferred Stock and Series C Warrants were each modified to allow for an optional early separation and conversion upon the cash exercise of all eight of the Series C Warrants within the Unit. In June 2015, 48,000 of the Units were separated early pursuant to the optional early separation resulting in the exercise of 384,000 Series C Warrants into 6,400 shares of common stock for cash proceeds of $979,200. On August 25, 2015 the remaining 2,676,000 Units separated into 2,676,000 shares of Series E Convertible Preferred Stock and 21,408,000 Series C Warrants. Each 60 shares of Series E Convertible Preferred Stock is convertible at the option of the holder into four shares of common stock. The Series E Convertible Preferred Stock has no voting rights. An amendment to the terms of the Series E Convertible Preferred Stock only requires the vote of the holders of Series E Convertible Preferred Stock. With respect to payment of dividends and distribution of assets upon liquidation or dissolution or winding up of the Company, the Series E Preferred Stock shall rank equal to the common stock of the Company. No sinking fund has been established for the retirement or redemption of the Convertible Preferred Stock. As such, the Series E Convertible Preferred Stock is not subject to any restriction on the repurchase or redemption of shares by the Company due to an arrearage in the payment of dividends or sinking fund installments. The Series E Convertible Preferred Stock also has no liquidation rights or preemption rights, and there are no special classifications of our Board of Directors related to the Series E Convertible Preferred Stock. During the year ended December 31, 2015, 14,750 Underwriter Purchase Options were exercised for cash in the amount of $162,250 or $11.00 per option. Pursuant to the exercise of these options, 14,750 shares of Series E Convertible Preferred Stock and 118,000 Series C Warrants were issued. During the year ended December 31, 2015, 2,650,403 shares of Series E Convertible Preferred Stock were converted into 176,695 shares of common stock at a conversion ratio of 60 preferred shares to 4 common shares. As of December 31, 2015, 88,347 shares of Series E Convertible Preferred Stock remain outstanding.

WARRANTS

WARRANTS	12 Months Ended
	Dec. 31, 2015
Derivative Instruments and Hedging Activities Disclosure [Abstract]
WARRANTS	NOTE 11 WARRANTS As of December 31, 2014, the Company had 5,447,940 warrants outstanding to purchase shares of common stock. The following table outlines the warrants outstanding and exercisable as of December 31, 2014: Warrants Outstanding Warrant Common Total Aggregate Expiration Class A 2,041,239 $4.92 60 : 1 34,021 $295.20 April 2021 - July Class B 1,645,845 $0.20 60 : 1 27,431 $12.00 April 2021 - July 2021 Series A 1,322,500 $7.00 60 : 1 22,042 $420.00 October 2015 Common 438,356 $2.00 - $32.00 60 : 1 7,306 $120.00 - $1,920.00 April 2016 - Total Warrants 5,447,940 90,800 During the year ended December 31, 2014 Class A and Class B warrants totaling 2,855,664 were granted as part of the sale for cash of the Series D preferred stock units (see NOTE 10 COMMON AND PREFERRED STOCK). In addition during 2014 prior to the IPO, 1,048,698 common warrants, Class A warrants and Class B warrants to purchase common stock and 7,200,000 warrants to purchase Series D preferred stock were granted in conjunction with the issuance of certain convertible notes payable, consulting services and as financing fees. The Company determined that the fair value of the warrants granted was nominal due to the fair value of the Company’s common stock as of the grant date being nominal as a result of the priority provisions of the preferred stock outstanding at that time. In October 2014, 57,500 common warrants and 1,322,500 Series A warrants were issued in conjunction with our IPO (see NOTE 10 COMMON AND PREFERRED STOCK). In October 2014 upon the closing of the IPO, 2,231,727 outstanding warrants to purchase shares of Series A preferred stock and 7,200,000 outstanding warrants to purchase shares of Series D preferred stock were converted at a ratio of 200 to 1 into 47,158 common warrants to purchase shares of common stock. In September 2014, 157,093 warrants previously issued were amended to eliminate a clause that would cancel the warrant upon the completion of an IPO. The Company recorded an expense for the incremental fair value based on the difference between the fair value of the modified award and the fair value of the original award immediately before it was modified using the Black-Scholes option valuation model to calculate the fair value. The Company determined the incremental fair value of the warrants to be $25,061 which was expensed in the period as the warrants were fully vested. The following is the weighted average of the assumptions used in calculating the fair value of the warrants at an exchange ratio of 60 warrants for one share of common stock after they were modified in September 2014 using the Black-Scholes method: Fair market value of one share of common stock $ 296.40 Aggregate exercise price of 60 warrants $ 600.00 Risk free rate 0.61 % Dividend yield 0.00 % Expected volatility 37.23 % Remaining contractual term 1.97 years The following table summarizes the Preferred A stock warrant activity during the year ended December 31, 2014: Preferred A Weighted Weighted As of December 31, 2014: Warrants outstanding as of January 1, 2014 2,231,727 $ 0.16 3.1 Granted — — — Converted (2,231,727 ) 0.16 2.3 Expired — — — Warrants outstanding as of December 31, 2014 — $ — — The following table summarizes the preferred D stock warrant activity during the year ended December 31, 2014: Preferred D Weighted Weighted As of December 31, 2014: Warrants outstanding as of January 1, 2014 — — — Granted 7,200,000 $ 0.025 6.8 Converted (7,200,000 ) $ 0.025 6.7 Expired — — — Warrants outstanding as of December 31, 2014 — $ — — As of December 31, 2015, the Company had 13,219,597 warrants outstanding to purchase shares of common stock. The following table outlines the warrants outstanding and exercisable as of December 31, 2015: Warrants Outstanding Warrant Common Total Aggregate Expiration Class A 1,532,598 $0.03 60 : 1 25,566 $1.85 April 2021 - July 2021 Class B 1,310,956 $0.03 60 : 1 21,862 $1.85 April 2021 - July 2021 Series B 1,074,082 $8.75 60 : 1 17,917 $525.00 March 2021 - July 2021 Series C 5,229,973 $2.55 60 : 1 87,167 $153.00 January 2017 Series D 3,503,116 $1.85 1 : 1 3,503,116 $1.85 June 2021 Subordination 105,516 $1.85 1 : 1 105,516 $1.85 June 2021 Common 463,356 $0.03 - $32.00 60 : 1 7,735 $1.85 - $1,920.00 April 2016 - July 2021 Total Warrants 13,219,597 3,768,879 Class A Warrants During the year ended December 31, 2015, 508,641 Class A Warrants were exercised pursuant to the cashless exercise provision of the warrant resulting in the issuance of 3,936 shares of common stock. The Class A Warrants include a provision which provides that the exercise price of the Class A Warrants will be adjusted in connection with certain equity issuances by the Company. In March 2015, as a result of the February 2015 Unit Offering, the price adjustment provision was triggered for our Class A Warrants and the exercise price was adjusted from $4.92 to $2.20. In December 2015, the price adjustment was triggered again for our Class A Warrants as the Company closed a senior secured convertible note financing and the exercise price was adjusted from $2.20 to $0.03. Class B Warrants During the year ended December 31, 2015, 334,889 Class B Warrants were exercised pursuant to the cashless exercise provision of the warrant resulting in the issuance of 5,284 shares of common stock. The Class B Warrants include a provision which provides that the exercise price of the Class B Warrants will be adjusted in connection with certain equity issuances by the Company. In December 2015, the Company closed a senior secured convertible note financing and the price adjustment provision was triggered for our Class B Warrants and the exercise price was adjusted from $0.20 to $0.03. Series A Warrants During the year ended December 31, 2015, 1,074,082 Series A Warrants were exercised into 17,917 shares of common stock resulting in net cash proceeds of $2,252,020. The Series A Warrants include a provision which provides that the exercise price of the Series A Warrants will be adjusted in connection with certain equity issuances by the Company. In March 2015, as a result of the February 2015 Unit Offering, the price adjustment provision was triggered for our Series A Warrants and the exercise price was adjusted from $7.00 to $2.20. The Series A Warrants expired on October 15, 2015 and all remaining 248,418 outstanding Series A Warrants expired unexercised. Series B Warrants The Company sold Units in connection with the Company’s IPO in October 2014, with one Unit consisting of one share of common stock and one Series A Warrant to purchase: (i) one share of common stock for every 60 Series A Warrants and (ii) one Series B Warrant to purchase one share of common stock for every 60 Series B Warrants. The Series B Warrants are only issued upon the exercise of the Series A Warrants, are exercisable immediately at an exercise price of 125% of the public offering price and expire 6 years from the date of issue. The exercise price and the number of shares for which each Series B Warrant may be exercised is subject to adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our common stock. In addition, subject to certain exceptions, the exercise price of the Series B Warrants is subject to reduction if the Company issues shares of common stock (or securities convertible into common stock) in the future at a price below the then current market price. There have been no issuances that have triggered the price adjustment provision on the Series B Warrants. During the year ended December 31, 2015, the Company issued 1,074,082 Series B Warrants pursuant to the exercise of 1,074,082 Series A Warrants. Series C Warrants In connection with the February 2015 Units Offering, the Company issued Series C Warrants to purchase 21,792,000 shares of common stock as part of the Units sold in the follow-on offering (see NOTE 10 COMMON AND PREFERRED STOCK) with and exercise price of $2.55 and expire in five years. The exercise price and number of shares of common stock issuable upon exercise is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our common stock and the exercise price. The Series C Warrants have a cashless exercise provision where in lieu of payment of the exercise price in cash, the holder may receive, at the Company’s discretion, either a cash payment of a predetermined Black Scholes Value of the number of shares the holder elects to exercise, or a number of shares of the Company’s common stock determined according to a cashless exercise formula using the predetermined Black Scholes Value. On December 11, 2015, an amendment was made to the Series C Warrants to require that all warrants be exercised within 25 trading days or be subject to a mandatory exercise provision. In June 2015, 48,000 of the Units were separated early pursuant to the optional early separation as 384,000 Series C Warrants were exercised into 6,400 shares of common stock resulting in cash proceeds of $979,200. On August 25, 2015 the remaining 2,676,000 Units separated into 2,676,000 shares of Series E Convertible Preferred Stock and 21,408,000 Series C Warrants. From August 25, 2015 through December 31, 2015, 15,128,027 Series C Warrants were exercised pursuant to the cashless exercise provision resulting in the issuance of 9,899,174 shares of Common Stock. During the year ended December 31, 2015, 14,750 Underwriter Purchase Options were exercised for cash in the amount of $162,250. Upon the exercise of these options, 118,000 Series C Warrants were issued and immediately exercised pursuant to the cashless exercise provision resulting in the issuance of 195,906 shares of common stock. As of December 31, 2015, 5,229,973 Series C Warrants remain outstanding. Had the cashless exercise provision been exercised by all holders of our Series C Warrants at December 31, 2015, the Company would have had to either pay $11.7 million in cash or issue 9,962,354 shares of common stock. The number of shares of common stock that would be required to satisfy the cashless exercise provision increases as the price of the Company’s stock decreases and decreases as the price of the Company’s stock increases. Series D Warrants In connection with the issuance of the Notes under the Securities Purchase Agreement, the Company issued Series D Warrants (the “Series D Warrants”), exercisable to acquire 3,503,116 shares of Common Stock. Each Series D Warrant is exercisable by the holder beginning six months after December 30, 2015 and continuing for a period five years thereafter. Each Series D Warrant will be exercisable initially at an exercise price of $1.85 per share, subject to adjustments for certain dilutive events and subject to an exercise price floor equal to $1.16 per share. On December 31, 2016, the number of warrants issuable upon exercise of the Series D Warrants will be increased to equal the difference, if positive, obtained by subtracting (x) the shares of Common Stock issuable under the Warrants on the date of issuance from (y) 16.6% of the sum of the number of shares of Common Stock actually outstanding on December 31, 2016, plus the number of shares of Common Stock deemed to be outstanding pursuant to all outstanding options or convertible securities of the Company. The Series D Warrants are exercisable on a cashless basis in the event that there is no effective registration statement under the Securities Act covering the resale of the shares of Common Stock issuable upon exercise of the Series D Warrants. Pursuant to the registration rights agreement between the investors under the Securities Purchase Agreement and the Company, the Company is required to file a registration statement for these shares of Common Stock and the Company intends to file the registration statement in early 2016. Subordination Warrants The Subordination Warrants were issued to Spring Forth Investments LLC and Utah Autism Foundation in relation to their agreement to enter into subordination agreements with the collateral agent in the Note Financing whereby each agreed to subordinate their debt to the Notes issued in the Note Financing. The Subordination Warrants have the same general material terms and conditions of the Series D Warrants. The Subordination Warrants are exercisable for 105,516 shares of common stock. On December 31, 2016, the number of warrants issuable upon exercise of the Subordination Warrants will be increased to equal the difference, if positive, obtained by subtracting (x) the shares of common stock issuable under the Subordination Warrants on the date of issuance from (y) 0.5% of the sum of the number of shares of common stock actually outstanding on December 31, 2016, plus the number of shares of common stock deemed to be outstanding pursuant to all outstanding options or convertible securities of the Company. Each Subordination Warrant is exercisable by the holder beginning six months after December 30, 2015 and continuing for a period five years thereafter. Each Subordination Warrant will be exercisable initially at a price of $1.85 per share, subject to adjustments for certain dilutive events (same as the Series D Warrants) and subject to an exercise price floor equal to the Series D Warrant exercise floor price of $1.16 per share. Common Warrants For the year ended December 31, 2015, the Company granted 25,000 Common Stock warrants to a consultant of the Company. The warrants are fully vested, have an exercise price of $2.56 and expire in August 2020. The Company recorded an expense in the amount of $54,489 on the date of grant which represents the fair value of the warrants. The Company estimates the fair value of the warrants at grant date using a Black-Scholes valuation model. The estimates in the Black-Scholes option-pricing model are based, in part, on assumptions, including a stock price volatility of 127.37%, the warrant life of 5 years, a risk free rate of 1.53%, the fair value of $153.60 of the equity stock underlying the option and the aggregate exercise price of $153.60 for one share of common stock. The following table summarizes the common stock warrant activity during the years ended December 31, 2015 and 2014: Common Weighted Weighted As of December 31, 2014: Warrants outstanding as of January 1, 2014 274,420 8.00 4.2 Granted 5,331,520 3.91 5.5 Exercised (158,000 ) 0.20 6.6 Expired — — — Warrants outstanding as of December 31, 2014 5,447,940 4.17 4.9 As of December 31, 2015: Warrants outstanding as of January 1, 2015 5,447,940 4.17 4.9 Granted 26,617,714 2.71 4.3 Exercised (17,547,639 ) 2.47 4.0 Expired (1,298,418 ) 2.48 3.4 Warrants outstanding as of December 31, 2015 13,219,597 2.71 4.7 Underwriters’ Unit Purchase Option In connection with the February 2015 Units Offering, the Company issued to the representative of the underwriters’ a Unit Purchase Option (“Option”) to purchase a number of our Units equal to an aggregate of 5% of the Units sold or 136,200 Units. The purchase option has an exercise price equal to 125% of the public offering price of the Units or $11.00, and the units may be exercised on a cashless basis and will expire 5 years from the date of issue. Each Unit consists of one share of Series E Convertible Preferred Stock and eight Series C Warrants. During the year ended December 31, 2015, 14,750 Underwriter Purchase Options were exercised for cash in the amount of $162,250. Pursuant to the exercise of these options, 14,750 shares of Series E Convertible Preferred Stock were issued and immediately converted into 984 shares of common stock and 118,000 Series C Warrants were issued and immediately exercise pursuant to the cashless exercise provision into 195,906 shares of common stock. As of December 31, 2015, 121,450 Unit Purchase Options remain outstanding.

DERIVATIVE LIABILITIES

DERIVATIVE LIABILITIES	12 Months Ended
	Dec. 31, 2015
Derivative Instruments and Hedging Activities Disclosure [Abstract]
DERIVATIVE LIABILITIES	NOTE 12 DERIVATIVE LIABILITIES The derivative liability for our instruments classified as derivative liabilities are recorded at fair value at inception and subsequently re-measured to fair value as long as such instruments are classified as derivative liabilities. Changes in the fair value of the derivative liability was included as a component of Other income (expense) and has no effect on the Company’s cash flows. The valuation methodologies used vary by instrument and include a modified Black-Scholes option valuation model utilizing the fair value of underlying common stock and a binomial model with Monte Carlo simulation. The Company has determined the fair value measurements to be a level 3 measurement (see NOTE 2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES). Class A Warrants, Class B Warrants, Series A Warrants, Series B Warrants and Certain Common Warrants Our Class A Warrants, Class B Warrants, Series A Warrants and certain common warrants, have an exercise price adjustment provision that in the event the Company sells shares of any additional stock, subject to certain exceptions, at a price per share less than the original exercise price of the respective warrant, the exercise price shall be adjusted to a price equal to the price paid per share for such additional stock. Our Series B Warrants have an exercise price adjustment provision that in the event the Company sells shares of any additional stock, subject to certain exceptions, at a price per share less than the then current market price, the exercise price shall be adjusted to a price equal to the price paid per share for such additional stock. Such exercise price adjustments prohibit the Company from being able to conclude that the warrants are indexed to the Company’s own stock. Accordingly, these warrants are accounted for as derivative liabilities and are recorded at fair value at each reporting date with the change in fair value being recorded in earnings for the period. In March 2015, as a result of the February 2015 Unit Offering, the price adjustment provision was triggered for our Class A Warrants, Series A Warrants and certain common warrants. In December 2015, as a result of the senior secured convertible note financing, the price adjustment provision was again triggered and the exercise price for our Class A, Class B and certain common warrants was adjusted to $0.03 or the equivalent of $1.85 per share. The fair value of these warrants was calculated using a modified Black-Scholes option valuation model utilizing the fair value of underlying common stock. Black-Scholes has inherent limitations for use in the case of a warrant with a price protection provision, since the model is designed to be used when the inputs to the model are static throughout the life of a security. Due to the significant variance between the fair market value of the stock and the exercise price, the Black-Scholes option-pricing model resulted in a fair value that equals the current market value of the stock. As such, the fair value of the Class A, Class B and certain other common warrants was estimated to be $0.94 per share, which was the closing price of the common stock on December 31, 2015. The total fair value of these warrants at December 31, 2015 was $61,941. Series C Warrants and Unit Purchase Option Our Series C Warrants contain a cashless exercise provision using a predetermined Black Scholes Value. Such provision, if exercised by the holder, would require the Company to settle these warrants, at its option, either by cash payment or the granting of a variable number of common shares. This provision results in the potential for the Company to either have to net cash settle the warrant or potentially issue an indeterminate number of common shares which prohibits the Company from being able to conclude that the warrants are indexed to the Company’s own stock. Accordingly, the warrants and the unit purchase option are accounted for as derivative liabilities and are recorded at fair value at each reporting date with the change in fair value being recorded in earnings for the period. The Series C Warrants have predetermined inputs to Black Scholes formula for the determination of the fair value of the warrant which the Company used for the calculation of the fair value of the Series C Warrants at December 31, 2015. The inputs to the Black-Scholes formula are a stock price volatility of 135.00%, the warrant life of 5 years, a risk free rate of 1.61%, the fair value of $153.00 of the equity stock underlying the option and the exercise price of $2.55. The total fair value of these warrants at December 31, 2015 was $12,404,503. Convertible Notes Conversion Feature The convertible notes issued on December 30, 2015 contain provisions that protect holders from future issuances of the Company’s common stock at prices below such convertible notes’ respective conversion price. These provisions could result in modification of the conversion price due to a future equity offering and as such the conversion feature cannot be considered indexed to the Company’s own stock. The note also provides that the Company will repay the principal amount at an initial conversion rate subject to certain adjustment with a floor price. These features represent an embedded derivative that requires bifurcation and was recorded at fair value at issuance and again at year end with the change in fair value being recorded in earnings for the period. The Company determined the fair value of the conversion feature using a binomial model with Monte Carlo simulation to reflect different scenarios where reset may be triggered using the following assumptions: Trading price of common stock on measurement date $0.94 - $1.10 Conversion price (1) $0.87 - $1.03 Risk free interest rate (2) 0.86% Conversion notes lives in years 1.33 Expected volatility (3) 215% Expected dividend yield (4) — Expected probability of shareholder approval (5) 85% (1) The conversion price of the convertible notes was calculated based the formula in the Notes agreement as of the respective measurement date (2) The risk-free interest rate was determined by management using the 1.5-year Treasury Bill as of the respective measurement date. (3) The volatility factor was estimated by using the historical volatilities of the Company’s trading history. (4) Management determined the dividend yield to be 0% based upon its expectation that it will not pay dividends for the foreseeable future. (5) Management has estimated a probability of 85% that shareholder approval will be obtained for the removal of the 19.9% conversion cap. This is based on past shareholder voting history and discussions with current shareholders and consultants. Series D Warrants and Subordination Warrants In connection with the issuance of convertible notes on December 30, 2015, the Company issued Series D Warrants to acquire 3,503,116 shares of common stock. In addition, the Company issued 105,510 shares of Subordination Warrants. The Company has determined that the provisions contained in the Series D Warrants and the Subordination Warrants could result in modification of the warrants exercise price resulting in a variable number of additional common shares that could be issued. These warrants also contain a provision for a one-time adjustment to the number of warrants issued. On December 31, 2016 the warrant share number for the Series D Warrants and the Subordination Warrants shall be increased by the difference, if positive, between the number of Series D Warrants and Subordination Warrants issued on the issuance date and 16.6%, in the case of the Series D Warrants, and 0.5%, in the case of the Subordination Warrants, of the number of shares of common stock actually outstanding or deemed to be outstanding on December 30, 2016. The issuance of shares of common stock upon conversion of the Notes is subject to an initial cap of 19.9% of the Company’s issued and outstanding shares of common stock on December 31, 2015 unless and until the Company’s shareholders approve removal of the cap (see NOTE 8 CONVERTIBLE NOTES PAYABLE). These provisions represent a derivative liability that requires recording at fair value at issuance and again at year end with the change in fair value being recorded in earnings for the period. The Company used a binomial model with Monte Carlo simulation to reflect different scenarios where reset may be triggered and to project the range of the additional shares to be issued on December 31, 2016 due to the 16.6% and 0.5% requirement. The fair values of the Series D Warrants and Subordination Warrants were determined using a binomial valuation model which included additional warrants to be issued on December 31, 2016 and the following assumptions: Trading price of common stock on measurement date $0.94 - $1.10 Conversion price (1) $1.85 Risk free interest rate (2) 1.80% Warrant lives in years 5.50 Expected volatility (3) 215% Expected dividend yield (4) — (1) The exercise price of the Series D Warrants calculated by 120% of the arithmetic average of five weighted average price of the common stock on the five consecutive trading days prior to issuance date on December 30, 2015. (2) The risk-free interest rate was determined by management using the 5-year Treasury Bill as of the respective measurement date. (3) The volatility factor was estimated by using the historical volatilities of the Company’s trading history. (4) Management determined the dividend yield to be 0% based upon its expectation that it will not pay dividends for the foreseeable future. The following summarizes the total change in the value of the derivative liabilities during the years ended December 31, 2015 and 2014: As of December 31, 2014: Balance at January 1, 2014 $ — Issuance of warrants and option 2,487,726 Exercise of warrants (885,259 ) Change in fair value of warrant and option liability 8,396,169 Balance at December 31, 2014 $ 9,998,636 As of December 31, 2015: Balance at January 1, 2015 $ 9,998,636 Issuance of warrants, unit purchase option and convertible note 56,026,979 Exercise and expiration of warrants and unit purchase option (42,558,951 ) Change in fair value of warrant, option and conversion feature liability 19,714,808 Balance at December 31, 2015 $ 43,181,472

EMPLOYEE STOCK OPTIONS

EMPLOYEE STOCK OPTIONS	12 Months Ended
	Dec. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
EMPLOYEE STOCK OPTIONS	NOTE 13 EMPLOYEE STOCK OPTIONS The Company has three stock based employee compensation plans, the 2006 Stock Option Plan, the 2014 Stock Option Plan, and the Omnibus Plan pursuant to which certain employees and non-employee directors have been granted options to purchase common stock. The Company had 792,534 and 703,034 employee stock options outstanding as of December 31, 2015 and 2014, respectively. All options vest in installments over a three to four year period and expire ten years from the date of grant. During the year ended December 31, 2014, the Company awarded 619,781 common stock options to certain employees and non-employee directors under the 2014 Stock Option and Omnibus Option plans. The options have an exercise price ranging from $2.00 to $7.00 per option expire ten years from date of issuance and vest over a period of three to four years. Pursuant to the reverse stock split on December 11, 2015, the exchange ratio upon the exercise of the options was adjusted such that for every 60 options exercised, one share of common stock would be issued. The Company accounts for employee stock options according to FASB ASC 718 which requires the Company to calculate the fair value of the stock options on the date of grant and amortize over the vesting period of the options. The Company determined the value of 483,000 options granted prior to our IPO in October 2014 to be nominal due to the fair value of the Company’s common stock as of the grant date being nominal as a result of the priority provisions of the preferred stock outstanding at the time. The Company determined the fair value of the remaining 136,784 stock options granted after our IPO in October 2014 to be $306,709 of which $54,394 was expensed in 2014 with the remainder to be expensed over the vesting term of the options. Also in the year ended December 31, 2014, the Company completed a tender offer to eligible employees to exchange 103,250 employee stock options under the 2006 Stock Option Plan for new options under the 2014 Stock Option Plan. The new options have an exercise price of $3.50 per option with all other terms the same as the original terms under the 2006 Option Plan. Pursuant to the reverse stock split on December 11, 2015, the exchange ratio upon the exercise of the options was adjusted such that for every 60 options exercised, one share of common stock would be issued. These transactions are accounted for under the provisions of FASB ASC 718 as a modification of a stock based compensation award and require the Company to record an expense for the incremental fair value based on the difference between the fair value of the modified award and the fair value of the original award immediately before it was modified. The Company used the Black-Scholes option valuation model to calculate the fair value of the stock options. The Company determined the incremental fair value of the options to be $223,031 which was expensed in 2014 as the options are fully vested. The following is the range of the weighted average of the assumptions used in calculating the fair value of the options granted after our IPO in October 2014 and the options modified in 2014 using the Black-Scholes method: Fair market value of one share of common stock $ 296.40 - 316.80 Aggregate exercise price of 60 options $ 210.00 - 354.60 Risk free rate 1.06% - 1.70% Dividend yield 0.00% Expected volatility 46.31% - 54.97% Expected term 2.74 - 6.06 years For the year ended December 31, 2015, the Company awarded 117,500 common stock options under the Omnibus Plan to certain employees and non-employee directors with an exercise price of $2.56 per option that expire in ten years and vest over a three and four year period. The Company determined the value of the 117,500 options granted during the year ended December 31, 2015 to be $268,202 of which $29,309 was expensed in 2015 with the remainder to be expensed over the vesting term of the options. The following is the weighted average of the assumptions used in calculating the fair value of the options granted in 2015 using the Black-Scholes method: Fair market value of one share of common stock $ 153.60 Aggregate exercise price of 60 options $ 153.60 Risk free rate 1.71% Dividend yield 0.00% Expected volatility 127.52% Expected term 6.14 years The following table summarizes the Company’s total option activity for the years ended December 31, 2015 and 2014: Options Weighted Weighted Intrinsic As of December 31, 2014: Options outstanding as of January 1, 2014 115,750 $ 30.00 6.3 Granted 619,784 $ 2.86 9.4 Exercised — — — Forfeited/expired (32,500 ) $ 8.92 5.7 Options outstanding as of December 31, 2014 703,034 $ 2.98 8.8 $ — As of December 31, 2015: Options outstanding as of January 1, 2015 703,034 $ 2.98 8.8 Granted 117,500 $ 2.56 9.6 Exercised — — — Forfeited/expired (28,000 ) $ 5.16 8.6 Options outstanding as of December 31, 2015 792,534 $ 2.84 8.0 $ — Outstanding and exercisable stock options as of December 31, 2015 and 2014 are as follows: Options Outstanding Options Exercisable Number of Remaining Exercise Number of Exercise Intrinsic December 31, 2014 703,034 8.8 $ 2.98 117,404 $ 3.86 $ — December 31, 2015 792,534 8.0 $ 2.84 328,445 $ 3.07 $ — The estimated fair value of the Company stock options, less expected forfeitures, is amortized over the options vesting period on the straight-line basis. The Company recognized the following equity-based compensation expenses during the twelve months ended December 31, 2015 and 2014: December 31, 2015 2014 Stock based compensation expense $ 110,123 $ 297,244 As of December 31, 2015 and 2014, there were $408,907 and $252,315 of total unrecognized compensation cost with a remaining vesting period of 2.71 and 3.44 years, respectively.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	12 Months Ended
	Dec. 31, 2015
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 14 RELATED PARTY TRANSACTIONS The Company’s obligations pursuant to its sale-leaseback agreements described in NOTE 6 LEASE COMMITMENTS are secured by letters of credit (Letters of Credit) in an aggregate amount of $3,000,000. The Letters of Credit were issued by a bank at the behest of a non-profit foundation (the “Foundation”) and Spring Forth Investments. The Company is obligated to reimburse the Foundation and Spring Forth Investments for any draws made under the Letters of Credit pursuant to two reimbursement agreements between the Company and the Foundation and Spring Forth Investments dated October 30, 2013. Mr. Spafford, one of our directors, and his wife, Susan Spafford, have been designated by the Foundation as “Founding Trustees” under its bylaws and have authority to control certain activities of the Foundation. Our obligations under the reimbursement agreements are secured by a security interest in all of our assets pursuant to a Security Agreement dated October 30, 2013. As of December 31, 2015, no draws on the line of credit had taken place. In February 2014, we issued a convertible promissory note with an 8% interest rate and 25,000 warrants to purchase common stock to Mr. Ashton. The consideration paid by Mr. Ashton for the note and warrants was $200,000. The maturity date for the promissory note was February 26, 2015, or upon or a qualified equity financing of at least $5 million. This financing was for general working capital purposes. The principal balance of this note, along with accrued interest of $6,751 converted to 8,270,027 Series D Units in July 2014 which separated into 8,270,027 shares of Series D Preferred Stock, 41,350 Class A warrants to purchase common stock exercisable at $4.92 per warrant which expire in July 2021 and 41,350 Class B warrants exercisable at $0.20 per warrant which expire in July 2021. Upon the closing of our IPO, the Series D Preferred Stock converted into 690 shares of common stock. The exercise price of the Class A warrants and Class B warrants has been adjusted pursuant to the price protection feature in the warrants and is currently at $0.03 for both the Class A warrants and Class B warrants. The exchange ratio for the Class A warrants and Class B warrants upon the exercise of the options is such that for every 60 options exercised, one share of common stock would be issued. In March 2014, we issued a convertible promissory note with an 8% interest rate and 12,500 warrants to purchase common stock to DRS, LLC, an entity controlled by Mr. Spafford. The consideration paid by DRS, LLC for the note and warrants was $100,000. The maturity date for the promissory note was March 10, 2015, or upon a qualified equity financing of at least $5 million. This financing was for general working capital purposes. The principal balance of this note, along with accrued interest of $3,112 converted to 4,124,493 Series D Units in July 2014 which separated into 4,124,493 shares of Series D Preferred Stock, 20,622 Class A warrants to purchase common stock exercisable at $4.92 per warrant which expire in July 2021 and 20,622 Series B warrants exercisable at $0.20 per warrant which expire in July 2021. Upon the closing of our IPO, the Series D Preferred Stock converted into 344 shares of common stock. The exercise price of the Class A warrants and Class B warrants has been adjusted pursuant to the price protection feature in the warrants and is currently at $0.03 for both the Class A warrants and Class B warrants. The exchange ratio for the Class A warrants and Class B warrants upon the exercise of the options is such that for every 60 options exercised, one share of common stock would be issued. In July 2014, the Company entered into a note agreement for $500,000 with Spring Forth Investments, LLC a company owned by Mr. Spafford. The maturity date for the note is July 18, 2015. The note pays interest at an annual rate of 20% and is paid monthly. The Company may extend the due date of the note to July 18, 2016 by giving notice no later than April 18, 2015 and paying an extension fee of $10,000. The Company prepaid the last three months of interest for a total of $25,000 at the time of issuance of the note. As additional consideration for the note, the Company issued 4,000,000 Series D preferred stock units at a value of $100,000 which separated into 4,000,000 shares of Series D preferred stock, 20,000 Class A warrants to purchase common stock exercisable at $4.92 per warrant and 20,000 Class B warrants to purchase common stock at $0.20 per share. The Series D preferred stock units were accounted as a debt discount to be amortized over the life of the note. As of December 31, 2015 the unamortized debt discount was $58,333. Upon the closing of our IPO, the 4,000,000 shares of Series D Preferred Stock converted into 334 shares of common stock. The exercise price of the Class A warrants and Class B warrants has been adjusted pursuant to the price protection feature in the warrants and is currently at $0.03 for both the Class A warrants and Class B warrants. The exchange ratio for the Class A warrants and Class B warrants upon the exercise of the options is such that for every 60 options exercised, one share of common stock would be issued. In April 2014, the Company entered into two Financial Advisory Agency Agreements with Rona Capital, LLC, an entity owned by Jeffrey A. Rona. Mr. Rona became our Chief Financial Officer in October 2014. The first agreement was for financial advisory services related to the Company’s ongoing financing activities prior to the filing of an S-1 registration with the SEC. The Company agreed to pay Rona Capital $15,000 per month plus reasonable out-or-pocket expenses. In addition, the Company issued warrants to Rona Capital to purchase 7,200,000 Series D units which separated into 7,200,000 Series D Preferred Shares, 36,000 Class A warrants to purchase common stock exercisable at $4.92 per warrant and 36,000 Class B warrants to purchase common stock exercisable at $0.20 per warrant pursuant to the initial S-1 filing with the SEC. The Company also indemnified Rona Capital for claims arising from the agreement, subject to certain exceptions. This agreement terminated upon the final closing of the Series D Preferred Stock financing. Upon the closing of our IPO, the 7,200,000 shares of Series D Preferred Stock converted into 600 shares of common stock. The exercise price of the Class A warrants and Class B warrants has been adjusted pursuant to the price protection feature in the warrants and is currently at $0.03 for both the Class A warrants and Class B warrants. The exchange ratio for the Class A warrants and Class B warrants upon the exercise of the options is such that for every 60 options exercised, one share of common stock would be issued. The Company also entered into a second Financial Advisory Agency Agreement with Rona Capital effective in June 2014, wherein Rona Capital provided the Company with financial advisory services related to the Company’s ongoing financing activities. The Company paid Rona Capital $15,000 per month and additional cash amounts on the achievement of specified milestones, including $50,000 upon the filing of an S-1 with the SEC and $100,000 upon the closing of an initial public offering. In relation to the convertible note financing on December 30, 2015, the Foundation and Spring Forth investments agreed to enter into subordination agreements with the collateral agent in the convertible note financing whereby each agreed to subordinate their debt to the notes issued in the convertible note financing. As consideration for their agreement the Company issued them Subordination Warrants exercisable for 105,516 shares of common stock (see NOTE 11 WARRANTS).

INCOME TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
INCOME TAXES	NOTE 15 INCOME TAXES The Company utilizes the asset and liability approach to measuring deferred tax assets and liabilities based on temporary differences existing at each balance sheet date using currently enacted tax rates in accordance with FASB ASC 740 . The income tax expense for the years ended December 31, 2015 and 2014 consists of the following: 2015 2014 Current Federal $ — $ — State and Local 1,250 5,297 1,250 5,297 Deferred Federal — — State and Local — — — — $ 1,250 $ 5,297 The following is a reconciliation of the reported amount of income tax expense (benefit) for the years ended December 31, 2015 and 2014 to the amount of income tax expenses that would result from applying the statutory rate to pretax income. The components of the Company’s deferred tax assets for the years ended December 31, 2015 and 2014 are as follows: 2015 2014 Deferred tax assets: Net operating losses 4,194,990 18,229,887 Depreciation and amortization (182,903 ) 162,344 Allowance for doubtful accounts 6,324 2,035 Accrued vacation 112,892 85,081 Accrued personal property tax 4,083 4,048 Other 1,652 171 Total deferred tax assets 4,137,036 18,483,566 Less: Valuation allowance (4,137,036 ) (18,483,566 ) Net deferred tax assets $ — $ — Reconciliation of reported amount of income tax expense for the years ended December 31, 2015 and 2014 consists of the following: 2015 2014 Benefit for income taxes computed at federal statutory rate $ (19,685,292 ) $ (7,385,656 ) State income taxes, net of federal tax benefit 1,998,974 (407,156 ) Non-deductible expenses 12,902,916 3,024,860 NOL write off due to Section 382 limitation 23,200,232 — Increase (decrease) in valuation allowance (14,346,481 ) 4,622,286 Other, net (71,150 ) 150,963 Provision for income taxes $ 1,250 $ 5,297 Effective tax rate (0.01 %) (0.07 %) As of December 31, 2015 the Company has generated operating losses. As a result the Company has recorded a full valuation allowance against its net deferred tax assets as of December 31, 2015 and 2014. The valuation allowance decreased by $14,346,481 during the tax year ended December 31, 2015. During 2015, the Corporation had a change of ownership for Internal Revenue Code purposes. The amount of the NOLs for federal and state purposes was reduced to the amount that can be used considering those limitations. The amount presented is reduced based on the section 382 limitation and the carryforward period as provided by the federal and state tax laws. As of December 31, 2015 and 2014, the Company has a net operating loss carry forwards for Federal income tax purposes of $11.5 million and $51.8 million, respectively, which expire in varying amounts during the tax years 2025 and 2035. The Company has net operating loss carry forwards for State income tax purposes of $8.2 million and $32.5 million which expire in varying years from 2025 to 2035. Under FASB ASC 740, tax benefits are recognized only for tax positions that are more likely than not to be sustained upon examination by tax authorities. The amount recognized is measured as the largest amount of benefit that is greater than 50 percent likely to be realized upon ultimate settlement. Unrecognized tax benefits are tax benefits claimed in the Company’s tax returns that do not meet these recognition and measurement standards. As of December 31, 2015 and 2014, the Company has no liabilities for unrecognized tax benefits. The Company’s policy is to recognize potential interest and penalties accrued related to unrecognized tax benefits within income tax expense. For the years ended December 31, 2015, and 2014, the Company did not recognize any interest or penalties in its statement of operations, nor did it have any interest or penalties accrued in its balance sheet at December 31, 2015 and 2014 relating to unrecognized tax benefits. The tax years 2012-2015 remain open to examination for federal income tax purposes and by the other major taxing jurisdictions to which the Company is subject.

LEGAL PROCEEDINGS

LEGAL PROCEEDINGS	12 Months Ended
	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
LEGAL PROCEEDINGS	NOTE 16 LEGAL PROCEEDINGS The Company is not currently a party to any pending or threatened legal proceeding or regulatory or government investigations. We may become involved in litigation from time to time relating to claims arising in the ordinary course of our business. We do not believe that the ultimate resolution of such claims would have a material effect on our business, results of operations, financial condition or cash flows. However, the results of these matters cannot be predicted with certainty, and an unfavorable resolution of one or more of these matters could have a material effect on our business, results of operations, financial condition and cash flows.

GEOGRAPHIC INFORMATION

GEOGRAPHIC INFORMATION	12 Months Ended
	Dec. 31, 2015
Text Block [Abstract]
GEOGRAPHIC INFORMATION	NOTE 17 GEOGRAPHIC INFORMATION The Company has both domestic (U.S.) and international customers for its products. Sales for the years ended December 31, 2015 and 2014 were as follows: 2015 2014 Domestic sales $ 2,096,825 $ 1,559,614 International sales 45,215 46,640 Total sales $ 2,142,040 $ 1,606,254

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Dec. 31, 2015
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 18 SUBSEQUENT EVENTS In January and February 2016, the Company issued 64,641,576 shares of common stock pursuant to the cashless exercise of 5,001,687 Series C Warrants, the conversion of 13,967 shares of Series E Preferred Stock and the exercise of 121,450 unit purchase options with the immediate conversion and exercise of the Series E Preferred Stock and Series C Warrants. In January 2016, the Company settled the cashless exercise of 138,158 Series C Warrants with cash in the amount of $304,017. On January 21, 2016 all outstanding Series C Warrants were mandatorily exercised utilizing the cashless provision of the warrants. As of March 1, 2016 there are 50,418 Series C Warrants that have yet to be delivered and upon delivery, the Company will issue 563,651 shares of common stock. In February 2016, the Company entered into a settlement agreement with Dawson James Securities, Inc. (“Dawson James”) pursuant to a dispute related to an underwriting agreement. Dawson James has agreed to terminate its right of first refusal for a one time payment by the Company of $80,000. In addition, Dawson James has agreed to provide consulting services for a 12 month period in consideration of the Company paying them an aggregate consulting fee of $800,000 consisting of $200,000 paid upon execution of the agreement and $50,000 per month for 12 months. In February 2016, the Company entered into amendment agreements with holders of the Notes and Series D Warrants. The amendments (i) reduced the number of shares of common stock required to be reserved for issuance upon the conversion of the Notes and exercise of the Series D Warrants from 120,000,000 to 85,000,000. The reduction will expire on April 1, 2016, and (ii) extend the deadline for filing the initial registration statement to register the common stock issuable upon conversion of the Notes and exercise of the Series D Warrants. In February 2016 the Company completed a public offering of 39.2 million Units. Each Unit consisted of one share of common stock and 1.5 Series E Warrants, each whole Series E Warrant is to purchase one share of our common stock at $0.25 per Series E Warrants. The Company received approximately $6.3 million of gross proceeds and approximately $5.6 million of net proceeds. The Series E Warrants expire six years from the date of issuance but are not exercisable for one year and are subject to a vote of the shareholders and an increase in the number of authorized common stock that the Company can issue.

SUMMARY OF SIGNIFICANT ACCOUN25

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation These financial statements have been prepared to reflect the financial position, results of operations and cash flows of the Company and have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).
Reverse Stock Split	Reverse Stock Split On December 11, 2015, the Company effected a reverse stock split of the Company’s common stock whereby each sixty shares of common stock was replaced with one share of common stock (with no fractional shares issued). The par value of the common stock was adjusted from $0.001 per share to $0.0001 per share as a result of the reverse stock split. The authorized shares of the common stock were not adjusted. All common share and per share amounts for all periods presented in these financial statements have been adjusted retroactively to reflect the reverse stock split. The quantity of Series E Preferred Stock, Common Warrants, Class A, Class B, Series A, Series B and Series C Warrants as well as employee and other options were not included in the reverse stock split and their outstanding quantities have not been adjusted. However, the conversion and exchange ratios were adjusted as a result of the reverse stock split such that upon conversion each 60 shares of Series E Preferred Stock will be converted into four shares of common stock and upon exercise each 60 warrants or options will be converted into one share of common stock.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. Such estimates include the warranty reserve, accounts receivable and inventory reserves, intangible assets and other long lived assets, legal and regulatory contingencies, income taxes, share based arrangements, the derivative liability and others. These estimates and assumptions are based on management’s best estimates and judgments. Actual amounts and results could differ from those estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers highly liquid investments with insignificant interest rate risk and original maturities to the Company of three months or less to be cash equivalents. Cash equivalents consist primarily of interest and non-interest bearing bank accounts held in checking, savings and money market accounts. These assets are generally available on a daily or weekly basis and are highly liquid in nature. If the balances are greater than $250,000, the Company does not have FDIC coverage on the entire amount of bank deposits.
Restricted Cash	Restricted Cash Cash and cash equivalents that are restricted as to withdrawal or use under the terms of certain contractual agreements are recorded as restricted cash on our balance sheet. On December 30, 2015, the Company entered into a Securities Purchase Agreement pursuant to which the Company issued $22.1 million senior secured convertible notes and received $18.4 million in cash proceeds. Under the terms of the notes, at closing an initial tranche of $4.6 million was available for immediate use by the Company for general corporate purposes. The remaining cash proceeds of $13.8 million is available in three additional tranches that are subject to an account control agreement whereby the restrictions on the proceeds are terminated when the Company meets certain equity conditions (see NOTE 8 CONVERTIBLE NOTES PAYABLE). The restricted cash is deposited in an account that is not FDIC insured.
Accounts Receivable	Accounts Receivable Accounts receivable are generated from the sale of single use diagnostic test cartridges to end users in the United States and to a network of distributors outside the United States. These accounts receivable are recorded at the invoiced amount, net of allowances for doubtful amounts. The Company routinely reviews outstanding accounts receivable balances for estimated uncollectible accounts and establishes or adjusts the allowances for doubtful accounts receivable using the specific identification method and records a reserve for amounts not expected to be fully recovered. Actual balances are not applied against the reserve until substantially all collection efforts have been exhausted. The Company does not have customer acceptance provisions, but it does provide its customers a limited right of return for defective diagnostic test cartridges. The allowance for doubtful accounts at December 31, 2015 and 2014 was $16,892 and $5,482, respectively.
Inventories	Inventories Inventories are stated at the lower of cost or market with cost determined according to the average cost method. Manufactured inventory consists of raw material, direct labor and manufacturing overhead cost components. The Company reviews the components of its inventory on a regular basis for excess and obsolete inventory and makes appropriate adjustments when necessary. Inventories consisted of the following at December 31, 2015 and 2014: December 31, 2015 2014 Raw materials $ 758,870 $ 360,019 Work-in-process 277,827 91,153 Finished goods 96,445 5,922 Total inventories $ 1,133,142 $ 457,094
Property and Equipment	Property and Equipment Property and equipment is recorded at cost and depreciated over the estimated useful lives of the assets (which range from three to ten years) using the straight-line method. Amortization of leasehold improvements is computed on the straight-line method over the shorter of the lease term or estimated useful lives of the assets. The analyzers that the Company manufactures and retains title over are placed with customers and are recorded in property and equipment under “Analyzers.” The materials used for the manufacture of the analyzers are recorded in property and equipment under “Construction in progress.” Major renewals and betterments are capitalized and depreciated over their estimated useful lives while minor expenditures for maintenance and minor repairs are charged to operations as incurred. The Company classifies assets to be sold as assets held for sale when (i) Company management has approved and commits to a plan to sell the asset, (ii) the asset is available for immediate sale in its present condition and is ready for sale, (iii) an active program to locate a buyer and other actions required to sell the asset have been initiated, (iv) the sale of the asset is probable, (v) the asset is being actively marketed for sale at a price that is reasonable in relation to its current fair value, and (vi) it is unlikely that significant changes to the plan will be made or that the plan will be withdrawn. Assets classified as held for sale are recorded at the lower of the carrying amount or fair value less the cost to sell and are a component of prepaid and other current assets in the balance sheets. The Company did not have any assets classified as held for sale as of December 31, 2015 and 2014.
Intangible Assets	Intangible Assets The Company records its intangible assets at cost which consist of two licensing and royalty agreements for certain intellectual property rights used in the development and manufacture of our products. These intangible assets are being amortized over an estimated useful life of seven years from the date that the technology licenses became effective. As of December 31, 2015 and 2014, intangible assets totaled $600,000 valued at cost, less accumulated amortization of $480,829 and $383,420, respectively. The Company recorded amortization associated with these agreements of $97,407 and $117,445 for the years ended December 31, 2015 and 2014, respectively. Estimated future intangible asset amortization expense for the next five years are as follows: Years ended December 31, 2016 $ 76,580 2017 42,591 Total estimated amortization expense $ 119,171
Impairment of Long Lived Assets	Impairment of Long Lived Assets Long-lived tangible assets, including property and equipment, and definite-lived intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying value of the asset may not be recoverable. The Company regularly evaluates whether events or circumstances have occurred that indicate possible impairment and relies on a number of factors, including expected future operating results, business plans, economic projections, and anticipated future cash flows. The Company uses an estimate of the future undiscounted net cash flows and comparisons to like-kind assets, as appropriate, of the related asset over the remaining life in measuring whether the assets are recoverable. Measurement of the amount of impairment, if any, is based upon the difference between the asset’s carrying value and estimated fair value. Fair value is determined through various valuation techniques, including cost-based, market and income approaches as considered necessary.
Derivative Instruments	Derivative Instruments The Company accounts for derivative instruments under the provisions of ASC 815 Derivatives and Hedging
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company measures at fair value certain of its financial and non-financial assets and liabilities by using a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, essentially an exit price, based on the highest and best use of the asset or liability. The levels of the fair value hierarchy are: Level 1—Quoted market prices in active markets for identical assets or liabilities; Level 2—Significant other observable inputs (e.g. quoted prices for similar items in active markets, quoted prices for identical or similar items in markets that are not active, inputs other than quoted prices that are observable, such as interest rate and yield curves, and market-corroborated inputs); and Level 3—Unobservable inputs in which there is little or no market data, which require the reporting unit to develop its own assumptions. The following tables set forth the financial liabilities measured at fair value on a recurring basis by level within the fair value hierarchy at December 31, 2015 and 2014 (see NOTE 12 DERIVATIVE LIABILITIES): Fair Value Measurements at December 31, 2015 Description Level 1 Level 2 Level 3 Total Derivative liability Common stock warrants $ — $ — $ 26,592,532 $ 26,592,532 Convertible notes payable $ — $ — $ 16,588,940 $ 16,588,940 Total derivative liability $ — $ — $ 43,181,472 $ 43,181,472 Fair Value Measurements at December 31, 2014 Description Level 1 Level 2 Level 3 Total Derivative liability Common stock warrants $ — $ — $ 9,998,636 $ 9,998,636 Total derivative liability $ — $ — $ 9,998,636 $ 9,998,636 The internal models used to determine fair value for these Level 3 instruments use certain significant unobservable inputs and their use requires determination of relevant inputs and assumptions. Accordingly, changes in these unobservable inputs may have a significant impact on fair value. Such inputs include risk free interest rate, expected average life, expected dividend yield, and expected volatility. These Level 3 liabilities would decrease (increase) in value based upon an increase (decrease) in risk free interest rate and expected dividend yield. Conversely, the fair value of these Level 3 liabilities would generally increase (decrease) in value if the expected average life or expected volatility were to increase (decrease).
Revenue Recognition	Revenue Recognition The Company derives its product revenue from the sale of single use diagnostic test cartridges sold through our dedicated sales force, except in the European Union where the Company sells through a network of distributors. Product revenue is recognized when all four of the following criteria are met: (1) persuasive evidence that an arrangement exists; (2) delivery of the products has occurred; (3) the selling price of the product is fixed or determinable; and (4) collectability of that price is reasonably assured. Change in title to the product and recognition of revenue from sales of diagnostic test cartridges occurs at the time of shipment. Shipping and handling fees and related freight costs and supplies for test kits are billed to customers. Additional costs associated with shipping products to customers are included as a component of cost of sales.
Research and Development Costs	Research and Development Costs Research and development costs are charged to operations as incurred. Research and development costs include, among other things, salaries and wages for research scientists and staff (including stock-based compensation), materials and supplies used in the development of new products, developing and validating the manufacturing process, costs for clinical trials, and costs for research and development facilities and equipment.
Stock Based Compensation	Stock Based Compensation The Company has accounted for stock-based compensation under the provisions of Financial Accounting Standards Board Accounting Standards Codification (“FASB ASC”) 718, “Compensation—Stock Compensation” .
Financial Instruments and Concentration of Credit Risk	Financial Instruments and Concentration of Credit Risk The Company’s financial instruments include cash and cash equivalents, accounts receivable, and accounts payable. The carrying amount of cash and cash equivalents, accounts receivable, and accounts payable approximate fair value because of their immediate or short-term maturities. All of the Company’s accounts receivable result from sales in the normal course of business to its customers primarily throughout the United States. The Company attempts to limit its credit risk by performing credit evaluations of new customers and maintaining adequate allowances for potential credit losses. As of December 31, 2015, 17% of the accounts receivable balance resulted from one customer. As of December 31, 2014, 30% of the accounts receivable balance resulted from one customer. Historically, the Company has not experienced any credit losses on such receivables. Allowances for bad debt in the amount of $16,892 and $5,482 were recorded against accounts receivable for the years ended December 31, 2015 and 2014, respectively. There was no bad debt for the year ended December 31, 2015. The Company cannot ensure that such losses will not be realized in the future. The Company’s customers consist of hospitals, clinics, laboratories and other healthcare providers in the United States, the European Union and New Zealand. For the year ended December 31, 2015, there were no customers that accounted for more than 10% of revenues. For the year ended December 31, 2014, 11% of revenues resulted from one customer who accounted for more than 10% of revenues.
Income Taxes	Income Taxes The Company accounts for income taxes under FASB ASC 740, “Income Taxes”. Deferred income tax assets and liabilities are determined based upon differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Accounting standards require the consideration of a valuation allowance for deferred tax assets if it is “more likely than not” that some component or all of the benefits of deferred tax assets will not be realized. The tax effects from an uncertain tax position can be recognized in the financial statements only if the position is more likely than not of being sustained if the position were to be challenged by a taxing authority. The Company has examined the tax positions taken in its tax returns and determined that there are no uncertain tax positions. As a result, the Company has recorded no uncertain tax liabilities in its balance sheet.
Loss per Common Share	Loss per Common Share Basic loss per share (“EPS”) is computed by dividing net loss, less cumulative preferred stock dividends for the period, including undeclared or unpaid cumulative dividends (the numerator) by the weighted average number of common shares outstanding for the period (the denominator). Diluted EPS is computed by dividing net loss by the weighted average number of common shares and potential common shares outstanding (if dilutive) during each period. Potential common shares include convertible preferred stock, stock options and warrants. The number of potential common shares outstanding is computed using the treasury stock method. As the Company has incurred losses for the years ended December 31, 2015 and 2014, the potentially dilutive shares are anti-dilutive and are thus not added into the loss per share calculations. As of December 31, 2015 and 2014, there were 27,468,018 and 102,516 potentially dilutive shares, respectively.
Reclassification	Reclassification During 2015, the Company’s auditors identified a clerical error made by the Company during the preparation of the 2014 cash flow statement, wherein the amount for a certain fixed asset that was included in accounts payable had the sign inadvertently switched. The Company has corrected the presentation of the 2014 cash flows for this clerical item and in doing so, the statement of cash flows for 2014 was adjusted to increase net cash used in operating activities by $786,238, with a corresponding decrease in net cash used from investing activities. Other than the 2014 cash flow statement, no other cash flow statement for any annual or quarterly period, was impacted by this presentation correction. The Company has evaluated the effect of the incorrect presentation, both qualitatively and quantitatively, and concluded that it did not have a material impact on, nor require amendment of, any previously filed annual or quarterly financial statements.
New Accounting Pronouncements	New Accounting Pronouncements From time to time, new accounting pronouncements are issued by the FASB that are adopted by the Company as of the specified effective date. If not discussed, management believes that the impact of recently issued standards, which are not yet effective, will not have a material impact on the Company’s financial statements upon adoption. In November 2015, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2015-17, “Balance Sheet Classification of Deferred Taxes,” that requires companies to classify all deferred tax assets and liabilities, along with any valuation allowance, as noncurrent on the balance sheet instead of separating deferred taxes into current and noncurrent amounts. The guidance does not change the existing requirement that only permits offsetting within a jurisdiction. The ASU is effective for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. Early adoption is permitted. During the fourth quarter of 2015, the Company elected early adoption of this standard as it improved the efficiency of the year end financial reporting process for income taxes and applied the changes retrospectively to all prior periods presented in its financial statements. In July 2015, the FASB issued ASU 2015-11, “Simplifying the Measurement of Inventory,” that simplifies the subsequent measurement of inventories by replacing the current lower of cost or market test with a lower of cost or net realizable value test. The ASU is effective for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. Early adoption is permitted. The Company is still evaluating the impact this standard will have on its financial statements and related disclosures. In April 2015, the FASB issued ASU 2015-03, “Simplifying the Presentation of Debt Issuance Costs,” which requires debt issuance costs to be presented in the balance sheet as a direct deduction from the carrying value of the associated debt liability, consistent with the presentation of debt discounts or premiums. The ASU is effective for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. During the year 2015, the Company elected early adoption of this standard and applied the changes in its financial statements and related disclosures. In August 2014, the FASB issued ASU No. 2014-15 Disclosure of Uncertainties About an Entity’s Ability to Continue as a Going Concern In May 2014, the FASB issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”), which supersedes nearly all existing revenue recognition guidance under GAAP. The core principle is that a company should recognize revenue when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, more judgment and estimates may be required within the revenue recognition process than are required under existing GAAP. The standard is effective for annual periods beginning after December 15, 2016, and interim periods therein, and shall be applied either retrospectively to each period presented or as a cumulative-effect adjustment as of the date of adoption. In April 2015, the FASB deferred the effective date of ASU 2014-09 to fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017. The Company is currently in the process of determining the impact of adoption of the provisions of ASU 2014-09 on its financial statements and related disclosures.

SUMMARY OF SIGNIFICANT ACCOUN26

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Schedule of Inventories	Inventories consisted of the following at December 31, 2015 and 2014: December 31, 2015 2014 Raw materials $ 758,870 $ 360,019 Work-in-process 277,827 91,153 Finished goods 96,445 5,922 Total inventories $ 1,133,142 $ 457,094
Estimated Future Intangible Asset Amortization Expense	Estimated future intangible asset amortization expense for the next five years are as follows: Years ended December 31, 2016 $ 76,580 2017 42,591 Total estimated amortization expense $ 119,171
Financial Liabilities Measured at Fair Value on a Recurring Basis	The following tables set forth the financial liabilities measured at fair value on a recurring basis by level within the fair value hierarchy at December 31, 2015 and 2014 (see NOTE 12 DERIVATIVE LIABILITIES): Fair Value Measurements at December 31, 2015 Description Level 1 Level 2 Level 3 Total Derivative liability Common stock warrants $ — $ — $ 26,592,532 $ 26,592,532 Convertible notes payable $ — $ — $ 16,588,940 $ 16,588,940 Total derivative liability $ — $ — $ 43,181,472 $ 43,181,472 Fair Value Measurements at December 31, 2014 Description Level 1 Level 2 Level 3 Total Derivative liability Common stock warrants $ — $ — $ 9,998,636 $ 9,998,636 Total derivative liability $ — $ — $ 9,998,636 $ 9,998,636

PROPERTY AND EQUIPMENT (Tables)

PROPERTY AND EQUIPMENT (Tables)	12 Months Ended
	Dec. 31, 2015
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment consisted of the following at December 31, 2015 and December 31, 2014: December 31, 2015 2014 Construction in progress $ 680,679 $ 1,133,654 Analyzers 5,045,481 1,139,352 Computers and office equipment 462,441 290,754 Machinery and equipment 2,372,558 1,060,993 Leasehold improvements 393,271 366,945 Furniture and fixtures 72,618 16,145 Equipment under capital lease 2,148,476 2,148,476 11,175,522 6,156,319 Less: accumulated depreciation and amortization (3,433,531 ) (1,918,852 ) Total property and equipment, net $ 7,741,991 $ 4,237,467

ACCRUED EXPENSES (Tables)

ACCRUED EXPENSES (Tables)	12 Months Ended
	Dec. 31, 2015
Payables and Accruals [Abstract]
Schedule of Accrued Liabilities	Accrued liabilities consisted of the following as of December 31, 2015 and 2014: December 31, 2015 2014 Accrued payroll $ 1,094,666 $ 421,645 Royalties 75,642 166,540 Accrued interest 44,291 — Accrued property and use tax 10,905 10,905 Other 87,645 13,269 Total accrued liabilities $ 1,313,149 $ 612,359

LEASE COMMITMENTS (Tables)

LEASE COMMITMENTS (Tables)	12 Months Ended
	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Schedule of Annual Future Minimum Lease Payments of Capital Leases	Annual future minimum lease payments of capital leases for the next five years are as follows: Years ended December 31, 2016 $ 1,694,006 2017 923,908 Total capital lease payments 2,617,914 Less amount representing interest (461,078 ) Total future minimum lease payments 2,156,836 Less current portion of capital leases (1,305,426 ) Long term portion of capital leases $ 851,410
Schedule of Operating Lease Commitments	Operating lease commitments for the next five years are as follows: Years ended December 31, 2016 $ 355,797 2017 246,255 2018 252,092 2019 259,132 2020 266,455 Total operating lease commitments $ 1,379,731

NOTES PAYABLE (Tables)

NOTES PAYABLE (Tables)	12 Months Ended
	Dec. 31, 2015
Debt Disclosure [Abstract]
Summary of Purchased Certain Machinery and Equipment under Two Note Payable Agreements	The Company purchased certain machinery and equipment under two note payable agreements which consist of the following as of December 31, 2015 and 2014: December 31, 2015 2014 Note payable, 15.2% interest, monthly payments of $1,328, due February 6, 2016, secured by equipment $ 2,607 $ 16,938 Note payable, 10.0% interest, monthly payments of $3,161, due January 1, 2016, secured by equipment 3,086 38,749 Total notes payable 5,693 55,687 Less: current portion of notes payable (5,693 ) (49,994 ) Long term portion of notes payable $ — $ 5,693

CONVERTIBLE NOTES PAYABLE (Tabl

CONVERTIBLE NOTES PAYABLE (Tables)	12 Months Ended
	Dec. 31, 2015
Text Block [Abstract]
Summary of Convertible Notes Outstanding	The following table summarizes the convertible notes outstanding at December 31, 2015: Convertible notes payable, principal $ 22,100,000 Debt discounts (19,936,283 ) Net convertible note payable 2,163,717 Less current portion (1,638,717 ) Convertible notes payable, long term $ 525,000

WARRANTS (Tables)

WARRANTS (Tables)	12 Months Ended
	Dec. 31, 2015
Schedule Of Warrants Outstanding and Exercisable	The following table outlines the warrants outstanding and exercisable as of December 31, 2014: Warrants Outstanding Warrant Common Stock Total Shares Aggregate Exercise Expiration Class A 2,041,239 $4.92 60 : 1 34,021 $295.20 April 2021 - July Class B 1,645,845 $0.20 60 : 1 27,431 $12.00 April 2021 - July 2021 Series A 1,322,500 $7.00 60 : 1 22,042 $420.00 October 2015 Common 438,356 $2.00 - $32.00 60 : 1 7,306 $120.00 - $1,920.00 April 2016 - July 2021 Total Warrants 5,447,940 90,800
Assumptions used in Calculating Fair Value of Warrants Granted	The following is the weighted average of the assumptions used in calculating the fair value of the warrants at an exchange ratio of 60 warrants for one share of common stock after they were modified in September 2014 using the Black-Scholes method: Fair market value of one share of common stock $ 296.40 Aggregate exercise price of 60 warrants $ 600.00 Risk free rate 0.61 % Dividend yield 0.00 % Expected volatility 37.23 % Remaining contractual term 1.97 years
Summary of Stock Option Activity	The following table summarizes the Company’s total option activity for the years ended December 31, 2015 and 2014: Options Weighted Weighted Intrinsic As of December 31, 2014: Options outstanding as of January 1, 2014 115,750 $ 30.00 6.3 Granted 619,784 $ 2.86 9.4 Exercised — — — Forfeited/expired (32,500 ) $ 8.92 5.7 Options outstanding as of December 31, 2014 703,034 $ 2.98 8.8 $ — As of December 31, 2015: Options outstanding as of January 1, 2015 703,034 $ 2.98 8.8 Granted 117,500 $ 2.56 9.6 Exercised — — — Forfeited/expired (28,000 ) $ 5.16 8.6 Options outstanding as of December 31, 2015 792,534 $ 2.84 8.0 $ —
Common Stock Warrants Activity	The following table summarizes the common stock warrant activity during the years ended December 31, 2015 and 2014: Common Weighted Weighted As of December 31, 2014: Warrants outstanding as of January 1, 2014 274,420 8.00 4.2 Granted 5,331,520 3.91 5.5 Exercised (158,000 ) 0.20 6.6 Expired — — — Warrants outstanding as of December 31, 2014 5,447,940 4.17 4.9 As of December 31, 2015: Warrants outstanding as of January 1, 2015 5,447,940 4.17 4.9 Granted 26,617,714 2.71 4.3 Exercised (17,547,639 ) 2.47 4.0 Expired (1,298,418 ) 2.48 3.4 Warrants outstanding as of December 31, 2015 13,219,597 2.71 4.7
Preferred A Stock Warrants
Summary of Stock Option Activity	The following table summarizes the Preferred A stock warrant activity during the year ended December 31, 2014: Preferred A Weighted Weighted As of December 31, 2014: Warrants outstanding as of January 1, 2014 2,231,727 $ 0.16 3.1 Granted — — — Converted (2,231,727 ) 0.16 2.3 Expired — — — Warrants outstanding as of December 31, 2014 — $ — —
Preferred D Stock Warrants
Summary of Stock Option Activity	The following table summarizes the preferred D stock warrant activity during the year ended December 31, 2014: Preferred D Weighted Weighted As of December 31, 2014: Warrants outstanding as of January 1, 2014 — — — Granted 7,200,000 $ 0.025 6.8 Converted (7,200,000 ) $ 0.025 6.7 Expired — — — Warrants outstanding as of December 31, 2014 — $ — —

DERIVATIVE LIABILITIES (Tables)

DERIVATIVE LIABILITIES (Tables)	12 Months Ended
	Dec. 31, 2015
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Summary of Assumptions for Fair Value Measurement Model	The Company determined the fair value of the conversion feature using a binomial model with Monte Carlo simulation to reflect different scenarios where reset may be triggered using the following assumptions: Trading price of common stock on measurement date $0.94 - $1.10 Conversion price (1) $0.87 - $1.03 Risk free interest rate (2) 0.86% Conversion notes lives in years 1.33 Expected volatility (3) 215% Expected dividend yield (4) — Expected probability of shareholder approval (5) 85% (1) The conversion price of the convertible notes was calculated based the formula in the Notes agreement as of the respective measurement date (2) The risk-free interest rate was determined by management using the 1.5-year Treasury Bill as of the respective measurement date. (3) The volatility factor was estimated by using the historical volatilities of the Company’s trading history. (4) Management determined the dividend yield to be 0% based upon its expectation that it will not pay dividends for the foreseeable future. (5) Management has estimated a probability of 85% that shareholder approval will be obtained for the removal of the 19.9% conversion cap. This is based on past shareholder voting history and discussions with current shareholders and consultants. The fair values of the Series D Warrants and Subordination Warrants were determined using a binomial valuation model which included additional warrants to be issued on December 31, 2016 and the following assumptions: Trading price of common stock on measurement date $0.94 - $1.10 Conversion price (1) $1.85 Risk free interest rate (2) 1.80% Warrant lives in years 5.50 Expected volatility (3) 215% Expected dividend yield (4) — (1) The exercise price of the Series D Warrants calculated by 120% of the arithmetic average of five weighted average price of the common stock on the five consecutive trading days prior to issuance date on December 30, 2015. (2) The risk-free interest rate was determined by management using the 5-year Treasury Bill as of the respective measurement date. (3) The volatility factor was estimated by using the historical volatilities of the Company’s trading history. (4) Management determined the dividend yield to be 0% based upon its expectation that it will not pay dividends for the foreseeable future.
Summary of Change in the Value of the Derivative Liabilities	The following summarizes the total change in the value of the derivative liabilities during the years ended December 31, 2015 and 2014: As of December 31, 2014: Balance at January 1, 2014 $ — Issuance of warrants and option 2,487,726 Exercise of warrants (885,259 ) Change in fair value of warrant and option liability 8,396,169 Balance at December 31, 2014 $ 9,998,636 As of December 31, 2015: Balance at January 1, 2015 $ 9,998,636 Issuance of warrants, unit purchase option and convertible note 56,026,979 Exercise and expiration of warrants and unit purchase option (42,558,951 ) Change in fair value of warrant, option and conversion feature liability 19,714,808 Balance at December 31, 2015 $ 43,181,472

EMPLOYEE STOCK OPTIONS (Tables)

EMPLOYEE STOCK OPTIONS (Tables)	12 Months Ended
	Dec. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Assumptions Used in Calculation of Fair Value of the Options Exchanged	The following is the range of the weighted average of the assumptions used in calculating the fair value of the options granted after our IPO in October 2014 and the options modified in 2014 using the Black-Scholes method: Fair market value of one share of common stock $ 296.40 - 316.80 Aggregate exercise price of 60 options $ 210.00 - 354.60 Risk free rate 1.06% - 1.70% Dividend yield 0.00% Expected volatility 46.31% - 54.97% Expected term 2.74 - 6.06 years The following is the weighted average of the assumptions used in calculating the fair value of the options granted in 2015 using the Black-Scholes method: Fair market value of one share of common stock $ 153.60 Aggregate exercise price of 60 options $ 153.60 Risk free rate 1.71% Dividend yield 0.00% Expected volatility 127.52% Expected term 6.14 years
Summary of Stock Options Outstanding and Exercisable	Outstanding and exercisable stock options as of December 31, 2015 and 2014 are as follows: Options Outstanding Options Exercisable Number of Remaining Exercise Number of Exercise Intrinsic December 31, 2014 703,034 8.8 $ 2.98 117,404 $ 3.86 $ — December 31, 2015 792,534 8.0 $ 2.84 328,445 $ 3.07 $ —
Schedule of Equity-Based Compensation Expenses	The estimated fair value of the Company stock options, less expected forfeitures, is amortized over the options vesting period on the straight-line basis. The Company recognized the following equity-based compensation expenses during the twelve months ended December 31, 2015 and 2014: December 31, 2015 2014 Stock based compensation expense $ 110,123 $ 297,244

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Income Tax Expense	The income tax expense for the years ended December 31, 2015 and 2014 consists of the following: 2015 2014 Current Federal $ — $ — State and Local 1,250 5,297 1,250 5,297 Deferred Federal — — State and Local — — — — $ 1,250 $ 5,297
Components of Deferred Tax Assets	The components of the Company’s deferred tax assets for the years ended December 31, 2015 and 2014 are as follows: 2015 2014 Deferred tax assets: Net operating losses 4,194,990 18,229,887 Depreciation and amortization (182,903 ) 162,344 Allowance for doubtful accounts 6,324 2,035 Accrued vacation 112,892 85,081 Accrued personal property tax 4,083 4,048 Other 1,652 171 Total deferred tax assets 4,137,036 18,483,566 Less: Valuation allowance (4,137,036 ) (18,483,566 ) Net deferred tax assets $ — $ —
Reconciliation of Reported Amount of Income Tax Expense	Reconciliation of reported amount of income tax expense for the years ended December 31, 2015 and 2014 consists of the following: 2015 2014 Benefit for income taxes computed at federal statutory rate $ (19,685,292 ) $ (7,385,656 ) State income taxes, net of federal tax benefit 1,998,974 (407,156 ) Non-deductible expenses 12,902,916 3,024,860 NOL write off due to Section 382 limitation 23,200,232 — Increase (decrease) in valuation allowance (14,346,481 ) 4,622,286 Other, net (71,150 ) 150,963 Provision for income taxes $ 1,250 $ 5,297 Effective tax rate (0.01 %) (0.07 %)

GEOGRAPHIC INFORMATION (Tables)

GEOGRAPHIC INFORMATION (Tables)	12 Months Ended
	Dec. 31, 2015
Text Block [Abstract]
Schedule of Domestic and International Customers Products Sales	The Company has both domestic (U.S.) and international customers for its products. Sales for the years ended December 31, 2015 and 2014 were as follows: 2015 2014 Domestic sales $ 2,096,825 $ 1,559,614 International sales 45,215 46,640 Total sales $ 2,142,040 $ 1,606,254

Description of Business - Addit

Description of Business - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2015
Description Of Business [Line Items]
Date of incorporation	Jun. 27, 2003
Nevada Corporation
Description Of Business [Line Items]
Date of merger	Aug. 29, 2008

Summary of Significant Accoun38

Summary of Significant Accounting Policies - Additional Information (Detail)	Dec. 30, 2015USD ($)	Dec. 11, 2015$ / shares	Dec. 31, 2015USD ($)CustomerAgreement$ / sharesshares	Dec. 31, 2014USD ($)Customer$ / sharesshares
Summary Of Significant Accounting Policies [Line Items]
Common Stock Per Share | $ / shares		$ 0.0001	$ 0.0001	$ 0.0001
Conversion and Exchange Ratio			The conversion and exchange ratios were adjusted as a result of the reverse stock split such that upon conversion each 60 shares of Series E Preferred Stock will be converted into four shares of common stock and upon exercise each 60 warrants or options will be converted into one share of common stock.
Cash, FDIC Insured Amount			$ 250,000
Proceeds from issuance of convertible notes payable			4,135,000	$ 100,000
Cash, Restricted			13,800,000
Allowance for doubtful accounts receivable, current			$ 16,892	5,482
Number of licensing and royalty agreements | Agreement			2
Intangible assets amortization period			7 years
Total intangible assets			$ 600,000	600,000
Accumulated amortization			480,829	383,420
Amortization of intangible assets			$ 97,407	$ 117,445
Dilutive shares excluded from computation of earnings per share | shares			27,468,018	102,516
Net cash used in operating activities			$ (20,669,754)	$ (12,397,418)
Accounts Receivable | Customer Concentration Risk
Summary Of Significant Accounting Policies [Line Items]
Concentration risk percentage			17.00%	30.00%
Number of customers | Customer			1	1
Sales Revenue | Customer Concentration Risk
Summary Of Significant Accounting Policies [Line Items]
Concentration risk percentage				11.00%
Number of customers | Customer			0	1
Senior Secured Convertible Note
Summary Of Significant Accounting Policies [Line Items]
Convertible notes payable, principal			$ 22,100,000
Securities Purchase Agreement | Senior Secured Convertible Note
Summary Of Significant Accounting Policies [Line Items]
Convertible notes payable, principal	$ 22,100,000
Note agreement carrying value	18,400,000
Subordination Warrants | Series D Warrant
Summary Of Significant Accounting Policies [Line Items]
Proceeds from issuance of convertible notes payable	4,600,000		$ 4,600,000
Cash, Restricted	$ 13,800,000
Common Stock
Summary Of Significant Accounting Policies [Line Items]
Reverse stock split ratio		0.01666667
Reverse stock split ratio, Description			Each sixty shares of common stock was replaced with one share of common stock
Scenario, Previously Reported
Summary Of Significant Accounting Policies [Line Items]
Common Stock Per Share | $ / shares		$ 0.001
Restatement Adjustment [Member]
Summary Of Significant Accounting Policies [Line Items]
Net cash used in operating activities			$ 786,238
Minimum
Summary Of Significant Accounting Policies [Line Items]
Estimated useful lives of assets			3 years
Maximum
Summary Of Significant Accounting Policies [Line Items]
Estimated useful lives of assets			10 years

Schedule of Inventories (Detail

Schedule of Inventories (Detail) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Inventory Disclosure [Abstract]
Raw materials	$ 758,870	$ 360,019
Work-in-process	277,827	91,153
Finished goods	96,445	5,922
Total inventories	$ 1,133,142	$ 457,094

Estimated Future Intangible Ass

Estimated Future Intangible Asset Amortization Expense (Detail) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
2,016	$ 76,580
2,017	42,591
Total estimated amortization expense	$ 119,171	$ 216,580

Financial Liabilities Measured

Financial Liabilities Measured at Fair Value on a Recurring Basis (Detail) - Fair Value, Measurements, Recurring - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability	$ 43,181,472	$ 9,998,636
Convertible Notes Payable
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability	16,588,940
Common Stock Warrants
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability	26,592,532	9,998,636
Fair Value, Inputs, Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability	0	0
Fair Value, Inputs, Level 1 | Convertible Notes Payable
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability	0
Fair Value, Inputs, Level 1 | Common Stock Warrants
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability	0	0
Fair Value, Inputs, Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability	0	0
Fair Value, Inputs, Level 2 | Convertible Notes Payable
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability	0
Fair Value, Inputs, Level 2 | Common Stock Warrants
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability	0	0
Fair Value, Inputs, Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability	43,181,472	9,998,636
Fair Value, Inputs, Level 3 | Convertible Notes Payable
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability	16,588,940
Fair Value, Inputs, Level 3 | Common Stock Warrants
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability	$ 26,592,532	$ 9,998,636

Going Concern - Additional Info

Going Concern - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Liquidity Disclosure Going Concern [Abstract]
Net loss	$ (57,899,169)	$ (21,727,818)
Accumulated deficit	$ (121,903,865)	$ (64,004,696)

Schedule of Property and Equipm

Schedule of Property and Equipment (Detail) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Property and Equipment, gross	$ 11,175,522	$ 6,156,319
Less: accumulated depreciation and amortization	(3,433,531)	(1,918,852)
Total property and equipment, net	7,741,991	4,237,467
Construction in Progress
Property, Plant and Equipment [Line Items]
Property and Equipment, gross	680,679	1,133,654
Analyzers
Property, Plant and Equipment [Line Items]
Property and Equipment, gross	5,045,481	1,139,352
Computers and office equipment
Property, Plant and Equipment [Line Items]
Property and Equipment, gross	462,441	290,754
Machinery and Equipment
Property, Plant and Equipment [Line Items]
Property and Equipment, gross	2,372,558	1,060,993
Leasehold Improvements
Property, Plant and Equipment [Line Items]
Property and Equipment, gross	393,271	366,945
Furniture and Fixtures
Property, Plant and Equipment [Line Items]
Property and Equipment, gross	72,618	16,145
Equipment under capital lease
Property, Plant and Equipment [Line Items]
Property and Equipment, gross	$ 2,148,476	$ 2,148,476

Property and Equipment - Additi

Property and Equipment - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Depreciation and amortization	$ 1,612,086	$ 1,157,976
Leasehold Improvements
Property, Plant and Equipment [Line Items]
Depreciation and amortization	1,514,679	1,040,531
Equipment under capital lease
Property, Plant and Equipment [Line Items]
Depreciation and amortization	$ 1,199,183	$ 601,947

Schedule of Accrued Liabilities

Schedule of Accrued Liabilities (Detail) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Payables and Accruals [Abstract]
Accrued payroll	$ 1,094,666	$ 421,645
Royalties	75,642	166,540
Accrued interest	44,291
Accrued property and use tax	10,905	10,905
Other	87,645	13,269
Total accrued liabilities	$ 1,313,149	$ 612,359

Lease Commitments - Additional

Lease Commitments - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2015USD ($)ft²	Dec. 31, 2014USD ($)
Operating Leased Assets [Line Items]
Proceeds from sale leaseback		$ 1,500,000
Capital lease obligations	$ 500,000
Sale-leaseback transaction lease term	At the end of each lease term, the leases shall automatically renew for twelve additional months at the current monthly rate unless the Company gives written notice 150 days prior to the end of the lease.
Amounts charged to expense under operating leases	$ 279,296	$ 293,773
Second Agreement
Operating Leased Assets [Line Items]
Sale-leaseback transaction agreement date	Apr. 30, 2014
Proceeds from sale leaseback	$ 1,500,000
Sale-leaseback transaction renewal period	24 months
Sale-leaseback transaction monthly payments	$ 64,665
Amortizing of capital lease	36 months
Period of future expense	12 months
First Agreement
Operating Leased Assets [Line Items]
Proceeds from sale leaseback	$ 2,500,000
Sale-leaseback transaction renewal period	36 months
Sale-leaseback transaction monthly payments	$ 74,875
Amortizing of capital lease	48 months
Sale-leaseback transaction renewal term	The Company shall have the opportunity to 1) repurchase the analyzers for a negotiated purchase price, not to exceed forty percent of their original cost; or 2) terminate the lease, return the property and enter into a new lease with new property that replaces the property of the old lease. Both the Company and the lessor shall have the right to reject any terms of option 1 or 2 and if rejected, the 12 month extension shall apply.
Building Space Lease
Operating Leased Assets [Line Items]
Area Of Leased Space | ft²	33,000
Operating Leases Monthly Base Rent Expense	$ 21,226
Lease Expiration Date	Apr. 30, 2016
Renewal Term	3 years
Office Space Lease
Operating Leased Assets [Line Items]
Area Of Leased Space | ft²	13,399
Operating Leases Monthly Base Rent Expense	$ 8,437
Aggregate lease, base	$ 1,231,526
Term of Contract	65 months

Schedule of Annual Maturities o

Schedule of Annual Maturities of Capital Leases (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Leases [Abstract]
2,016	$ 1,694,006
2,017	923,908
Total capital lease payments	2,617,914
Less amount representing interest	(461,078)
Total future minimum lease payments	2,156,836
Less: current portion of capital leases	(1,305,426)
Long term portion of capital leases	851,410	$ 2,156,837
Total future minimum lease payments	$ 2,156,836

Schedule of Operating Lease Com

Schedule of Operating Lease Commitments (Detail)	Dec. 31, 2015USD ($)
Leases [Abstract]
2,016	$ 355,797
2,017	246,255
2,018	252,092
2,019	259,132
2,020	266,455
Total operating lease commitments	$ 1,379,731

Notes Payable - Summary of Purc

Notes Payable - Summary of Purchased Certain Machinery and Equipment under Two Note Payable Agreements (Detail) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Debt Instrument [Line Items]
Total notes payable	$ 5,693	$ 55,687
Less: current portion of notes payable	(5,693)	(49,994)
Long term portion of notes payable		5,693
Note Payable, 15.2% Interest
Debt Instrument [Line Items]
Total notes payable	2,607	16,938
Note Payable, 10.0% Interest
Debt Instrument [Line Items]
Total notes payable	$ 3,086	$ 38,749

Notes Payable - Summary of Pu50

Notes Payable - Summary of Purchased Certain Machinery and Equipment under Two Note Payable Agreements (Parenthetical) (Detail)	12 Months Ended
	Dec. 31, 2015USD ($)
Note Payable, 15.2% Interest
Debt Instrument [Line Items]
Notes payable, interest rate	15.20%
Notes payable, monthly payments	$ 1,328
Maturity date of notes	Feb. 6, 2016
Note Payable, 10.0% Interest
Debt Instrument [Line Items]
Notes payable, interest rate	10.00%
Notes payable, monthly payments	$ 3,161
Maturity date of notes	Jan. 1, 2016

Convertible Notes Payable - Add

Convertible Notes Payable - Additional Information (Detail)	Dec. 30, 2015USD ($)$ / shares$ / Unitshares	Dec. 31, 2015USD ($)$ / sharesshares	Dec. 31, 2014USD ($)shares	Feb. 28, 2015shares
Debt Instrument [Line Items]
Warrants Exercisable | shares		13,219,597	5,447,940
Proceeds from issuance of convertible notes payable		$ 4,135,000	$ 100,000
Interest expense		11,757,445	1,136,054
Amortization of Discount costs		$ 122,050	$ 41,667
Outstanding warrants converted | shares		13,219,597	5,447,940
Loss on extinguishment of warrants		$ (4,038,063)
Series D Warrant
Debt Instrument [Line Items]
Exercise price | $ / shares		$ 1.85
Warrants Exercisable | shares		3,503,116
Outstanding warrants converted | shares		3,503,116
Series C Warrant
Debt Instrument [Line Items]
Exercise price | $ / shares		$ 2.55
Warrants Exercisable | shares		5,229,973		21,792,000
Outstanding warrants converted | shares		5,229,973
Securities Purchase Agreement
Debt Instrument [Line Items]
Note tranche receivable terms		The remaining cash purchase price of $13.8 million will be released to the Company in subsequent tranches subject to the following terms and conditions: (1) 25% will be released 30 trading days following the later of (x) the “Control Account Release Eligibility Date” and (ii) the first installment date under the Note, (2) 25% will be released 90 trading days following the Control Account Release Eligibility Date and (3) 25% will be released 120 trading days following the Control Account Release Eligibility Date.
Subordination Warrants | Series D Warrant
Debt Instrument [Line Items]
Proceeds from issuance of convertible notes payable	$ 4,600,000	$ 4,600,000
Remaining proceed from issuance of debt		13,800,000
Senior Secured Convertible Note
Debt Instrument [Line Items]
Convertible notes payable, principal		22,100,000
Debt instrument, original issue discount		$ 19,936,283
Debt Instrument Frequency Of Periodic Payment		The Company has agreed to make amortization payments with respect to the Notes in twelve (12) equal installments beginning four (4) months after the original date of issuance of December 30, 2015 (each, an “Installment Date”). On each installment date, assuming certain equity conditions are met, the installment payment shall automatically be converted into shares of Common Stock at (i) at 80% of the five day volume weighted average price of the common stock for the first four payments and (ii) at 85% of the five day volume weighted average price of the common stock for the last 8 payments with both conversion rates being subject to a floor conversion price of $0.20.
Senior Secured Convertible Note | Securities Purchase Agreement
Debt Instrument [Line Items]
Convertible notes payable, principal	$ 22,100,000
Debt instrument, number shares to be issued upon conversion | shares	11,945,946
Convertible debt, conversion price | $ / shares	$ 1.85
Price adjustment percentage	19.90%
Note agreement carrying value	$ 18,400,000
Senior Secured Convertible Note | Securities Purchase Agreement | Notes issued for cash
Debt Instrument [Line Items]
Convertible notes payable, principal	20,000,000
Note agreement carrying value	18,400,000
Debt instrument, original issue discount	$ 1,600,000	$ 20,000,000
Notes payable, interest rate	6.00%
Debt Issuance cost incurred	$ 568,685
Interest expense		10,594,182
Amortization of Discount costs		63,717
Senior Secured Convertible Note | Securities Purchase Agreement | Notes issued for cash | Embedded Derivative Financial Instruments [Member]
Debt Instrument [Line Items]
Convertible Debt, Fair Value Disclosures		14,788,365
Senior Secured Convertible Note | Securities Purchase Agreement | Notes issued upon exchange of outstanding Series C Warrants
Debt Instrument [Line Items]
Convertible notes payable, principal	$ 2,100,000
Conversion of stock, shares converted | shares	1,050,000
Exercise price | $ / shares	$ 2
Loss on extinguishment of warrants		4,038,063
Senior Secured Convertible Note | Securities Purchase Agreement | Notes issued upon exchange of outstanding Series C Warrants | Embedded Derivative Financial Instruments [Member]
Debt Instrument [Line Items]
Convertible Debt, Fair Value Disclosures		1,865,729
Senior Secured Convertible Note | Securities Purchase Agreement | Series D Warrant
Debt Instrument [Line Items]
Exercise price | $ / shares	$ 1.85
Common Stock, Capital Shares Reserved for Future Issuance | shares	120,000,000
Warrants Exercisable | shares	3,503,116
Weighted Average Remainder Contractual Term in Years, Exercised	5 years
Conversion feature, floor price | $ / Unit	1.16
Senior Secured Convertible Note | Securities Purchase Agreement | Series D Warrant | Notes issued for cash
Debt Instrument [Line Items]
Warrant, Fair Value Disclosures		13,637,132
Senior Secured Convertible Note | Securities Purchase Agreement | Series D Warrant | Notes issued upon exchange of outstanding Series C Warrants
Debt Instrument [Line Items]
Warrant, Fair Value Disclosures		2,412,574
Senior Secured Convertible Note | Securities Purchase Agreement | Series C Warrant | Notes issued upon exchange of outstanding Series C Warrants
Debt Instrument [Line Items]
Warrant, Fair Value Disclosures		$ 2,340,240
Outstanding warrants converted | shares		1,050,000

Convertible Notes Payable - Sum

Convertible Notes Payable - Summary of Convertible Notes Outstanding (Detail)	Dec. 31, 2015USD ($)
Debt Instrument [Line Items]
Net convertible note payable	$ 2,163,717
Less current portion	(1,638,717)
Convertible notes payable, long term	525,000
Net convertible note payable	2,163,717
Senior Secured Convertible Note
Debt Instrument [Line Items]
Convertible notes payable, principal	22,100,000
Debt discounts	$ (19,936,283)

Notes Payable - Related Party -

Notes Payable - Related Party - Additional Information (Detail)	Oct. 08, 2014$ / sharesshares	Apr. 30, 2015USD ($)	Feb. 28, 2015USD ($)$ / shares	Oct. 31, 2014	Jul. 31, 2014USD ($)$ / sharesshares	Dec. 31, 2015$ / sharesshares	Dec. 31, 2014USD ($)$ / sharesshares	Dec. 30, 2015$ / shares	Mar. 31, 2015$ / shares
Related Party Transaction [Line Items]
Warrants Exercisable						13,219,597	5,447,940
Common Stock
Related Party Transaction [Line Items]
Conversion of stock, shares issued							771
IPO | Common Stock
Related Party Transaction [Line Items]
Conversion of stock, shares issued	60,279
Series D Convertible Preferred Stock
Related Party Transaction [Line Items]
Conversion of preferred stock to common stock, conversion ratio				200	12,000
Class A Warrant
Related Party Transaction [Line Items]
Common stock exchange ratio						60	60
Preferred units issued as consideration, warrants price per share | $ / shares			$ 4.92			$ 0.03	$ 4.92	$ 0.03	$ 2.20
Warrants Exercisable						1,532,598	2,041,239
Class A Warrant | IPO
Related Party Transaction [Line Items]
Preferred units issued as consideration, warrants price per share | $ / shares	$ 7
Class B Warrant
Related Party Transaction [Line Items]
Common stock exchange ratio						60	60
Preferred units issued as consideration, warrants price per share | $ / shares						$ 0.03	$ 0.2	$ 0.03
Warrants Exercisable						1,310,956	1,645,845
Notes Payable To Related Party
Related Party Transaction [Line Items]
Convertible notes payable, principal | $					$ 500,000
Notes payable, interest rate					20.00%
Note maturity date description						The Company may extend the due date of the note to July 18, 2016 by giving notice no later than April 18, 2015
Note extension fee amount | $					$ 10,000
Notes, maturity date					Jul. 18, 2015
Prepaid interest | $					$ 25,000
Number of preferred units issued as consideration					4,000,000		4,000,000
Value of preferred units issued as consideration | $					$ 100,000		$ 100,000
Preferred units issued as consideration, series D preferred shares					4,000,000
Preferred units issued as consideration, price per share | $ / shares							$ 0.025
Notes Payable To Related Party | IPO | Common Stock
Related Party Transaction [Line Items]
Conversion of stock, shares issued						20,000
Notes Payable To Related Party | Series D Convertible Preferred Stock | IPO
Related Party Transaction [Line Items]
Conversion of stock, shares converted						4,000,000
Notes Payable To Related Party | Class A Warrant
Related Party Transaction [Line Items]
Preferred units issued as consideration, warrants price per share | $ / shares						$ 0.03	4.92
Warrants Exercisable					20,000
Notes Payable To Related Party | Class B Warrant
Related Party Transaction [Line Items]
Preferred units issued as consideration, warrants price per share | $ / shares						$ 0.03	$ 0.20
Warrants Exercisable					20,000
Spring Forth Investments, LLC
Related Party Transaction [Line Items]
Convertible notes payable, principal | $			$ 250,000
Notes payable, interest rate			12.00%
Note maturity date description						The loan had an interest rate of twelve percent (12%) per year and matured the earlier of (i) 90 days from the date of the loan agreement, or (ii) five days after the closing of a registered public offering of securities of the Company.
Debt instrument maturity period after loan agreement			90 days
Debt instrument maturity period after closing of registered public offering			5 days
Notes payable, interest rate | $		$ 4,192
Termination Fee | $		$ 12,500
Spring Forth Investments, LLC | Notes Payable To Related Party
Related Party Transaction [Line Items]
Convertible notes payable, principal | $					$ 500,000
Notes payable, interest rate					20.00%
Debt Instrument Frequency Of Periodic Payment						Monthly
Note maturity date description						The original maturity date for the note was July 18, 2015, which was extended by the Company to July 18, 2016 by giving notice and paying an extension fee of $10,000.
Note extension fee amount | $					$ 10,000
Notes, maturity date					Jul. 18, 2015	Jul. 18, 2016
Prepaid interest | $					$ 25,000
Number of preferred units issued as consideration					4,000,000
Value of preferred units issued as consideration | $					$ 100,000
Preferred units issued as consideration, series D preferred shares					4,000,000
Preferred units issued as consideration, price per share | $ / shares					$ 0.025
Spring Forth Investments, LLC | Notes Payable To Related Party | IPO
Related Party Transaction [Line Items]
Conversion of preferred stock to common stock, conversion ratio					12,000
Spring Forth Investments, LLC | Notes Payable To Related Party | IPO | Common Stock
Related Party Transaction [Line Items]
Conversion of stock, shares issued					334
Spring Forth Investments, LLC | Notes Payable To Related Party | Series D Convertible Preferred Stock | IPO
Related Party Transaction [Line Items]
Conversion of stock, shares converted					4,000,000
Spring Forth Investments, LLC | Notes Payable To Related Party | Class A Warrant
Related Party Transaction [Line Items]
Common stock exchange ratio					60
Warrants issued					20,000
Preferred units issued as consideration, warrants price per share | $ / shares					$ 295.20
Spring Forth Investments, LLC | Notes Payable To Related Party | Class B Warrant
Related Party Transaction [Line Items]
Common stock exchange ratio					60
Preferred units issued as consideration, warrants price per share | $ / shares					$ 12
Warrants Exercisable					20,000

Common Stock - Additional Infor

Common Stock - Additional Information (Detail)	Dec. 11, 2015$ / shares	Aug. 25, 2015shares	Oct. 08, 2014USD ($)$ / sharesshares	Sep. 21, 2015shares	Jun. 30, 2015USD ($)shares	Dec. 31, 2015USD ($)$ / sharesshares	Dec. 31, 2014USD ($)$ / sharesshares	Dec. 30, 2015$ / shares	Mar. 31, 2015$ / shares	Feb. 28, 2015$ / sharesshares
Class Of Stock [Line Items]
Common stock, shares authorized						200,000,000	50,000,000
Common stock, par value | $ / shares	$ 0.0001					$ 0.0001	$ 0.0001
Common stock, shares issued						10,390,408	84,777
Common stock, shares outstanding						10,390,408	84,777
Proceeds from Warrant | $						$ 3,161,220	$ 31,600
Warrants Exercisable						13,219,597	5,447,940
Warrants exercised by underwriter			172,500
Proceeds from Issuance of Initial Public Offering | $			$ 6,400,000
Proceeds from exercise of warrants | $							$ 31,600
Common shares issued upon cash less exercise of warrants						9,220
Proceeds from issuance of common stock | $							$ 6,375,837
Series A Convertible Preferred Stock
Class Of Stock [Line Items]
Conversion of stock, shares converted							9,250,000
Conversion of preferred stock to common stock, conversion ratio							771
Series E Convertible Preferred Stock
Class Of Stock [Line Items]
Conversion of stock, shares converted						2,650,403
Common shares issued upon exercise of warrants						176,695
Issuance of stock						14,750
Conversion of preferred stock to common stock, conversion ratio						15
Common Stock
Class Of Stock [Line Items]
Conversion of stock, shares issued							771
Conversion of preferred stock to common stock, conversion ratio	0.01666667
Common shares issued upon exercise of warrants							2,634
Issuance of stock						0	19,167
Common Stock | IPO
Class Of Stock [Line Items]
Conversion of stock, shares issued			60,279
Conversion of preferred stock to common stock, conversion ratio			12,000
Issuance of stock			19,167
Common Stock | Series E Convertible Preferred Stock
Class Of Stock [Line Items]
Conversion of stock, shares issued						176,695
Conversion of stock, shares converted						2,650,403
Conversion of preferred stock to common stock, conversion ratio						15
Convertible Preferred Stock | Series A Convertible Preferred Stock
Class Of Stock [Line Items]
Conversion of stock, shares converted							9,250,000
Conversion of preferred stock to common stock, conversion ratio							12,000
Series D Warrant
Class Of Stock [Line Items]
Shares issued price per share | $ / shares						$ 1.85
Warrants Exercisable						3,503,116
Series D Warrant | Common Stock
Class Of Stock [Line Items]
Shares issued price per share | $ / shares						$ 1.85
Warrants Exercisable						3,503,116
Class B Warrant
Class Of Stock [Line Items]
Common shares issued upon exercise of warrants							2,634
Warrants exercised							158,000
Proceeds from Warrant | $							$ 31,600
Shares issued price per share | $ / shares						$ 0.03	$ 0.2	$ 0.03
Warrants Exercisable						1,310,956	1,645,845
Cashless exercise of Warrants						334,889
Class A Warrant
Class Of Stock [Line Items]
Shares issued price per share | $ / shares						$ 0.03	$ 4.92	0.03	$ 2.20	$ 4.92
Warrants Exercisable						1,532,598	2,041,239
Cashless exercise of Warrants						508,641
Class A Warrant | IPO
Class Of Stock [Line Items]
Warrants issued during period			1,150,000
Number of shares can be converted description						In October 2014, the Company completed an IPO, whereby the Company sold 19,167 shares of its common stock and 1,150,000 Series A Warrants, which were sold in units of one share of common stock for every 60 units and one Series A Warrant at a public offering price of $7.00 per unit.
Shares issued price per share | $ / shares			$ 7
Common Warrants
Class Of Stock [Line Items]
Shares issued price per share | $ / shares								$ 0.03
Warrants Exercisable						463,356	438,356
Common Warrants | IPO | Underwriter Purchase Options
Class Of Stock [Line Items]
Warrants Exercisable			57,500
Series A Warrant
Class Of Stock [Line Items]
Common shares issued upon exercise of warrants						17,917
Warrants exercised						1,074,082
Proceeds from Warrant | $						$ 2,252,020
Shares issued price per share | $ / shares						$ 2.20	$ 7		$ 7
Warrants Exercisable							1,322,500
Proceeds from exercise of warrants | $						$ 2,252,020
Series B Warrant
Class Of Stock [Line Items]
Shares issued price per share | $ / shares						$ 8.75
Warrants Exercisable						1,074,082
Series C Warrant
Class Of Stock [Line Items]
Common shares issued upon exercise of warrants					6,400
Warrants exercised					384,000
Proceeds from Warrant | $					$ 979,200
Warrants issued during period		21,408,000
Shares issued price per share | $ / shares						$ 2.55
Warrants Exercisable						5,229,973				21,792,000
Proceeds from exercise of warrants | $						$ 979,200
Common shares issued upon cash less exercise of warrants						10,101,480
Cashless exercise of Warrants				15,128,027		15,630,027
Proceeds from issuance of common stock | $						$ 979,200
Series C Warrant | Cashless Exercise
Class Of Stock [Line Items]
Conversion of stock, shares converted						15,246,027
Issuance of stock						10,095,080
Series C Warrant | Warrant, Cash Exercise
Class Of Stock [Line Items]
Conversion of stock, shares converted						384,000
Issuance of stock						6,400
Series C Warrant | Series E Convertible Preferred Stock
Class Of Stock [Line Items]
Issuance of stock		2,676,000
Series C Warrant | Common Stock
Class Of Stock [Line Items]
Common shares issued upon exercise of warrants						6,400
Issuance of stock					6,400
Notes issued upon exchange of outstanding Series C Warrants | Securities Purchase Agreement | Series D Warrant
Class Of Stock [Line Items]
Common Stock, Capital Shares Reserved for Future Issuance						120,000,000

Preferred Stock - Additional In

Preferred Stock - Additional Information (Detail)	Dec. 11, 2015	Aug. 25, 2015shares	Oct. 08, 2014$ / sharesshares	Jun. 30, 2015USD ($)shares	Feb. 28, 2015USD ($)$ / sharesshares	Oct. 31, 2014	Jul. 31, 2014USD ($)$ / sharesshares	Dec. 31, 2015USD ($)$ / sharesshares	Dec. 31, 2014USD ($)$ / sharesshares	Dec. 30, 2015$ / shares	Mar. 31, 2015$ / shares
Class Of Stock [Line Items]
Preferred stock, shares authorized								5,000,000	5,000,000
Preferred stock, par value | $ / shares								$ 0.001	$ 0.001
Preferred stock, shares issued								88,347	0
Preferred Stock, Shares Outstanding								88,347	0
Proceeds from issuance of convertible preferred stock value | $					$ 21,800,000				$ 6,569,886
Preferred shares issued, price per share | $ / shares					$ 8.80
Warrants Exercisable								13,219,597	5,447,940
Conversion of preferred stock to common stock | $								$ 2,651	$ 18,846,539
Common stock, shares authorized								200,000,000	50,000,000
Preferred unit description								Each unit consisted of one share of our Series E Convertible Preferred Stock and eight Series C Warrants (the "Units").
Separation description								The original terms of the Units provided that shares of Series E Convertible Preferred Stock and the Series C Warrants would automatically separate on August 25, 2015. However, the shares of Series E Convertible Preferred Stock and the Series C Warrants would separate prior to August 25, 2015 if at any time after 30 days from February 25, 2015 the closing price of our common stock was greater than $240.00 per share for 20 consecutive trading days (the “Separation Trigger Date”). The Company refers to this separation herein as Early Separation. In the event of Early Separation, the shares of Series E Convertible Preferred Stock and the Series C Warrants would separate 15 days after the Separation Trigger Date. In June 2015, the above terms of the Series E Convertible Preferred Stock and Series C Warrants were each modified to allow for an optional early separation and conversion upon the cash exercise of all eight of the Series C Warrants within the Unit.
Proceeds from exercise of warrants | $								$ 3,161,220	$ 31,600
Preferred units outstanding		2,676,000
Convertible Notes Payable
Class Of Stock [Line Items]
Notes qualified for equity financing | $									$ 5,000,000
Notes Payable To Related Party
Class Of Stock [Line Items]
Number of preferred units issued as consideration							4,000,000		4,000,000
Value of preferred units issued as consideration | $							$ 100,000		$ 100,000
Preferred units issued as consideration, price per share | $ / shares									$ 0.025
Series C Warrant
Class Of Stock [Line Items]
Warrants Exercisable					21,792,000			5,229,973
Preferred units issued as consideration, warrants price per share | $ / shares								$ 2.55
Number of shares included in preferred unit					8
Separation description								The Series C Warrants have an exercise price of $153.00 per common share and will expire on February 25, 2020. The original terms of the Units provided that shares of Series E Convertible Preferred Stock and the Series C Warrants would automatically separate on August 25, 2015. However, the shares of Series E Convertible Preferred Stock and the Series C Warrants would separate prior to August 25, 2015 if at any time after 30 days from February 25, 2015 the closing price of our common stock was greater than $240.00 per share for 20 consecutive trading days (the “Separation Trigger Date”). The Company refers to this separation herein as Early Separation. In the event of Early Separation, the shares of Series E Convertible Preferred Stock and the Series C Warrants would separate 15 days after the Separation Trigger Date. In June 2015, the above terms of the Series E Convertible Preferred Stock and Series C Warrants were each modified to allow for an optional early separation and conversion upon the cash exercise of all eight of the Series C Warrants within the Unit.
Number of preferred units separated		2,676,000		48,000
Warrants exercised				384,000
Common shares issued upon exercise of warrants				6,400
Proceeds from exercise of warrants | $				$ 979,200
Number of warrants separated		21,408,000
Class A Warrant
Class Of Stock [Line Items]
Warrants Exercisable								1,532,598	2,041,239
Preferred units issued as consideration, warrants price per share | $ / shares					$ 4.92			$ 0.03	$ 4.92	$ 0.03	$ 2.20
Class A Warrant | Convertible Notes Payable
Class Of Stock [Line Items]
Warrants Exercisable							82,625
Preferred units issued as consideration, warrants price per share | $ / shares							$ 4.92
Class A Warrant | Notes Payable To Related Party
Class Of Stock [Line Items]
Warrants Exercisable							20,000
Preferred units issued as consideration, warrants price per share | $ / shares								$ 0.03	$ 4.92
Preferred units issued as consideration, warrants									20,000
Class B Warrant
Class Of Stock [Line Items]
Warrants Exercisable								1,310,956	1,645,845
Preferred units issued as consideration, warrants price per share | $ / shares								$ 0.03	$ 0.2	$ 0.03
Warrants exercised									158,000
Common shares issued upon exercise of warrants									2,634
Proceeds from exercise of warrants | $									$ 31,600
Class B Warrant | Convertible Notes Payable
Class Of Stock [Line Items]
Warrants Exercisable							82,625
Preferred units issued as consideration, warrants price per share | $ / shares							$ 0.20
Class B Warrant | Notes Payable To Related Party
Class Of Stock [Line Items]
Warrants Exercisable							20,000
Preferred units issued as consideration, warrants price per share | $ / shares								$ 0.03	$ 0.20
Preferred units issued as consideration, warrants									20,000
IPO | Class A Warrant
Class Of Stock [Line Items]
Preferred units issued as consideration, warrants price per share | $ / shares			$ 7
Underwriters Warrants
Class Of Stock [Line Items]
Exercised								14,750
Proceeds from Options Exercised | $								$ 162,250
Options Exercisable , Exercise Price | $ / shares								$ 11
Common Stock
Class Of Stock [Line Items]
Issuance of stock								0	19,167
Conversion of stock, shares issued									771
Conversion of preferred stock to common stock, conversion ratio	0.01666667
Common shares issued upon exercise of warrants									2,634
Exercised								0
Common Stock | Series C Warrant
Class Of Stock [Line Items]
Issuance of stock				6,400
Common shares issued upon exercise of warrants								6,400
Common Stock | IPO
Class Of Stock [Line Items]
Issuance of stock			19,167
Conversion of stock, shares issued			60,279
Conversion of preferred stock to common stock, conversion ratio			12,000
Common Stock | IPO | Notes Payable To Related Party
Class Of Stock [Line Items]
Conversion of stock, shares issued								20,000
Convertible Preferred Stock
Class Of Stock [Line Items]
Preferred stock, shares authorized								5,000,000	5,000,000
Preferred stock, par value | $ / shares								$ 0.001	$ 0.001
Issuance of stock					2,724,000
Series E Convertible Preferred Stock
Class Of Stock [Line Items]
Preferred stock, shares issued								88,347
Preferred Stock, Shares Outstanding								88,347
Issuance of stock								14,750
Conversion of preferred stock to common stock, conversion ratio								15
Conversion of stock, shares converted								2,650,403
Number of shares included in preferred unit					1
Number of preferred units separated		2,676,000
Common shares issued upon exercise of warrants								176,695
Preferred units outstanding								88,347
Series E Convertible Preferred Stock | Series C Warrant
Class Of Stock [Line Items]
Issuance of stock		2,676,000
Series E Convertible Preferred Stock | Common Stock
Class Of Stock [Line Items]
Conversion of preferred stock to common stock, conversion ratio								15
Conversion of stock, shares converted								2,650,403
Conversion of stock, shares issued								176,695
Series C Warrant
Class Of Stock [Line Items]
Issuance of stock								118,000
Series C Convertible Preferred Stock | Convertible Preferred Stock
Class Of Stock [Line Items]
Issuance of stock									14,888,211
Proceeds from issuance of convertible preferred stock value | $									$ 366,250
Preferred shares issued, price per share | $ / shares									$ 0.0246
Series D Convertible Preferred Stock
Class Of Stock [Line Items]
Proceeds from issuance of convertible preferred stock value | $									$ 6,203,636
Preferred shares issued, price per share | $ / shares									$ 0.025
Gross proceeds from issuance of convertible preferred stock value | $									$ 7,139,164
Convertible debt, amount converted | $							$ 400,000
Conversion of notes payable to preferred stock, accrued interest | $							$ 13,129
Convertible debt, conversion price | $ / shares							$ 0.025
Conversion of preferred stock to common stock, conversion ratio						200	12,000
Series D Convertible Preferred Stock | Class A Warrant | Convertible Notes Payable
Class Of Stock [Line Items]
Warrants Exercisable									1,427,832
Preferred units issued as consideration, warrants price per share | $ / shares									$ 4.92
Warrants granted as part of offering costs									466,436
Series D Convertible Preferred Stock | Class B Warrant | Convertible Notes Payable
Class Of Stock [Line Items]
Warrants Exercisable									1,427,832
Warrants granted as part of offering costs									251,216
Series D Convertible Preferred Stock | Series D Preferred Stock Warrant
Class Of Stock [Line Items]
Warrants granted as part of offering costs									7,200,000
Series D Convertible Preferred Stock | IPO | Notes Payable To Related Party
Class Of Stock [Line Items]
Conversion of stock, shares converted								4,000,000
Series D Convertible Preferred Stock | Convertible Preferred Stock
Class Of Stock [Line Items]
Issuance of stock									285,566,560
Preferred stock, shares issued									285,566,560
Stock issued during period upon conversion of debt, shares							16,525,121
Series A Convertible Preferred Stock
Class Of Stock [Line Items]
Conversion of preferred stock to common stock, conversion ratio									771
Conversion of stock, shares converted									9,250,000
Conversion of preferred stock to common stock | $									$ 1,480,000
Series A Convertible Preferred Stock | Convertible Preferred Stock
Class Of Stock [Line Items]
Conversion of stock, shares converted									9,250,000
Conversion of preferred stock to common stock, conversion ratio									12,000

Warrants - Warrants Outstanding

Warrants - Warrants Outstanding and Exercisable (Detail)	12 Months Ended
	Dec. 31, 2015$ / sharesshares	Dec. 31, 2014$ / sharesshares	Dec. 30, 2015$ / shares	Mar. 31, 2015$ / shares	Feb. 28, 2015$ / sharesshares
Class Of Warrant Or Right [Line Items]
Warrants outstanding	13,219,597	5,447,940
Warrants Exercisable	13,219,597	5,447,940
Share of Common stock underlying Warrant	3,768,879	90,800
Class A Warrant
Class Of Warrant Or Right [Line Items]
Warrants outstanding	1,532,598	2,041,239
Warrants Exercisable	1,532,598	2,041,239
Exercise price | $ / shares	$ 0.03	$ 4.92	$ 0.03	$ 2.20	$ 4.92
Common stock exchange ratio	60	60
Share of Common stock underlying Warrant	25,566	34,021
Exercise Price Per One Common Share | $ / shares	$ 1.85	$ 295.20
Class B Warrant
Class Of Warrant Or Right [Line Items]
Warrants outstanding	1,310,956	1,645,845
Warrants Exercisable	1,310,956	1,645,845
Exercise price | $ / shares	$ 0.03	$ 0.2	0.03
Common stock exchange ratio	60	60
Share of Common stock underlying Warrant	21,862	27,431
Exercise Price Per One Common Share | $ / shares	$ 1.85	$ 12
Series A Warrant
Class Of Warrant Or Right [Line Items]
Warrants outstanding		1,322,500
Warrants Exercisable		1,322,500
Exercise price | $ / shares	$ 2.20	$ 7		$ 7
Common stock exchange ratio		60
Share of Common stock underlying Warrant		22,042
Exercise Price Per One Common Share | $ / shares		$ 420
Warrants Expiration		2015-10
Common Warrants
Class Of Warrant Or Right [Line Items]
Warrants outstanding	463,356	438,356
Warrants Exercisable	463,356	438,356
Exercise price | $ / shares			$ 0.03
Common stock exchange ratio	60	60
Share of Common stock underlying Warrant	7,735	7,306
Series B Warrant
Class Of Warrant Or Right [Line Items]
Warrants outstanding	1,074,082
Warrants Exercisable	1,074,082
Exercise price | $ / shares	$ 8.75
Common stock exchange ratio	60
Share of Common stock underlying Warrant	17,917
Exercise Price Per One Common Share | $ / shares	$ 525
Series C Warrant
Class Of Warrant Or Right [Line Items]
Warrants outstanding	5,229,973
Warrants Exercisable	5,229,973				21,792,000
Exercise price | $ / shares	$ 2.55
Common stock exchange ratio	60
Share of Common stock underlying Warrant	87,167
Exercise Price Per One Common Share | $ / shares	$ 153
Warrants Expiration	2017-01
Series D Warrant
Class Of Warrant Or Right [Line Items]
Warrants outstanding	3,503,116
Warrants Exercisable	3,503,116
Exercise price | $ / shares	$ 1.85
Common stock exchange ratio	1
Share of Common stock underlying Warrant	3,503,116
Exercise Price Per One Common Share | $ / shares	$ 1.85
Warrants Expiration	2021-06
Subordination
Class Of Warrant Or Right [Line Items]
Warrants outstanding	105,516
Warrants Exercisable	105,516
Exercise price | $ / shares	$ 1.85
Common stock exchange ratio	1
Share of Common stock underlying Warrant	105,516
Exercise Price Per One Common Share | $ / shares	$ 1.85
Warrants Expiration	2021-06
Minimum | Class A Warrant
Class Of Warrant Or Right [Line Items]
Warrants Expiration	2021-04	2021-04
Minimum | Class B Warrant
Class Of Warrant Or Right [Line Items]
Warrants Expiration	2021-04	2021-04
Minimum | Common Warrants
Class Of Warrant Or Right [Line Items]
Exercise price | $ / shares	$ 0.03	$ 2
Exercise Price Per One Common Share | $ / shares	$ 1.85	$ 120
Warrants Expiration	2016-04	2016-04
Minimum | Series B Warrant
Class Of Warrant Or Right [Line Items]
Warrants Expiration	2021-03
Maximum | Class A Warrant
Class Of Warrant Or Right [Line Items]
Warrants Expiration	2021-07	2021-07
Maximum | Class B Warrant
Class Of Warrant Or Right [Line Items]
Warrants Expiration	2021-07	2021-07
Maximum | Common Warrants
Class Of Warrant Or Right [Line Items]
Exercise price | $ / shares	$ 32	$ 32
Exercise Price Per One Common Share | $ / shares	$ 1,920	$ 1,920
Warrants Expiration	2021-07	2021-07
Maximum | Series B Warrant
Class Of Warrant Or Right [Line Items]
Warrants Expiration	2021-07

Warrants - Additional Informati

Warrants - Additional Information (Detail)	1 Months Ended			12 Months Ended
	Oct. 31, 2014shares	Sep. 30, 2014USD ($)shares	Jul. 31, 2014	Dec. 31, 2015USD ($)shares	Dec. 31, 2014USD ($)shares	Dec. 31, 2013shares
Class Of Warrant Or Right [Line Items]
Warrants outstanding				13,219,597	5,447,940
Warrants previously issued		157,093
Fair value of warrant expensed | $		$ 25,061		$ 19,714,808	$ 8,396,169
Series A Convertible Preferred Stock
Class Of Warrant Or Right [Line Items]
Warrants issued	2,231,727
Conversion of preferred stock to common stock, conversion ratio					771
Series D Convertible Preferred Stock
Class Of Warrant Or Right [Line Items]
Warrants issued	7,200,000
Conversion of preferred stock to common stock, conversion ratio	200		12,000
Common Stock Warrants
Class Of Warrant Or Right [Line Items]
Warrants issued upon conversion	47,158
Class A And Class B Warrants
Class Of Warrant Or Right [Line Items]
Warrants granted					2,855,664
Warrants Issued Convertible Notes Payable
Class Of Warrant Or Right [Line Items]
Common stock warrants granted with nominal value					1,048,698
Preferred D Stock Warrants
Class Of Warrant Or Right [Line Items]
Warrants outstanding					0	0
Warrants granted					7,200,000
Warrants issued					7,200,000
Common Stock Warrants
Class Of Warrant Or Right [Line Items]
Warrants outstanding				13,219,597	5,447,940	274,420
Warrants granted				26,617,714	5,331,520
Common Stock Warrants | IPO
Class Of Warrant Or Right [Line Items]
Warrants granted	57,500
Series A Warrants | IPO
Class Of Warrant Or Right [Line Items]
Warrants granted	1,322,500

Warrants - Schedule of Assumpti

Warrants - Schedule of Assumptions Used in Calculation of Fair Value of the Options Exchanged (Detail) - Warrant	1 Months Ended
	Sep. 30, 2014$ / shares
Class Of Warrant Or Right [Line Items]
Fair market value of one share of common stock	$ 296.40
Aggregate exercise price of 60 warrants	$ 600
Risk Free Rate	0.61%
Dividend yield	0.00%
Expected volatility	37.23%
Contractual Term	1 year 11 months 19 days

Warrants - Preferred A Stock Wa

Warrants - Preferred A Stock Warrants Activity (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Class Of Warrant Or Right [Line Items]
Warrants, Beginning Balance	5,447,940
Warrants, Ending Balance	13,219,597	5,447,940
Preferred A Stock Warrants
Class Of Warrant Or Right [Line Items]
Warrants, Beginning Balance		2,231,727
Warrants granted		0
Warrants Converted		(2,231,727)
Warrants Expired		0
Warrants, Ending Balance
Weighted Average Exercise Price, Warrants Outstanding Beginning Balance	$ 0	$ 0.16
Weighted Average Exercise Price, Granted		0
Weighted Average Exercise Price, Converted		0.16
Weighted Average Exercise Price, Expired		0
Weighted Average Exercise Price, Warrants Outstanding Ending Balance		$ 0
Weighted Average Remainder Contractual Term in Years, Warrants Outstanding		3 years 1 month 6 days
Weighted Average Remainder Contractual Term in Years, Converted		2 years 3 months 18 days

Warrants - Preferred D Stock Wa

Warrants - Preferred D Stock Warrants Activity (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Class Of Warrant Or Right [Line Items]
Warrants, Beginning Balance	5,447,940
Warrants, Ending Balance	13,219,597	5,447,940
Preferred D Stock Warrants
Class Of Warrant Or Right [Line Items]
Warrants, Beginning Balance	0	0
Warrants granted		7,200,000
Warrants Converted		(7,200,000)
Warrants Expired		0
Warrants, Ending Balance		0
Weighted Average Exercise Price, Warrants Outstanding Beginning Balance	$ 0	$ 0
Weighted Average Exercise Price, Granted		0.025
Weighted Average Exercise Price, Converted		0.025
Weighted Average Exercise Price, Expired		0
Weighted Average Exercise Price, Warrants Outstanding Ending Balance		$ 0
Weighted Average Remainder Contractual Term in Years, Warrants Outstanding		0 years
Warrants Weighted Average Remainder Contractual Terms Granted		6 years 9 months 18 days
Weighted Average Remainder Contractual Term in Years, Converted		6 years 8 months 12 days
Weighted Average Remainder Contractual Term in Years, Expired		0 years
Weighted Average Remainder Contractual Term in Years, Warrants Outstanding		0 years

Warrants - Class A Warrants - A

Warrants - Class A Warrants - Additional Information (Detail) - Class A Warrant - $ / shares	12 Months Ended
	Dec. 31, 2015	Dec. 30, 2015	Mar. 31, 2015	Feb. 28, 2015	Dec. 31, 2014
Class Of Warrant Or Right [Line Items]
Cashless exercise of Warrants	508,641
Issuance of common stock upon exercise of warrants under cashless exercise provision	3,936
Exercise price	$ 0.03	$ 0.03	$ 2.20	$ 4.92	$ 4.92

Warrants - Class B Warrants - A

Warrants - Class B Warrants - Additional Information (Detail) - Class B Warrant - $ / shares	12 Months Ended
	Dec. 31, 2015	Dec. 30, 2015	Dec. 31, 2014
Class Of Warrant Or Right [Line Items]
Cashless exercise of Warrants	334,889
Issuance of common stock upon exercise of warrants under cashless exercise provision	5,284
Exercise price	$ 0.03	$ 0.03	$ 0.2

Warrants - Series A Warrants -

Warrants - Series A Warrants - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Mar. 31, 2015
Class Of Warrant Or Right [Line Items]
Proceeds from exercise of warrants	$ 3,161,220	$ 31,600
Series A Warrant
Class Of Warrant Or Right [Line Items]
Warrants exercised	1,074,082
Proceeds from exercise of warrants	$ 2,252,020
Issuance of common stock upon exercise of warrants under cashless exercise provision	17,917
Warrants Expiration Date	Oct. 15, 2015
Number of warrants expired	248,418
Exercise price	$ 2.20	$ 7	$ 7

Warrants - Series B Warrants -

Warrants - Series B Warrants - Additional Information (Detail) - shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Class Of Warrant Or Right [Line Items]
Warrants Exercisable	13,219,597	5,447,940
Series B Warrant
Class Of Warrant Or Right [Line Items]
Warrants Exercisable	1,074,082
Weighted Average Remainder Contractual Term in Years, Exercised	6 years
Percentage of public offering price	125.00%
Series A Warrant
Class Of Warrant Or Right [Line Items]
Warrants Exercisable		1,322,500
Warrants exercised	1,074,082

Warrants - Series C Warrants -

Warrants - Series C Warrants - Additional Information (Detail) - USD ($)	Aug. 25, 2015	Sep. 21, 2015	Jun. 30, 2015	Feb. 28, 2015	Dec. 31, 2015	Dec. 31, 2014
Class Of Warrant Or Right [Line Items]
Warrants Exercisable					13,219,597	5,447,940
Separation description					The original terms of the Units provided that shares of Series E Convertible Preferred Stock and the Series C Warrants would automatically separate on August 25, 2015. However, the shares of Series E Convertible Preferred Stock and the Series C Warrants would separate prior to August 25, 2015 if at any time after 30 days from February 25, 2015 the closing price of our common stock was greater than $240.00 per share for 20 consecutive trading days (the “Separation Trigger Date”). The Company refers to this separation herein as Early Separation. In the event of Early Separation, the shares of Series E Convertible Preferred Stock and the Series C Warrants would separate 15 days after the Separation Trigger Date. In June 2015, the above terms of the Series E Convertible Preferred Stock and Series C Warrants were each modified to allow for an optional early separation and conversion upon the cash exercise of all eight of the Series C Warrants within the Unit.
Proceeds from exercise of warrants					$ 3,161,220	$ 31,600
Warrants outstanding					13,219,597	5,447,940
Series E Convertible Preferred Stock
Class Of Warrant Or Right [Line Items]
Number of preferred units separated	2,676,000
Shares, new Issues					14,750
Common Stock
Class Of Warrant Or Right [Line Items]
Shares, new Issues					0	19,167
Share issued upon exercise of option					0
Series C Warrant
Class Of Warrant Or Right [Line Items]
Warrants Exercisable				21,792,000	5,229,973
Warrants expire period				2020-02
Separation description					The Series C Warrants have an exercise price of $153.00 per common share and will expire on February 25, 2020. The original terms of the Units provided that shares of Series E Convertible Preferred Stock and the Series C Warrants would automatically separate on August 25, 2015. However, the shares of Series E Convertible Preferred Stock and the Series C Warrants would separate prior to August 25, 2015 if at any time after 30 days from February 25, 2015 the closing price of our common stock was greater than $240.00 per share for 20 consecutive trading days (the “Separation Trigger Date”). The Company refers to this separation herein as Early Separation. In the event of Early Separation, the shares of Series E Convertible Preferred Stock and the Series C Warrants would separate 15 days after the Separation Trigger Date. In June 2015, the above terms of the Series E Convertible Preferred Stock and Series C Warrants were each modified to allow for an optional early separation and conversion upon the cash exercise of all eight of the Series C Warrants within the Unit.
Number of preferred units separated	2,676,000		48,000
Warrants exercised			384,000
Proceeds from exercise of warrants			$ 979,200
Warrants Issued	21,408,000
Cashless exercise of Warrants		15,128,027			15,630,027
Issuance of common stock upon exercise of warrants under cashless exercise provision		9,899,174			9,962,354
Warrants outstanding					5,229,973
Payable on exercise of warrants under cashless exercise provision					$ 11,700,000
Series C Warrant | Underwriter Purchase Options
Class Of Warrant Or Right [Line Items]
Options exercised					14,750
Proceeds from Options Exercised					$ 162,250
Share issued upon exercise of option					195,906
Warrant or Right, Issued in Period					118,000
Series C Warrant | Series E Convertible Preferred Stock
Class Of Warrant Or Right [Line Items]
Shares, new Issues	2,676,000
Series C Warrant | Common Stock
Class Of Warrant Or Right [Line Items]
Shares, new Issues			6,400

Warrants - Series D Warrants -

Warrants - Series D Warrants - Additional Information (Detail)	Dec. 31, 2016	Dec. 30, 2016	Dec. 30, 2015$ / shares$ / Unitshares	Dec. 31, 2015$ / shares$ / Unitshares	Dec. 31, 2014shares
Class Of Warrant Or Right [Line Items]
Warrants Exercisable				13,219,597	5,447,940
Senior Secured Convertible Note | Securities Purchase Agreement
Class Of Warrant Or Right [Line Items]
Percentage of common stock outstanding			19.90%
Series D Warrant
Class Of Warrant Or Right [Line Items]
Warrants Exercisable				3,503,116
Exercise price | $ / shares				$ 1.85
Series D Warrant | Senior Secured Convertible Note | Securities Purchase Agreement
Class Of Warrant Or Right [Line Items]
Warrants Exercisable			3,503,116
Exercise price | $ / shares			$ 1.85
Conversion feature, floor price | $ / Unit			1.16
Series D Warrant | Scenario, Forecast
Class Of Warrant Or Right [Line Items]
Percentage of common stock outstanding		16.60%
Series D Warrant | Scenario, Forecast | Senior Secured Convertible Note | Securities Purchase Agreement
Class Of Warrant Or Right [Line Items]
Percentage of common stock outstanding	16.60%
Series D Warrant | Common Stock
Class Of Warrant Or Right [Line Items]
Warrants Exercisable				3,503,116
Exercise price | $ / shares				$ 1.85
Exercise period				5 years
Description of warrant terms				Each Series D Warrant will be exercisable initially at an exercise price of $1.85 per share, subject to adjustments for certain dilutive events and subject to an exercise price floor equal to $1.16 per share.
Series D Warrant | Common Stock | Minimum
Class Of Warrant Or Right [Line Items]
Conversion feature, floor price | $ / Unit				1.16

Warrants - Subordination Warran

Warrants - Subordination Warrants - Additional Information (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Class Of Warrant Or Right [Line Items]
Warrants Exercisable	13,219,597	5,447,940
Subordination Warrants | Common Stock
Class Of Warrant Or Right [Line Items]
Warrants Exercisable	105,516
Exercise price	$ 1,850,000
Exercise period	5 years
Description of warrant terms	On December 31, 2016, the number of warrants issuable upon exercise of the Subordination Warrants will be increased to equal the difference, if positive, obtained by subtracting (x) the shares of common stock issuable under the Subordination Warrants on the date of issuance from (y) 0.5% of the sum of the number of shares of common stock actually outstanding on December 31, 2016, plus the number of shares of common stock deemed to be outstanding pursuant to all outstanding options or convertible securities of the Company. Each Subordination Warrant is exercisable by the holder beginning six months after December 30, 2015 and continuing for a period five years thereafter. Each Subordination Warrant will be exercisable initially at a price of $1.85 per share, subject to adjustments for certain dilutive events (same as the Series D Warrants) and subject to an exercise price floor equal to the Series D Warrant exercise floor price of $1.16 per share.
Subordination Warrants | Common Stock | Minimum
Class Of Warrant Or Right [Line Items]
Exercise price	$ 1.16

Warrants - Common Warrants - Ad

Warrants - Common Warrants - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Class Of Warrant Or Right [Line Items]
Warrant issuance and modifications	$ 612,006	$ 25,063
Common Stock Warrants
Class Of Warrant Or Right [Line Items]
Weighted Average Exercise Price, Granted	$ 2.71	$ 3.91
Warrants granted	26,617,714	5,331,520
Common Stock Warrants | Consultant [Member]
Class Of Warrant Or Right [Line Items]
Weighted Average Exercise Price, Granted	$ 2.56
Warrants granted	25,000
Warrants Expiration	2020-08
Warrant issuance and modifications	$ 54,489
Stock price volatility	127.37%
Warrant life	5 years
Risk Free Rate	1.53%
Closing price of common stock	$ 153.60
Exercise Price	$ 153.60

Warrants - Common Stock Warrant

Warrants - Common Stock Warrants Activity (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Class Of Warrant Or Right [Line Items]
Warrants, Beginning Balance	5,447,940
Warrants, Ending Balance	13,219,597	5,447,940
Common Stock Warrants
Class Of Warrant Or Right [Line Items]
Warrants, Beginning Balance	5,447,940	274,420
Warrants granted	26,617,714	5,331,520
Warrants Exercised	(17,547,639)	(158,000)
Warrants Expired	1,298,418
Warrants, Ending Balance	13,219,597	5,447,940	274,420
Weighted Average Exercise Price, Warrants Outstanding Beginning Balance	$ 4.17	$ 8
Weighted Average Exercise Price, Granted	2.71	3.91
Weighted Average Exercise Price, Exercised	2.47	0.20
Weighted Average Exercise Price, Expired	2.48
Weighted Average Exercise Price, Warrants Outstanding Ending Balance	$ 2.71	$ 4.17	$ 8
Warrants Weighted Average Remainder Contractual Terms Granted	4 years 3 months 18 days	5 years 6 months
Weighted Average Remainder Contractual Term in Years, Exercised	4 years	6 years 7 months 6 days
Weighted Average Remainder Contractual Term in Years, Expired	3 years 4 months 24 days	0 years
Weighted Average Remainder Contractual Term in Years, Warrants Outstanding	4 years 8 months 12 days	4 years 10 months 24 days	4 years 2 months 12 days

Warrants - underwriters Unit Pu

Warrants - underwriters Unit Purchase Options - Additional Information (Detail) - USD ($)	1 Months Ended		12 Months Ended
	Jun. 30, 2015	Feb. 28, 2015	Dec. 31, 2015
Series C Warrant
Class Of Warrant Or Right [Line Items]
Warrants exercised	384,000
Exercise price			$ 2.55
Number of shares included in preferred unit		8
Underwriters Unit Purchase Option
Class Of Warrant Or Right [Line Items]
Warrants exercised			14,750
Exercise price		$ 11	$ 11
Weighted Average Remainder Contractual Term in Years, Exercised		5 years
Percentage of public offering price		125.00%
Aggregate number of units purchased		5.00%
Aggregate number of units Sold		136,200
Underwriters Unit Purchase Option | Series C Warrant
Class Of Warrant Or Right [Line Items]
Warrants exercised			118,000
Number of shares included in preferred unit		8
Warrant exercise for cash			$ 162,250
Warrants and rights outstanding			121,450

Derivative Liabilities - Additi

Derivative Liabilities - Additional Information (Detail) - USD ($)		Dec. 30, 2016	Dec. 31, 2015	Dec. 30, 2015	Dec. 31, 2015	Mar. 31, 2015	Feb. 28, 2015	Dec. 31, 2014
Derivative [Line Items]
Valuation method					The Black-Scholes option-pricing model
Derivative liability fair value			$ 43,181,472		$ 43,181,472			$ 9,998,636
Maximum
Derivative [Line Items]
Percentage of common stock outstanding				19.90%
Common Stock
Derivative [Line Items]
Valuation method				Binomial model with Monte Carlo simulation
Common Stock | Subordination Warrants
Derivative [Line Items]
Warrants issued				105,510
Scenario, Forecast | Common Stock | Subordination Warrants
Derivative [Line Items]
Percentage of common stock outstanding		0.50%
Class A Warrant
Derivative [Line Items]
Fair Market Value				$ 1.85
Warrant, exercise price			$ 0.03	0.03	$ 0.03	$ 2.20	$ 4.92	$ 4.92
Warrant, fair value					0.94
Class B Warrant
Derivative [Line Items]
Fair Market Value				1.85
Warrant, exercise price			0.03	0.03	0.03			0.2
Warrant, fair value					0.94
Common Warrants
Derivative [Line Items]
Fair Market Value				1.85
Warrant, exercise price				$ 0.03
Warrant, fair value					0.94
Common Warrants | Maximum
Derivative [Line Items]
Warrant, exercise price			$ 32		$ 32			$ 32
Class A And Class B Warrants
Derivative [Line Items]
Derivative liability fair value			$ 61,941		$ 61,941
Series C Warrant
Derivative [Line Items]
Fair Market Value			$ 153		$ 153
Warrant, exercise price			$ 2.55		$ 2.55
Valuation method					Black Scholes formula
Derivative liability fair value			$ 12,404,503		$ 12,404,503
Expected volatility					135.00%
Contractual Term					5 years
Risk Free Rate					1.61%
Exercise Price			$ 2.55		$ 2.55
Series D Warrant
Derivative [Line Items]
Warrant, exercise price			$ 1.85		$ 1.85
Derivative liability fair value			$ 43,181,472		$ 43,181,472			$ 9,998,636
Warrant to acquire common stock				3,503,116
Series D Warrant | Subordination Warrants
Derivative [Line Items]
Expected volatility	[1]		215.00%
Contractual Term			5 years 6 months
Risk Free Rate	[2]		1.80%
Exercise Price	[3]		$ 1.85		$ 1.85
Series D Warrant | Subordination Warrants | Maximum
Derivative [Line Items]
Fair Market Value			1.10		1.10
Series D Warrant | Common Stock
Derivative [Line Items]
Warrant, exercise price			$ 1.85		$ 1.85
Series D Warrant | Scenario, Forecast
Derivative [Line Items]
Percentage of common stock outstanding		16.60%
[1]	The volatility factor was estimated by using the historical volatilities of the Company's trading history.
[2]	The risk-free interest rate was determined by management using the 5-year Treasury Bill as of the respective measurement date.
[3]	The exercise price of the Series D Warrants calculated by 120% of the arithmetic average of five weighted average price of the common stock on the five consecutive trading days prior to issuance date on December 30, 2015.

Derivative Liabilities - Assump

Derivative Liabilities - Assumptions Used to Calculate Fair Value (Detail) - $ / shares		Dec. 31, 2015	Dec. 30, 2015
Series D Warrant
Fair Value Assumptions and Methodology for Liabilities [Abstract]
Expected dividend yield			0.00%
Series D Warrant | Subordination Warrants
Fair Value Assumptions and Methodology for Liabilities [Abstract]
Conversion price	[1]	$ 1.85
Risk free interest rate	[2]	1.80%
Contractual Term		5 years 6 months
Expected volatility	[3]	215.00%
Series D Warrant | Subordination Warrants | Minimum
Fair Value Assumptions and Methodology for Liabilities [Abstract]
Trading price of common stock on measurement date		$ 0.94
Series D Warrant | Subordination Warrants | Maximum
Fair Value Assumptions and Methodology for Liabilities [Abstract]
Trading price of common stock on measurement date		$ 1.10
Convertible Notes Payable
Fair Value Assumptions and Methodology for Liabilities [Abstract]
Risk free interest rate	[4]		0.86%
Contractual Term			1 year 3 months 29 days
Expected volatility	[3]		215.00%
Expected dividend yield			0.00%
Expected probability of Shareholder approval	[5]		85.00%
Convertible Notes Payable | Minimum
Fair Value Assumptions and Methodology for Liabilities [Abstract]
Trading price of common stock on measurement date	[6]		$ 0.94
Conversion price			0.87
Convertible Notes Payable | Maximum
Fair Value Assumptions and Methodology for Liabilities [Abstract]
Trading price of common stock on measurement date	[6]		1.10
Conversion price			$ 1.03
[1]	The exercise price of the Series D Warrants calculated by 120% of the arithmetic average of five weighted average price of the common stock on the five consecutive trading days prior to issuance date on December 30, 2015.
[2]	The risk-free interest rate was determined by management using the 5-year Treasury Bill as of the respective measurement date.
[3]	The volatility factor was estimated by using the historical volatilities of the Company's trading history.
[4]	The risk-free interest rate was determined by management using the 1.5-year Treasury Bill as of the respective measurement date.
[5]	Management has estimated a probability of 85% that Shareholder approval will be obtained for the removal of the 19.9% conversion cap. This is based on past Shareholder voting history and discussions with current Shareholders and consultants.
[6]	The conversion price of the convertible notes was calculated based the formula in the Notes agreement as of the respective measurement date

Derivative Liabilities - Assu73

Derivative Liabilities - Assumptions Used to Calculate Fair Value (Parenthetical) (Detail)		Dec. 30, 2015	Dec. 31, 2015
Maximum
Derivative [Line Items]
Percentage of common stock outstanding		19.90%
Series D Warrant
Derivative [Line Items]
Dividend yield		0.00%
Debt instrument, conversion feature			The exercise price of the Series D Warrants calculated by 120% of the arithmetic average of five weighted average price of the common stock on the five consecutive trading days prior to issuance date on December 30, 2015.
Conversion feature, threshold consecutive trading days			5 days
Series D Warrant | US Treasury Bill Securities [Member]
Derivative [Line Items]
Contractual Term		5 years
Convertible Notes Payable
Derivative [Line Items]
Contractual Term		1 year 3 months 29 days
Dividend yield		0.00%
Expected probability of Shareholder approval	[1]	85.00%
Convertible Notes Payable | US Treasury Bill Securities [Member]
Derivative [Line Items]
Contractual Term		1 year 6 months
Convertible Notes Payable | Maximum
Derivative [Line Items]
Percentage of common stock outstanding		19.90%
[1]	Management has estimated a probability of 85% that Shareholder approval will be obtained for the removal of the 19.9% conversion cap. This is based on past Shareholder voting history and discussions with current Shareholders and consultants.

Derivative Liabilities - Summar

Derivative Liabilities - Summary of Change in the Value of the Warrant Derivative Liability (Detail) - USD ($)	1 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2015	Dec. 31, 2014
Derivative [Line Items]
Balance at beginning of period		$ 9,998,636
Change in fair value of warrant and option liability	$ 25,061	19,714,808	$ 8,396,169
Balance at end of period		43,181,472	9,998,636
Series D Warrant
Derivative [Line Items]
Balance at beginning of period		9,998,636
Issuance of warrants and option		56,026,979	(2,487,726)
Exercise and expiration of warrants and unit purchase option		(42,558,951)	(885,259)
Change in fair value of warrant and option liability		19,714,808	(8,396,169)
Balance at end of period		$ 43,181,472	$ 9,998,636

Employee Stock Options - Additi

Employee Stock Options - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2015USD ($)CompensationPlan$ / sharesshares	Dec. 31, 2014USD ($)$ / sharesshares	Dec. 31, 2013shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Expense | $	$ 110,123	$ 297,244
Unrecognized compensation cost related to stock option | $	$ 408,907	$ 252,315
Remaining vesting period of stock option	2 years 8 months 16 days	3 years 5 months 9 days
Employee Stock Option
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of stock options, outstanding	792,534	703,034	115,750
Stock options, maturity period	10 years
Number of stock based compensation plans | CompensationPlan	3
Options, Grants in Period, Exercise Price | $ / shares	$ 2.56	$ 2.86
Deferred Compensation | $	$ 306,709
Share-based Compensation Expense | $		$ 54,394
Number of stock options, granted	117,500	619,784
Employee Stock Option | Pre IPO
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of stock options, outstanding	483,000
Employee Stock Option | Post IPO
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of stock options, outstanding	136,784
Employee Stock Option | Two Thousand Six Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Payment Award, Options, Grants in Period		103,250
Employee Stock Option | Two Thousand Fourteen Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options, Grants in Period, Exercise Price | $ / shares		$ 3.50
Share-based Compensation Expense | $		$ 223,031
Number of stock options, granted		103,250
Valuation Method	Black-Scholes method
Employee Stock Option | 2014 and Omnibus Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of stock options, granted		619,781
Stock options, conversion	0.016666667
Employee Stock Option | Omnibus Plans [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options, Grants in Period, Exercise Price | $ / shares	$ 2.56
Deferred Compensation | $	$ 268,202
Share-based Compensation Expense | $	$ 29,309
Number of stock options, granted	117,500
Valuation Method	Black-Scholes method
Options expiration period	10 years
Employee Stock Option | Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Option vesting period	3 years
Employee Stock Option | Minimum | 2014 and Omnibus Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options, Grants in Period, Exercise Price | $ / shares		$ 2
Employee Stock Option | Minimum | Omnibus Plans [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Option vesting period	3 years
Employee Stock Option | Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Option vesting period	4 years
Employee Stock Option | Maximum | 2014 and Omnibus Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options, Grants in Period, Exercise Price | $ / shares		$ 7
Employee Stock Option | Maximum | Omnibus Plans [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Option vesting period	4 years

Employee Stock Options - Schedu

Employee Stock Options - Schedule of Assumption for Stock Option Valuation (Detail) - Employee Stock Option - Two Thousand Fourteen Plan [Member]	12 Months Ended
	Dec. 31, 2015$ / shares
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Risk free rate, minimum	1.06%
Risk free rate, maximum	1.70%
Dividend yield	0.00%
Expected volatility, minimum	46.31%
Expected volatility, maximum	54.97%
Minimum
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Fair market value of one share of common stock	$ 296.40
Aggregate exercise price of 60 options	$ 210
Expected term, maximum	2 years 8 months 27 days
Maximum
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Fair market value of one share of common stock	$ 316.80
Aggregate exercise price of 60 options	$ 354.60
Expected term, maximum	6 years 22 days

Employee Stock Options - Sche77

Employee Stock Options - Schedule of Assumptions Used in Calculation of Fair Value of the Options Exchanged (Detail) - Employee Stock Option - Omnibus Plans [Member]	12 Months Ended
	Dec. 31, 2015$ / shares
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Fair market value of one share of common stock	$ 153.60
Aggregate exercise price of 60 options	$ 153.60
Risk free rate	1.71%
Dividend yield	0.00%
Expected volatility	127.52%
Expected term	6 years 1 month 21 days

Employee Stock Options - Summar

Employee Stock Options - Summary of Stock Option Activity (Detail) - Employee Stock Option - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Number of stock options, outstanding	703,034	115,750
Number of options, Granted	117,500	619,784
Number of options, exercised	0	0
Number of options, forfeited/expired	(28,000)	(32,500)
Number of stock options, outstanding	792,534	703,034	115,750
Number of stock options, outstanding	703,034	115,750
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Balance	$ 2.98	$ 30
Weighted Average Exercise Price, granted	2.56	2.86
Weighted Average Exercise Price, exercise	0	0
Weighted Average Exercise Price, forfeited/expired	5.16	8.92
Balance	$ 2.84	$ 2.98	$ 30
Number of options, Granted	117,500	619,784
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Weighted average remaining contractual term in Years, granted	9 years 7 months 6 days	9 years 4 months 24 days
Weighted average remaining contractual term in Years, forfeited/expired	8 years 7 months 6 days	5 years 8 months 12 days
Weighted average remaining contractual term in Years, outstanding	8 years	8 years 9 months 18 days	6 years 3 months 18 days
Balance	$ 0	$ 0
Number of options, exercised	0	0
Number of options, forfeited/expired	(28,000)	(32,500)
Number of stock options, outstanding	792,534	703,034	115,750

Employee Stock Options - Summ79

Employee Stock Options - Summary of Stock Options Outstanding and Exercisable (Detail) - Employee Stock Option - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of stock options, outstanding	792,534	703,034	115,750
Options Outstanding , Remaining Life (Years)	8 years	8 years 9 months 18 days	6 years 3 months 18 days
Options Outstanding , Exercise Price	$ 2.84	$ 2.98	$ 30
Options Exercisable , Number of Options Exercisable	328,445	117,404
Options Exercisable , Exercise Price	$ 3.07	$ 3.86
Options Exercisable , Intrinsic Value	$ 0	$ 0

Employee Stock Options - Sche80

Employee Stock Options - Schedule of Equity-Based Compensation Expenses (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock based compensation expense	$ 110,123	$ 297,244

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail)

Oct. 08, 2014$ / sharesshares

Oct. 31, 2014

Jul. 31, 2014USD ($)$ / sharesshares

Jun. 30, 2014USD ($)

Apr. 30, 2014USD ($)$ / sharesshares

Mar. 31, 2014USD ($)$ / sharesshares

Feb. 28, 2014USD ($)$ / sharesshares

Dec. 31, 2015USD ($)$ / sharesshares

Dec. 31, 2014USD ($)$ / sharesshares

Dec. 30, 2015$ / shares

Mar. 31, 2015$ / shares

Feb. 28, 2015$ / shares

Related Party Transaction [Line Items]

Warrants Exercisable

13,219,597

5,447,940

Common Stock

Related Party Transaction [Line Items]

Conversion of stock, shares issued

771

IPO | Common Stock

Related Party Transaction [Line Items]

Conversion of stock, shares issued

60,279

Series D Convertible Preferred Stock

Related Party Transaction [Line Items]

Convertible debt, amount converted | $

$ 400,000

Conversion of preferred stock to common stock, conversion ratio

200

12,000

Sale Leaseback Obligations

Related Party Transaction [Line Items]

Letter of credit | $

$ 3,000,000

Sale Leaseback Obligations | Letter of Credit

Related Party Transaction [Line Items]

Line of credit, amount drawn | $

$ 0

Class A Warrant

Related Party Transaction [Line Items]

Warrants Exercisable

1,532,598

2,041,239

Exercise Price of Warrants or Rights | $ / shares

$ 0.03

$ 4.92

$ 0.03

$ 2.20

$ 4.92

Share price | $ / shares

1.85

Class A Warrant | IPO

Related Party Transaction [Line Items]

Exercise Price of Warrants or Rights | $ / shares

$ 7

Class B Warrant

Related Party Transaction [Line Items]

Warrants Exercisable

1,310,956

1,645,845

Exercise Price of Warrants or Rights | $ / shares

$ 0.03

$ 0.2

0.03

Share price | $ / shares

$ 1.85

Subordination Warrants | Common Stock

Related Party Transaction [Line Items]

Warrants Exercisable

105,516

Convertible Promissory Notes

Related Party Transaction [Line Items]

Maturity date of notes

Feb. 26, 2015

Notes qualified for equity financing | $

$ 5,000,000

Convertible Promissory Notes | IPO | Common Stock

Related Party Transaction [Line Items]

Conversion of stock, shares issued

690

Convertible Promissory Notes | Series D Convertible Preferred Stock

Related Party Transaction [Line Items]

Shares issued upon conversion of debt

8,270,027

Convertible Promissory Notes | Class A Warrant

Related Party Transaction [Line Items]

Warrants Exercisable

41,350

Exercise Price of Warrants or Rights | $ / shares

$ 4.92

Convertible Promissory Notes | Class A Warrant | Common Stock

Related Party Transaction [Line Items]

Exercise Price of Warrants or Rights | $ / shares

$ 0.03

Convertible Promissory Notes | Class B Warrant

Related Party Transaction [Line Items]

Warrants Exercisable

41,350

Exercise Price of Warrants or Rights | $ / shares

$ 0.20

Convertible Promissory Notes | Class B Warrant | Common Stock

Related Party Transaction [Line Items]

Exercise Price of Warrants or Rights | $ / shares

$ 0.03

Convertible Promissory Notes | Accrued Interest

Related Party Transaction [Line Items]

Convertible debt, amount converted | $

$ 6,751

Second Financial Advisory Agency Agreement

Related Party Transaction [Line Items]

Financial advisory fees | $

$ 15,000

$ 15,000

Fee paid upon the filling of S-1 with SEC | $

$ 50,000

Fee payment upon closure of initial public offering | $

$ 100,000

Second Financial Advisory Agency Agreement | IPO

Related Party Transaction [Line Items]

Conversion of preferred stock to common stock, conversion ratio

200

Second Financial Advisory Agency Agreement | IPO | Common Stock

Related Party Transaction [Line Items]

Conversion of stock, shares issued

600

Second Financial Advisory Agency Agreement | Series D Convertible Preferred Stock

Related Party Transaction [Line Items]

Number of preferred units issued as consideration

7,200,000

Second Financial Advisory Agency Agreement | Series D Convertible Preferred Stock | IPO

Related Party Transaction [Line Items]

Conversion of stock, shares converted

7,200,000

Second Financial Advisory Agency Agreement | Class A Warrant

Related Party Transaction [Line Items]

Warrants Exercisable

36,000

Exercise Price of Warrants or Rights | $ / shares

$ 4.92

Second Financial Advisory Agency Agreement | Class A Warrant | IPO

Related Party Transaction [Line Items]

Exercise Price of Warrants or Rights | $ / shares

$ 0.03

Exchange ratio of options exercised to common stock

60

Second Financial Advisory Agency Agreement | Class B Warrant

Related Party Transaction [Line Items]

Warrants Exercisable

36,000

Exercise Price of Warrants or Rights | $ / shares

$ 0.20

Second Financial Advisory Agency Agreement | Class B Warrant | IPO

Related Party Transaction [Line Items]

Exercise Price of Warrants or Rights | $ / shares

$ 0.03

Exchange ratio of options exercised to common stock

60

Notes Payable To Related Party

Related Party Transaction [Line Items]

Interest rate on notes

20.00%

Maturity date of notes

Jul. 18, 2015

Convertible notes payable, principal | $

$ 500,000

Note maturity date description

The Company may extend the due date of the note to July 18, 2016 by giving notice no later than April 18, 2015

Note extension fee amount | $

10,000

Prepaid interest | $

$ 25,000

Number of preferred units issued as consideration

4,000,000

4,000,000

Value of preferred units issued as consideration | $

$ 100,000

$ 100,000

Preferred units issued as consideration, series D preferred shares

4,000,000

Notes payable - related party, discount | $

$ 58,333

Notes Payable To Related Party | IPO | Common Stock

Related Party Transaction [Line Items]

Conversion of stock, shares issued

20,000

Notes Payable To Related Party | Series D Convertible Preferred Stock | IPO

Related Party Transaction [Line Items]

Conversion of stock, shares converted

4,000,000

Notes Payable To Related Party | Class A Warrant

Related Party Transaction [Line Items]

Warrants Exercisable

20,000

Preferred units issued as consideration, warrants

20,000

Exercise Price of Warrants or Rights | $ / shares

$ 0.03

$ 4.92

Exchange ratio of options exercised to common stock

60

Notes Payable To Related Party | Class A Warrant | Common Stock

Related Party Transaction [Line Items]

Share price | $ / shares

$ 4.92

Notes Payable To Related Party | Class B Warrant

Related Party Transaction [Line Items]

Warrants Exercisable

20,000

Preferred units issued as consideration, warrants

20,000

Exercise Price of Warrants or Rights | $ / shares

$ 0.03

$ 0.20

Exchange ratio of options exercised to common stock

60

Notes Payable To Related Party | Class B Warrant | Common Stock

Related Party Transaction [Line Items]

Share price | $ / shares

$ 0.20

Ryan Ashton, Chief Executive Officer | Convertible Promissory Notes

Related Party Transaction [Line Items]

Interest rate on notes

8.00%

Warrants Exercisable

25,000

Preferred units issued as consideration, warrants

200,000

Spring Forth Investments and the Bourne Spafford Charitable Trust | Convertible Promissory Notes

Related Party Transaction [Line Items]

Interest rate on notes

8.00%

Warrants Exercisable

12,500

Preferred units issued as consideration, warrants

100,000

Maturity date of notes

Mar. 10, 2015

Notes qualified for equity financing | $

$ 5,000,000

Spring Forth Investments and the Bourne Spafford Charitable Trust | Convertible Promissory Notes | IPO | Common Stock

Related Party Transaction [Line Items]

Conversion of stock, shares issued

344

Spring Forth Investments and the Bourne Spafford Charitable Trust | Convertible Promissory Notes | Series D Convertible Preferred Stock

Related Party Transaction [Line Items]

Shares issued upon conversion of debt

4,124,493

Spring Forth Investments and the Bourne Spafford Charitable Trust | Convertible Promissory Notes | Class A Warrant

Related Party Transaction [Line Items]

Warrants Exercisable

20,622

Exercise Price of Warrants or Rights | $ / shares

$ 4.92

Spring Forth Investments and the Bourne Spafford Charitable Trust | Convertible Promissory Notes | Class A Warrant | IPO

Related Party Transaction [Line Items]

Exercise Price of Warrants or Rights | $ / shares

$ 0.03

Spring Forth Investments and the Bourne Spafford Charitable Trust | Convertible Promissory Notes | Class B Warrant

Related Party Transaction [Line Items]

Warrants Exercisable

20,622

Exercise Price of Warrants or Rights | $ / shares

$ 0.20

Spring Forth Investments and the Bourne Spafford Charitable Trust | Convertible Promissory Notes | Class B Warrant | IPO

Related Party Transaction [Line Items]

Exercise Price of Warrants or Rights | $ / shares

$ 0.03

Spring Forth Investments and the Bourne Spafford Charitable Trust | Convertible Promissory Notes | Accrued Interest

Related Party Transaction [Line Items]

Convertible debt, amount converted | $

$ 3,112

Income Tax Expense (Detail)

Income Tax Expense (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Current
Federal	$ 0	$ 0
State and Local	1,250	5,297
Current income tax expense benefit	1,250	5,297
Deferred
Federal	0	0
State and Local	0	0
Deferred income tax expense benefit	0	0
Provision for income taxes	$ 1,250	$ 5,297

Components of Deferred Tax Asse

Components of Deferred Tax Assets (Detail) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Deferred tax assets:
Net operating losses	$ 4,194,990	$ 18,229,887
Depreciation and amortization		162,344
Depreciation and amortization	(182,903)
Allowance for doubtful accounts	6,324	2,035
Accrued vacation	112,892	85,081
Accrued personal property tax	4,083	4,048
Other	1,652	171
Total deferred tax assets	4,137,036	18,483,566
Less: Valuation allowance	(4,137,036)	(18,483,566)
Net deferred tax assets	$ 0	$ 0

Reconciliation of Reported Amou

Reconciliation of Reported Amount of Income Tax Expense (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Effective Income Tax Rate Reconciliation, Amount [Abstract]
Benefit for income taxes computed at federal statutory rate	$ (19,685,292)	$ (7,385,656)
State income taxes, net of federal tax benefit	(1,998,974)	(407,156)
Non-deductible expenses	12,902,916	3,024,860
NOL write off due to Section 382 limitation	23,200,232
Increase (decrease) in valuation allowance	(14,346,481)	4,622,286
Other, net	(71,150)	150,963
Provision for income taxes	$ 1,250	$ 5,297
Effective tax rate	(0.01%)	(0.07%)

Income Tax - Additional Informa

Income Tax - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Income Taxes [Line Items]
Increase in valuation allowance	$ 14,346,481
Unrecognized tax benefits	0	$ 0
Unrecognized tax benefits income tax penalties and interest recognized	0	0
Unrecognized tax benefits income tax penalties and interest accrued	0	0
Federal
Income Taxes [Line Items]
Net operating loss carry forwards	$ 11,500,000	51,800,000
Net tax operating losses, expiration	Expire in varying amounts during the tax years 2025 and 2035.
Federal | Earliest Tax Year [Member]
Income Taxes [Line Items]
Tax years open to examination	2,012
Federal | Latest Tax Year [Member]
Income Taxes [Line Items]
Tax years open to examination	2,015
State
Income Taxes [Line Items]
Net operating loss carry forwards	$ 8,200,000	$ 32,500,000
Net tax operating losses, expiration	Expire in varying years from 2025 to 2035.

Schedule of Domestic and Intern

Schedule of Domestic and International Customers Products Sales (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Schedule Of Geographical Information [Line Items]
Total sales	$ 2,142,040	$ 1,606,254
Domestic (U.S.)
Schedule Of Geographical Information [Line Items]
Total sales	2,096,825	1,559,614
International
Schedule Of Geographical Information [Line Items]
Total sales	$ 45,215	$ 46,640

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail) - USD ($)	Oct. 08, 2014	Feb. 29, 2016	Jan. 31, 2016	Feb. 29, 2016	Dec. 31, 2015	Dec. 31, 2014	Mar. 01, 2016
Subsequent Event [Line Items]
Proceeds from exercise of warrants					$ 3,161,220	$ 31,600
Warrants yet to deliver					13,219,597	5,447,940
Warrants Exercisable					13,219,597	5,447,940
Proceeds from Issuance of Initial Public Offering	$ 6,400,000
Common Stock
Subsequent Event [Line Items]
Shares issued, IPO					0	19,167
IPO | Common Stock
Subsequent Event [Line Items]
Shares issued, IPO	19,167
Series D Convertible Preferred Stock
Subsequent Event [Line Items]
Common Stock, Capital Shares Reserved for Future Issuance					120,000,000
Subsequent Event
Subsequent Event [Line Items]
Cashless exercise of warrants				64,641,576
Consulting services for settlement of disputes		$ 80,000
Consulting fee incurred		800,000		$ 800,000
Consulting fee, paid		$ 200,000
Subsequent Event | IPO
Subsequent Event [Line Items]
Shares issued, IPO		39,200,000
Proceeds from Issuance of Initial Public Offering, gross		$ 6,300,000
Proceeds from Issuance of Initial Public Offering		$ 5,600,000
Subsequent Event | IPO | Common Stock
Subsequent Event [Line Items]
Number of shares included in preferred unit		1		1
Subsequent Event | Purchased Options [Member]
Subsequent Event [Line Items]
Conversion of stock, shares converted				121,450
Subsequent Event | Monthly Payment
Subsequent Event [Line Items]
Consulting fee incurred		$ 50,000		$ 50,000
Subsequent Event | Series C Convertible Preferred Stock
Subsequent Event [Line Items]
Cashless exercise of Warrants				5,001,687
Conversion of stock, shares converted			138,158
Proceeds from exercise of warrants			$ 304,017
Warrants yet to deliver							50,418
Warrants Exercisable							563,651
Subsequent Event | Series E Convertible Preferred Stock
Subsequent Event [Line Items]
Conversion of stock, shares converted				13,967
Subsequent Event | Series D Convertible Preferred Stock
Subsequent Event [Line Items]
Common Stock, Capital Shares Reserved for Future Issuance		85,000,000		85,000,000
Subsequent Event | Series E Warrants [Member] | IPO
Subsequent Event [Line Items]
Number of shares included in preferred unit		1.5		1.5
Closing price of common stock		$ 0.25		$ 0.25
Warrants expiration		6 years